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Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder characterised by the progressive 
loss of dopaminergic neurons, particularly in the ventral substantia nigra. Growing evidence 
implicates biometal dyshomeostasis and subsequent metal-catalysed neurotoxicity in 
vulnerable regions of the PD brain. Through meta-analysis, I confirm previously reported 
reductions in Cu, and elevations in Fe specifically in the substantia nigra of the PD brain, 
which are not reflected by similar changes in biofluid tissues. These changes are further 
restricted to the soluble fraction of nigral tissue – suggesting that soluble metalloproteins may 
be affected by these biometal perturbations. Superoxide dismutase 1 (SOD1) is one soluble 
Cu-associated protein that has recently demonstrated impaired antioxidant capacity and 
altered structural conformation in the PD brain and may present with an altered metalation 
profile in PD brain. I describe, for the first time, the cutting-edge technique of simultaneous 
synchrotron X-ray fluorescence microscopy and ptychography performed in situ to identify 
and directly image Lewy bodies, SOD1 aggregates and neuromelanin in human PD 
substantia nigra. The resulting nanoscale imaging demonstrate that SOD1 and Lewy body 
proteinopathies share similar structures. SOD1 and Lewy aggregates also exhibited similar 
elemental compositions, suggesting that these distinct proteinaceous aggregates may share an 
overlapping protein misfolding pathway. Further, I demonstrate an altered Cu:Zn ratio in 
SOD1 aggregates, supporting the hypothesis that altered metalation of SOD1 results in 
aggregate formation in this Cu-deficient region. These data suggest that Cu dyshomeostasis 
in the vulnerable substantia nigra of the PD brain may be attenuated by biometal modulation 
therapies, and that SOD1 may present as viable therapeutic target for PD. 
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CHAPTER 1: BIOMETAL 
DYSHOMEOSTASIS IN PARKINSON’S 
DISEASE: IMPLICATIONS FOR 
PATHOGENESIS AND RELEVANCE FOR 
NOVEL THERAPEUTICS
2 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) is an increasingly common movement disorder affecting over 10 
million worldwide and expected to rise exponentially with our aging population - predicted to 
double in the next 20 years[1,2]. The substantial total economic cost associated with PD 
imparts a significant burden on the health community, also concurrently rising in Australia 
from $3.2 billion to $9.9 billion in the past 10 years[3]. As no currently available treatments 
effectively halt or slow the disease process, establishing the underlying pathogenesis is 
essential for the development of more effective therapeutic approaches for this increasingly 
prevalent neurodegenerative disorder. 
Currently, PD is only conclusively diagnosed post-mortem following observation of 
aggregations of α-synuclein protein termed Lewy aggregates in the substantia nigra (SN) and 
the relatively selective degeneration of dopaminergic neurons primarily in the SN[4,5]. 
Neuronal loss also occurs in the locus coeruleus, throughout the basal ganglia and olfactory 
bulbs[4,6] (Figure 1). The ventral tier of dopaminergic neurons within the SN are particularly 
vulnerable and display the most substantial neuronal loss[7,8]. It is estimated that >50% of 
dopaminergic neurons in the nigro-striatal pathway are lost prior to the presentation of the 
characteristic motor symptoms of the disease[9]. Clinically, PD is diagnosed by the 
presentation of the cardinal motor feature bradykinesia, with at least one additional symptom 
including muscle rigidity and/or resting tremor[10,11]. This debilitating immobility invariably 
leads to death through difficulty swallowing, aspiration pneumonia and pulmonary 
embolism[12,13]. Although largely overlooked, non-motor preclinical symptoms are also a key 
feature of PD and many are proposed to predate motor symptoms by as much as 10 
years[14,15]. In particular, constipation[16,17], hyposmia[18] and restless eye movement-sleep 
behaviour[19] are associated with an increased risk of later being diagnosed with PD. Other 
non-motor symptoms such as depression and difficulty sleeping arise due to disease 
processes and occur later as the disease progresses[20]. 
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Figure 1.1 Staging of neurodegeneration in clinical Parkinson’s disease 
a. Pattern of neuronal cell loss in PD with distribution of cell loss increasing with time and
disease duration. Dark colour indicates more neuronal loss. B. Transverse midbrain sections
depicting heavily pigmented dopaminergic neurons in substantia nigra pars compacta (SNc;
green), less pigmented neurons of ventral tegmental area (VTA; blue), neurons in SN pars
reticulata (SNr; pink). 3N, third nerve; AM, amygdala; BF, magnocellular nuclei of the basal
forebrain; Cl, claustrum; cp, cerebral peduncle; DMV, dorsal motor nucleus of the vagus; IZ,
intermediate reticular zone; LC, locus coeruleus and sub-coeruleus; LH, lateral
hypothalamus; MRN, median raphe nucleus; PGRN/GRN, paragigantocellular and
gigantocellular reticular nucleus; PPN, pedunculopontine nucleus; preSMA,
presupplementary motor area; R, red nucleus; SNd, dorsal tier of the SNc; SNv, ventral tier
of the SNc. Figure from Surmeier et al. (2017)[21]
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1.2 Current therapeutic approaches for Parkinson’s disease 
Currently, no pharmacological or surgical therapeutic approaches to PD effectively attenuate 
neuronal loss or slow the progression of the disease[22]. Most available treatments such as L-
DOPA and dopamine agonists act to mitigate depleted dopamine in the nigrostriatal pathway 
and provide temporary improvement of motor symptoms of the disease[13,23]. Other non-
dopaminergic pathways are also affected in PD[24] and targeting these pathways have 
demonstrated efficacy in attenuating motor disturbances[25,26]. Another approach reported to 
ameliorate movement symptoms of PD is deep brain stimulation, an invasive procedure 
involving a high frequency stimulation targeting dysfunctional regions of the PD brain, 
demonstrating efficacy for up to 10 years[27,28]. All of these approaches come with severe 
limitations however, for example significant adverse and debilitating effects are reported 
following their continuous use[23,29]. Further, none of these treatments address the underlying 
disease aetiology and are thus ineffective in halting or slowing the progression of disease. 
Determining the molecular pathways involved in neuronal death in vulnerable brain regions 
of this disorder is a key step towards the development of more sustainable, disease modifying 
therapeutic approaches. Understanding disease aetiology will also aid the development of 
prodromal and pre-clinical biomarkers to provide more accurate diagnosis and prediction of 
disease risk to enable the administration of therapeutic interventions earlier in the disease.  
1.3 Neuronal vulnerability in Parkinson’s disease 
As neuronal death in the PD brain is relatively specific, understanding why these regions are 
vulnerable to neurodegeneration is important in understanding PD aetiology. Cell death 
reportedly results from a cascade of molecular processes including protein misfolding[30], 
impaired clearance of cellular debris[31], oxidative stress[32], mitochondrial dysfunction[33] and 
biometal alterations[34].  
1.3.1 Protein aggregation 
In the healthy brain, the folding and assembly of proteins into their natively stable state 
occurs with the aid of molecular chaperones that also play a key role in preventing 
inappropriate polypeptide interactions[35,36]. Molecular chaperones also stabilise transiently 
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unfolded protein substrates and promote the refolding of proteins that have misfolded due to 
cellular stress[36]. With protein misfolding and the formation of proteinaceous aggregates 
indicative of a loss of normal function, investigating the factors affecting protein misfolding 
may aid in understanding the pathways leading to dysfunction in disorders involving protein 
aggregation such as PD. Protein misfolding propensity is attributed to a variety of factors 
including; regional alterations in pH[37], temperature[38] and oxidative stress[39], disruption to 
normal protein folding machinery[35,40] and post-translational modifications[41] including 
interactions of these proteins with metals[42,43]. Misfolded proteins can then readily form 
aggregates categorised as either amyloid or non-amyloid depending on their biophysical 
nature[44,45]. 
1.3.2 α-synuclein and Lewy pathology 
A current requirement for the neuropathological diagnosis of PD is the presence of Lewy 
pathology – abnormal amyloid-like protein aggregates comprised of the synaptic protein a-
synuclein – in the SN[46]. Lewy pathology are typified by intracytoplasmic inclusions of 5-
25µm in diameter located within the soma of neurons termed Lewy bodies[29]. Although a-
synuclein exists in the healthy brain as an unfolded monomer, it readily aggregates into 
oligomers with varying morphology – spherical, chainlike, annular and tubular[47], which then 
self-associate to form fibrillar aggregates[48]. Other forms of a-synuclein-rich inclusions have 
been identified in axonal processes termed Lewy neurites, while diffuse, granular structures 
represent oligomeric forms of these misfolded proteins[49]. Lewy pathology typically follows 
a specific temporal and spatial pattern in sporadic form of PD, resulting in a standardised 
pathological staging system[4](Figure 1.1). 
Although the precise function of α-synuclein in the healthy brain remains unclear, its high 
abundance, close association with synaptic terminals and ability to promote SNARE 
assembly[50] suggests its involvement in vesicular trafficking[51] with a proposed role in the 
negative regulation of dopamine release[52]. A reduction of striatal dopamine concurrent with 
that observed in the PD brain was demonstrated in post-mortem analysis of α-synuclein 
knockout mice, yet no characteristic neuronal loss was observed[53] – suggesting α-synuclein 
dysfunction alone is insufficient to produce the neuronal loss observed in the PD vulnerable 
brain.  
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Despite a proposed association of α-synuclein-containing Lewy aggregates, with the 
degeneration of susceptible nerve cells in PD[4,54], this hypothesis has significant limitations. 
The presence of Lewy pathology in the absence of neuronal loss in certain brain regions of 
PD patients, such as the anterior cingulate cortex (ACC)[55] and their absence in the 
degenerating SN in certain familial cases[56–58], contradicts their widely defined association 
with neuronal toxicity in PD. For example, numerous studies involving PD patients and 
models with leucine-rich repeat kinase 2 (LRRK2) mutations have exhibited 
neurodegeneration both with and without Lewy pathology[21,58,59]. Further, a recent study has 
determined minimal association between the presence of Lewy aggregates and cell loss[60], 
and a stronger correlation between the presence of a-synuclein oligomers and neuronal 
loss[61]. These data supports the emerging hypothesis that Lewy aggregates may, in fact, be 
neuroprotective, and that α-synuclein oligomeric fibrils confer neurotoxicity[51,62]. The lack of 
Lewy pathology in murine models attempting to recapitulate human PD including the toxin-
induced model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a-synculein 
overexpression and LRRK2 mutated model, further question their role in PD[63–65]. It is noted 
however, that animal models do not recreate the full spectrum of pathological features of 
human PD and therefore are a limited representation of the disease. Although a-synuclein no 
doubt plays a role in PD, this discordant distribution of Lewy pathology with 
neurodegeneration has urged a re-evaluation of their direct association with neuronal death in 
PD[66,67]. 
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Figure 1.2 Staging of Lewy pathology in Parkinson’s disease.  
Schematic depicting the spread of Lewy pathology throughout the brain during clinical 
progression of Parkinson’s disease. The darker colour indicates more Lewy pathology. AM, 
amygdala; BF, magnocellular nuclei of the basal forebrain; Cl, claustrum; DMV, dorsal 
motor nucleus of the vagus; DRN, dorsal raphe nucleus; FCtx, frontal cortex; IL, intralaminar 
nuclei of the thalamus; IZ, intermediate reticular zone; LC, locus coeruleus and subcoeruleus; 
LCtx, limbic cortex; LH, lateral hypothalamus; MRN, median raphe nucleus; OB, olfactory 
bulb; PGRN/GRN, paragigantocellular and gigantocellular reticular nucleus; PPN, 
pedunculopontine nucleus; RM, raphe magnus; Se, septum; SNc, substantia nigra pars 
compacta; SO, solitary tract nuclei; VTA, ventral tegmental area. Figure adapted from 
Surmeier et al. (2017)[21] 
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Regardless, as protein misfolding indicates impairment of normal function, it is important to 
elucidate the factors initiating and instigating the misfolding and aggregation of a-synuclein 
in the PD brain. Increases in hydrophobicity and reductions in net charge are demonstrated to 
induce a-synuclein folding[68], as well as alterations in pH, temperature, and post-
translational modifications[69]. Phosphorylation at serine 129 is one such post-translational 
modification that occurs in around 90% of a-synuclein in Lewy bodies [69,70]. Oxidative 
modifications, and the binding of various metals including Fe2+, Cu2+,Zn2+, Mg2+, Al3+ Ti3+,
Mn2+, Ca2+, Pb2+ are all demonstrated to promote a-synuclein fibrillation in vitro[71–76]. As 
these studies were performed in vitro, to more comprehensively understand the mechanisms 
underlying a-synuclein aggregation in the PD brain, more research is needed in vivo, and 
more specifically, in the human brain. Although determining the role of endogenous 
biometals in a-synuclein aggregation into Lewy pathology is of particular interest, 
understanding the role of a-synuclein and all of the factors potentiating its aggregation in the 
PD brain is an essential step in the understanding of PD aetiology.  
1.3.3 Oxidative Stress 
As well as the deposition of misfolded proteins, vulnerable regions of the PD brain exhibit 
elevations of oxidative stress. Oxidative stress arises due to an imbalance of reactive oxygen 
species (ROS) production, and cellular antioxidant activity[77]. ROS are produced as natural 
intermediates of normal metabolic processes, and act as pivotal mediators of protein 
interactions and aspects of cell signalling[78]. Regions under high metabolic demand however, 
may produce an excess of ROS[32,79]. To quench excess ROS, antioxidants scavenge or 
convert ROS to less toxic forms[80]. If this activity is insufficient to account for excess ROS, 
oxidative stress ensues. The resulting oxidative damage produces widespread impact on 
proteins, lipids and DNA (reviewed in Birben et al., 2012[81]), contributing to many 
pathological conditions including cancer[82] and neurodegeneration[79,83]. 
Oxidative stress has been implicated in pathogenic mechanisms underlying both familial and 
idiopathic PD[32,84]. As the heightened production of oxidative species and malfunction of 
various antioxidant proteins is a natural feature of the ageing brain[85], and as age is the most 
significant risk factor for PD, excessive oxidative stress has been implicated as a main 
contributor of neuronal damage in PD[79,86]. This is further supported by the naturally high 
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oxidative environment[87,88], and evidence of oxidatively modified nucleic acids in the 
primary brain region exhibiting degeneration in PD, the SN[89].  
Products of dopamine metabolism and mitochondria appear to be the main intracellular 
source of increased ROS and superoxide production in the PD brain[90]. Increases in oxidative 
stress markers identified in the human post-mortem PD brain include protein 
carbonylation[91,92], dopamine o-quinone formation[93], markers of lipid oxidation[94] and 
markers of DNA oxidation[95]. Meanwhile, reduced antioxidant activity of superoxide 
dismutase (SOD1)[96], catalase[97] and glutathione peroxidase[98,99] have also been reported in 
degenerating regions of the PD brain – suggesting a combination of overproduction and 
reduced elimination of these oxidative products produces oxidative stress in this disease. 
Oxidative stress-induced cell death is an indirect result of multiple pathways, primarily 
involving the activation of caspase, receptors, kinases and other components of both necrotic 
and apoptotic cell death pathways[100–102]. One of the primary oxidative stress-mediated cell 
death mechanisms is through mitochondrial dysfunction which readily leads to 
neuroinflammation, exacerbated oxidative and nitroxidative damage, and eventual apoptotic 
or caspase-independent cell death[101,103,104].  
1.3.4 Mitochondrial dysfunction in PD 
One characteristic distinguishing feature of neurons experiencing degeneration in PD, is their 
long branched axons and high number of transmitter release sites[21,105], reflecting a high 
demand for energy in the form of ATP[106]. The heightened basal mitochondrial respiration 
required of these dopaminergic neurons compared to their neighbouring, non-degenerating 
counterparts, elevates oxidative load and subsequently increases neuronal vulnerability[21,107]. 
Although other sources of ROS are likely to contribute to this highly oxidative environment, 
increased mitochondrial density and evidence of ROS originating from mitochondria[107] 
indicate an important role of mitochondrial oxidative stress in PD neuronal vulnerability.   
Mitochondria have essential functions for cellular health including energy formation, lipid 
and amino acid metabolism, calcium homeostasis and roles in free radical scavenging and 
programmed cell death[108]. To maintain functional integrity, mitochondria undergo frequent 
cycles of fusion whereby two mitochondria combine, and fission whereby long tubular 
mitochondria separate into multiple parts[108,109]. This is particularly important as damaged 
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mitochondria can regain functionality following fusion with functional mitochondria[108], and 
damaged mitochondria can be removed by fission[110]. Numerous PD-associated genes 
encode proteins involved in mitochondrial processes or mitophagy, and mutations in these 
genes have elucidated potential pathogenic pathways involved in the disease process, 
highlighting aspects of mitochondrial function requiring investigation in sporadic forms of 
the disease (Figure 4).  
Mitochondrial fidelity and quality control is maintained by an interplay between PTEN-
induced kinase 1 (PINK1) and Parkin, with PINK1 responsible for detecting mitochondrial 
dysfunction and Parkin involved in its removal[111,112]. Mutations in both Parkin and PINK1 
are the most common causes of autosomal recessive PD, and present with mitochondrial 
dysfunction[111,113]. Mutations in SNCA, a gene encoding a-synuclein produce dominant 
early-onset PD[114] characterised by mitochondrial fragmentation, fusion-fission, transport 
impairment and mitophagy[113,115]. Mutations in another gene involved in mitochondrial 
regulation, LRRK2, are implicated in a late-onset form of autosomal dominant PD[116] and are 
currently the most common genetic cause of both familial and sporadic PD[117]. LRRK2 
mutations can induce mitochondrial fragmentation[118,119], impaired function and 
morphology[120] and present with diverse neuropathological features. 
Mutations in the gene PARK7 encoding protein deglycase 1, have been associated with 
recessive early-onset PD[121]. A multifunctional protein, protein deglycase 1 is proposed to 
play a role in mitochondrial function[122] with a reported role in the maintenance of complex I 
activity[123], modulating mitochondrial dynamics[124,125] and rescuing PINK1 loss of 
function[126]. Protein deglycase 1 is also suggested to act as an antioxidant, as its expression is 
increased with oxidative stress[127]; and is proposed to act as an oxidative stress sensor, 
altering gene expression of antioxidant components accordingly[128,129]. Another 
mitochondrial regulator specifically involved in mitochondrial fusion, vacuolar sorting 
protein-associated protein 35, exhibits PD-associated mutations that impair 
lysosomal/autophagy pathway[130], producing fragmented and functionally impaired 
mitochondria[131]. 
Complex 1 is the initial, and largest enzyme complex of the mitochondrial respiratory chain 
and is involved in the transfer of electrons from nicotinamide adenine dinucleotide phosphate 
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to ubiquinone for the eventual production of ATP and ROS. Dysfunction of complex 1 
activity in PD was first identified following the observation that MPP+, the product of MPTP 
oxidation, selectively inhibits complex 1 and subsequently induces dopaminergic neuronal 
death[132,133]. Another toxin-induced PD model rotenone also exhibits dopaminergic neuronal 
loss following complex 1 inhibition[134] – although dopaminergic neuronal death is reported 
to occur independently of complex I inhibition[135]. Oxidative damage to complex I subunits 
impairs complex I activity and subsequently reduces ATP synthesis[136]. Interestingly, this 
oxidative damage also produces a large amount of ROS, further exacerbating oxidative 
stress[137]. 
In PD patients, complex 1 activity is significantly reduced in the SN[138] and in platelets[139]. It 
is important to note however, that not all PD patients exhibit reductions in complex 1 activity, 
and it is therefore not suggested to be a sole contributor of the disease process[140]. Seventy 
percent of complex I activity inhibition is required before major alterations in ATP synthesis 
and oxygen consumption are observed[141], and only around a 25-30% reduction is identified 
in PD patients[142,143]. Despite an apparent role in PD aetiology, these data suggest complex 1 
inhibition alone is insufficient to cause neuronal death in PD.   
Cytochrome c oxidase also known as complex IV, is another component of the mitochondrial 
respiratory chain that has demonstrated impairment in PD. Cytochrome c oxidase activity is 
reduced in lymphocytes of PD patients compared with age-matched controls[144], however 
cytochrome c oxidase activity in the SN in PD is unchanged[145,146] despite normal age-related 
reductions[147]. Increased cytochrome c oxidase activity reported in MPTP models was 
reversed by L-DOPA treatment, suggesting any alterations in cytochrome c oxidase activity 
in PD patients may be masked by L-DOPA treatment[145]. Evidence of an interaction between 
a-synuclein and cytochrome c oxidase [148], supports further investigation of this
mitochondrial component and its potential role in the PD brain.
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Figure 1.3 Mitochondrial dysfunction in sporadic and familial Parkinson’s disease.   
Mitochondrial dysfunction in Parkinson’s disease includes altered mitophagy, morphology, 
impaired fusion, fission and complex I activity, and increased ROS production via the 
mitochondrial respiratory chain. These numerous impairments arise from exposure to toxins 
such as MPTP in murine models of disease, mutations resulting in familial PD, and from 
unknown causes in sporadic PD. MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; DJ-1: 
Protein declygase 1; LRRK2: Leucine-rich repeat kinase 2; PINK1: phosphatase and tensin 
homolog (PTEN)-induced putative kinase 1; VPS35: Vacuolar protein sorting-associated 
protein 35; IMS: intramitochondrial space; NAD: Nicotinamide adenine dinucleotide; ATP: 
adenosine triphosphate; ADP: adenosine diphosphate; FAD: flavin adenine dinucleotide.  
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1.4 Essential biometals and PD neuronal vulnerability 
1.4.1 Copper 
Cu is transported into the brain as a free ion across both the blood brain barrier and the blood-
cerebrospinal fluid barrier[149,150]. The blood-brain barrier is the main determinant of Cu 
influx into the brain, whilst the blood-cerebrospinal fluid barrier is mainly responsible for 
export into extracellular fluid first via the cerebrospinal fluid, before being exported into the 
blood[151]. The choroid plexus also plays an important role in Cu homeostasis, with the 
predominant Cu transporter, Cu transporter 1 (Ctr1) enriched in this region[149,152] and 
demonstrated to upregulate under Cu deficient conditions[152]. A role for the transport of Cu 
from periphery to brain is also suggested as exposure to a high Cu diet produces an 
overexpression of Ctr1 on brain capillary endothelial cells and choroid epithelial cells[153].  
1.4.2 Cu metabolism 
Cu concentration and distribution is tightly restricted by Cu-regulatory proteins, which bind 
most soluble or cytosolic Cu. Maintaining sufficient Cu is essential as it is a key cofactor for 
numerous metalloproteins, however excess Cu can be detrimental as it can participate in free 
radical chemistry. In the blood plasma, Cu is predominantly bound to ceruloplasmin and 
around 10% is bound to albumin[154]. Ceruloplasmin is a cytosolic multi-Cu enzyme involved 
in the cellular Fe efflux pathway via ferroxidase activity involving Fe(II) oxidation to Fe(III) 
– a process necessary for the subsequent interaction of Fe with transferrin receptor[155–157].
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Figure 1.4 Intraneuronal Cu metabolism in Parkinson’s disease.  
Cu predominantly exists in the body bound to either ceruloplasmin or metallothionein (MT) 
which then release Cu(I) for transport across the membrane via the main Cu transporter 1 
(Ctr1). Cu transporter 2 (Ctr2) and Divalent metal transporter 1 (DMT1) also mediate Cu 
transport across the neuronal membrane. Intracellular Cu(I) binds to MT and glutathione 
(GSH) before being trafficked to higher affinity chaperones such as Cytochrome c oxidase 
chaperone (COX17), antioxidant protein 1 (Atox1), copper chaperone for SOD1 (CCS) and 
various cuproenzymes. COX17 delivers Cu to the mitochondrial cochaperones Sco1 and 
Sco2, which then transfers Cu(I) to cytochrome c oxidase (CCO) for respiratory chain 
function. Atox1 delivers Cu(I) to the Trans-golgi network via ATP7A and ATP7B, while 
superoxide dismutase 1 (SOD1) acquires Cu(I) through an interaction with CCS. Intracellular 
Cu also binds to Neuromelanin or various cuproenzymes before cellular export via ATP7A. 
Cu(I) then binds to ceruloplasmin for transport and ferroxidase activity. Cu homeostasis is 
altered in Parkinson’s disease, with reduced intracellular Cu, Ctr1 expression, Ceruloplasmin 
activity, reduced glutathione (GSH) levels, binding to neuromelanin and COX17. Cu binding 
to SOD1 is also reduced, implicating a reduction in Cu binding to CCS.  
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Although predominantly synthesised in the liver, brain ceruloplasmin is synthesised by 
astrocytes and can exert antioxidant activity through the direct scavenging of hydrogen 
peroxide[158,159] and inhibition of superoxide-induced lipid peroxidation[160].  
Ceruloplasmin can also act as an amine oxidase, anti-inflammatory, nitric oxidase and 
glutathione peroxidase[161]. Despite these other suggested roles, the predominant function of 
ceruloplasmin is in Fe metabolism – as highlighted in the neurodegenerative disorder 
aceruloplasminemia, a rare genetic disorder affecting ceruloplasmin and resulting in cellular 
Fe accumulation[162,163]. Presenting with Fe deposition in most brain and visceral organs, 
aceruloplasminemia is associated with neurodegeneration and parkinsonian symptoms[164], 
which are alleviated following Fe chelation[165–167].  
Metallothioneins are cysteine rich, low molecular weight proteins, capable of binding up to 7 
divalent metal ions in metal-thiolate complexes[168]. Although predominantly associated with 
Zn, the high affinity of metallothionein for Cu suggests a role in Cu homeostasis[169]. 
Metallothionein, along with reduced glutathione is suggested to immediately bind excess Cu 
for storage and buffering to avoid free intracellular Cu[170]. Increased metallothionein 
expression is observed in the bovine brain following brain Cu elevation[171], suggesting 
another role for metallothionein in neuroprotection against Cu-toxicity – however this is yet 
to be investigated in the human brain.  
1.4.3 Cu transport 
Intracellular Cu transport is predominantly mediated by Ctr1[172], a homotrimeric polypeptide 
that forms a pore in the cellular membrane to allow the passage of Cu+[173–175]. This process 
is regulated by Cu-dependent internalisation and recycling of Ctr1 to the plasma 
membrane[176]. Ctr1 is expressed ubiquitously in the human brain with high expression on the 
apical surface of the choroid plexus, within neuronal cytoplasm of visual cortex, ACC, 
caudate and putamen and, also in association with neuromelanin granules in dopaminergic 
neurons of the SN pars compacta[177]. Ctr2 and divalent metal ion transporter 1 (DMT1) are 
suggested alternative intracellular Cu transporters, however their role in Cu homeostasis is 
unclear[178,179] 
Intracellular Cu homeostasis is regulated by multiple Cu chaperones including antioxidant 
protein 1, a small cytosolic protein involved in facilitating Cu transfer to the ATP-ase type 
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transporters ATP7A/B in the trans-Golgi network[180,181](Figure 2). ATP7A and ATP7B are 
large transmembrane proteins with 6 Cu-binding motifs employed for the transfer of Cu 
across cellular membranes into the secretory pathway for metalation of various  
cuproproteins[182], achieved by exploiting energy generated through ATP-hydrolysis[183]. No 
correlation exists however, between ATP7A, AT7B and Cu levels in the human brain[184]. 
Copper transporter for cytochrome c oxidase (COX17), is involved in transport of Cu to the 
mitochondrial respiratory chain, and Cu chaperone for SOD1 (CCS) is the predominant form 
of Cu delivery to the antioxidant protein SOD1[185,186].   
1.4.4 Cu delivery to SOD1 
The delivery of Cu to SOD1 is a key process in SOD1 maturation, and predominantly occurs 
via an interaction with CCS (Figure 4). CCS is a homodimer with each monomer comprised 
of three distinct domains. Domain 1 is structurally comparable to antioxidant protein 1, with 
a similar metal-binding loop, however contains two disulphide bonds instead of the one 
identified in antioxidant protein-1[187]. Domain 2 resembles SOD1, with 6 of 7 metal binding 
residues conserved. Despite this, with an absent extended loop region and altered metal 
binding residues, it is proposed that domain 1, not domain 2, binds Cu. Domain 2 is instead 
proposed be involved in the interaction between monomers and forming the dimer 
interface[187], and play a main role in the CCS-SOD1 interaction[188]. Domain 3 is proposed to 
act as an oxidoreductase[189].  
Each domain 2 monomer of dimeric apo-CCS binds a Zn ion to enhance protein stability[190] 
– though the mechanism of Zn acquisition is yet to be characterised. Ctr1, reduced
glutathione or antioxidant protein 1 are demonstrated to deliver Cu in vitro, which is inserted
into the Cu-binding motifs of domain 1 or, to a lesser extent, domain 3[188,191]. Cu acquisition
then promotes the dissociation of CCS into holo-monomers for interaction with a Zn-bound
monomeric SOD1 – forming a SOD1-CCS heterodimer via the domain 2 subunit[188].
Following SOD1-CCS dimer formation, domain 3 undergoes conformation changes allowing
the translocation of Cu to the SOD1 Cu-binding site, and the dissociation of CCS and SOD1
to trigger the formation of the more thermodynamically favourable SOD1 homodimer[192].
Although CCS was initially believed to be the only form of Cu delivery to SOD1[193], 15-20%
SOD1 function in CCS knockout models indicated a CCS-independent form of Cu delivery to
SOD1[194]. In addition to CCS-independent SOD1 Cu delivery, CCS-independent disulphide
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oxidation of SOD1 has also been identified[195]. This demonstrates that although CCS is the 
predominant mechanism of SOD1 maturation, under Cu and CCS-depletion, other pathways 
such as reduced glutathione, protein deglycase 1 and metallothionein have emerged as 
possible candidates[196–198].  
Containing two Cu-binding sites, protein deglycase 1 is demonstrated to increase SOD1 
maturation of Cu-deficient SOD1 in vitro[196], and directly interact with SOD1[199]– indicating 
a possible role as a Cu chaperone for SOD1 under certain conditions. As protein deglycase 1 
plays an important role in regulating mitochondrial activity and mitigating oxidative damage, 
its correct functioning is crucial for normal neuronal function, and its potential alteration in 
the PD brain requires further investigation. Reduced glutathione has also been implicated as 
an intermediary Cu chaperone, with evidence of Cu acquisition from Ctr1 and delivery to 
higher affinity Cu binding sites of intracellular Cu-dependent proteins[170,200]. Reduced 
glutathione levels compared with its oxidised counterpart have been identified in the human 
PD brain[201]. The role of reduced glutathione in impaired Cu homeostasis in the PD brain is 
however, yet to be investigated.  
1.4.5 Disorders of altered brain Cu metabolism 
The tight regulation of Cu in the brain is crucial for normal neuronal function as Cu is 
involved in multiple neuronal pathways and also exhibits a unique redox potential that can be 
detrimental when unregulated. Disruptions in Cu homeostasis result in a cascade of 
deleterious events for cellular health. The detrimental effect of Cu accumulation is 
highlighted in Wilson’s disease, an autosomal recessive condition attributed to predominantly 
loss-of-function mutations in the gene responsible for encoding an essential Cu transporter 
ATP7A[202,203]. Wilson’s disease is characterised by accumulation of Cu in hepatic and 
neuronal tissues – specifically in the basal ganglia[204] resulting from impaired efflux of Cu 
into bile for excretion [205]. Although presenting with some motor symptoms overlapping with 
those in PD such as tremor, dystonia and dysarthria, the atrophy and structural changes are 
not specific to a brain region, but occur throughout the brain as a result of widespread Cu and 
Fe accumulation[206,207].  
Although neurotoxic in excess, reduced bioavailability of Cu is also detrimental to cellular 
health. An essential component of mitochondrial respiration, marked Cu deficiency severely 
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affects mitochondrial function, morphology[208] and cytochrome c oxidase activities[209] – 
eventuating in neuronal death via apoptotic mitochondrial pathways[210]. Cu deficiency can 
also exacerbate oxidative stress through affecting SOD1 antioxidant properties[209], and 
through impairing ferroxidase function via ceruloplasmin – subsequently elevating redox 
active Fe[211]. The effects of Cu deficiency are exemplified in Menke’s disease, a fatal X-
linked recessive disorder resulting from mutations in the gene encoding another ATPase 
transporter, ATP7A[212]. The resulting impairment of Cu transport across the basolateral 
membrane, reduces brain Cu[213] and therefore reduces Cu supply to Cu-dependent 
enzymes[214]. In addition to impaired neurodevelopment resulting from reduced Cu 
bioavailability, extensive neurodegeneration – particularly of grey matter – ensues, producing 
cerebral and cerebellar atrophy[212], and eventually resulting in death around 3 years of 
age[215]. These disorders emphasise the importance of tight Cu regulation in the brain, and the 
detrimental effects of Cu dyshomeostasis.  
 
1.4.6 Cu alterations in Parkinson’s disease  
 
The first observations of reduced Cu in the PD brain arose in 1987 with Dexter et al., 
demonstrating a 34% reduction in the degenerating SN[216]. Since then, reports of Cu 
alterations in the PD brain have been conflicting, with some reporting reductions[159,177,217,218] 
and others no difference[219–221] when compared with healthy aged controls. These 
discrepancies may be attributed to inconsistencies in methodological approaches or diverse 
PD cohorts. A meta-analysis of data from currently available studies would be valuable to 
assess the level of evidence for changes in Cu levels within the SN of the PD brain. Similarly 
levels of Cu in PD blood and cerebrospinal fluid are under contention, with reports of 
increases[222,223], decreases [224–227] and no change[228–232] when compared with healthy 
controls. Again, this could be attributed to variations in methodology, however as biometals 
in biofluids are influenced by a variety of factors, variation in levels in PD patients may 
indicate that biometals in blood and cerebrospinal fluid are not an accurate representation of 
more central disease processes occurring in the degenerating PD brain.  
 
Reductions of Cu in vulnerable regions of the PD brain, are suggested to precede neuronal 
loss in this disorder, with evidence of marked Cu reductions in incidental Lewy body 
disease[177], a disorder suggested to represent preclinical PD[233]. This has implications for the 
aetiology of PD, with these early Cu changes potentially representing initial stages of PD. 
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Marked reductions in Cu are also identified in morphologically healthy, neuromelanised 
neurons within the SN in PD, suggesting that these changes are not a secondary process of 
PD pathogenesis[234]. As these changes are not observed in the degenerating regions of the 
Alzheimer’s disease brain[234], it is likely that Cu alterations are not merely a product of 
neurodegeneration – suggesting reduced Cu is a feature associated with PD aetiology. The 
high specificity of Cu depletion and neuronal loss in PD, further supports the hypothesis that 
Cu deficiency plays a role in cell death – although the mechanisms underlying this pathway 
are yet to be identified. Determining the specific subcellular compartment where these 
changes occur within degenerating brain regions would help elucidate the potential causes 
and consequences of Cu deficiency in the PD brain. Further, analysing the quality and 
strength of data on Cu levels in PD through meta-analysis would unequivocally determine 
whether Cu is altered in PD, and whether this is restricted to the degenerating brain region.  
1.4.7 Alterations in Cu proteins in Parkinson’s disease 
As Cu is involved in many cellular processes, determining the effects of alterations in the 
distribution, expression and Cu-binding capacity of various Cu-associated proteins and 
transporters is key in understanding Cu-associated dysfunction in the PD brain. The 
predominant intracellular Cu transporter Ctr1 is depleted specifically in sites of neuronal loss 
in the PD brain and this becomes more marked with longer disease duration and greater cell 
loss[177]. This suggests that Cu and Ctr1 levels may be depleted due to impaired Cu delivery 
to these regions of the PD brain. Other Cu transporters such as ATP7A, ATP7B and 
antioxidant protein 1 appear to have an unaltered distribution in the PD brain[177], however 
their levels, activity and metalation are yet to be investigated.  
Reduction of intracellular Cu and a subsequent lack of Cu bioavailability for the 
mitochondrial Cu chaperone COX17 is proposed to account for the reduced cytochrome c 
oxidase activity reported within the mitochondrial respiratory chain of degenerating regions 
of the PD brain[235]. Reduced cytochrome c oxidase increases ROS production, ultimately 
leading to mitochondria-mediated apoptotic neurodegeneration[236]. Despite strong evidence 
for mitochondrial dysfunction in PD, the specific activity and metalation of cytochrome c 
oxidase and its respective chaperones COX17, Sco1 and Sco2 in PD has been little 
investigated, with only reduced activity recorded in PD platelets[237] and no studies conducted 
in the human SN. With a marked Cu reduction in the degenerating SN, determining the Cu-
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metalation and transferal of Cu from these chaperones may indicate which Cu associated 
pathways are affected in PD.  
1.5 Fe 
1.5.1 Brain Fe metabolism 
Fe is an essential metal in biological systems, and predominantly exists as Fe2+ and Fe3+ 
within the body. Transferrin, the major Fe transporter binds around 99% of circulating Fe and 
is responsible for Fe trafficking into and out of the brain, whilst the remaining 1% of Fe 
exists as non-transferrin bound Fe[238]. As Fe2+ is highly reactive, ferroxidases such as 
ceruloplasmin oxidise this form to the less harmful Fe3+ to minimise Fe-induced cellular 
damage. Ceruloplasmin is also involved in releasing Fe from various cells and transporting 
circulating Fe[239]. Ferritin is the major Fe storage protein in the body, with free Fe rapidly 
sequestered by ferritin to prevent Fe overload and Fe-mediated toxicity[240]. Composed of a 
light and heavy chain, ferritin is able to bind and store numerous ferric ions and increases 
expression in response to increased Fe[240]. Fe enters cells through transferrin receptor 1, a 
dimeric membrane protein with high affinity for transferrin-bound Fe3+ which, upon binding, 
is endocytosed[241,242]. Once inside the cell, Fe can be distributed to mitochondria lysosome, 
or incorporated into Fe-containing proteins, with excess soluble Fe stored in ferritin[243]. 
Ferroportin exports Fe2+ into the bloodstream when required, where it is rapidly oxidised to 
Fe3+  for transport via transferrin[244](Figure 1.5). One of the most highly abundant metals in 
the brain, Fe plays a fundamental role in a variety of neuronal processes such as cellular 
energy production, neurotransmitter synthesis, and involvement in myelin production[245]. 
Brain Fe uptake mainly occurs via transferrin-transferrin receptor systems of the blood brain 
barrier[246], with astrocytes, neurons and other cells then able to take up Fe once inside the 
extracellular compartment[247]. 
1.5.2 Fe, oxidative stress and cell death mechanisms 
Free labile Fe is extremely redox active, and therefore exists only in small pools (<20µM) in 
the cytosol, mitochondrial matrix and lysosome where it is tightly regulated[248]. As both 
redox-active Fe pools and superoxide can directly produce toxic free radicals via Fenton and 
Haber-Weiss reactions, excess labile Fe and superoxide can directly exhibit neurotoxicity and 
therefore need to remain in check[249]. The direct and damaging effects of Fe accumulation is 
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evidenced in neuronal loss following the direct injection of Fe into rat brains[250]. Fe-
mediated cell death can occur via a variety of mechanisms, however additional stresses are 
often required to induce cell death[251], for example in programmed cell death, a process that 
occurs following increased ROS production generated by excess labile Fe[251,252]. The SN 
naturally has a high oxidative environment due to dopamine metabolism, neuromelanin, high 
Fe content and low antioxidant complement[5,253]. Further increases in labile Fe, and 
impairment in antioxidant exacerbate oxidative stress in this region in PD.  
Fe-induced cell death also occurs via an interaction of Fe with dopamine, which produces 
toxic quinone intermediates and leads to apoptosis[254,255]. Quinones alkylate protein thiol and 
amine groups, promoting protein oxidation in the presence of ROS, producing impaired 
cellular membrane integrity and eventuating in cell death[256]. Ferroptosis, is a newly 
characterised mechanism of regulated cell death involving lethal, Fe-catalysed lipid 
damage[257–260]. Although ferroptosis is yet to be demonstrated in neuronal death in the 
human PD brain, depleted levels of reduced glutathione[261] and increased labile Fe are 
characteristic features of both ferroptosis[262,263] and of PD[201]. With multiple cell death 
pathways induced by labile Fe, maintaining its tight regulation in the brain is crucial for 
cellular health.  
1.5.3 Disorders of disrupted Fe homeostasis 
The detrimental effect of Fe elevations in the brain are highlighted in multiple 
neurodegenerative diseases characterised by regional Fe deposition including 
Neurodegeneration with Brain Iron accumulation[264], Alzheimer’s disease[265,266], PD[218,267], 
and Freidreich’s ataxia[268] and animal models attempting to recapitulate these disorders[269–
271]. One of the best examples is Neurodegeneration with Brain Iron Accumulation, a 
heterogenous group of variously progressing neurodegenerative disorders associated with 
excess neuronal Fe[272] – often including the basal ganglia[273]. The predominant form of 
Neurodegeneration with Brain Iron Accumulation is Pantothenate kinase-associated 
neurodegeneration (PKAN), an autosomal recessive disorder arising from mutations of the 
PANK2 gene[274]. Ubiquitously expressed, PKAN2 encodes an essential enzyme for the 
biosynthesis of Coenzyme A, a crucial component of numerous metabolism pathways[274]. 
Defective PKAN2 function causes mitochondrial dysfunction[275], cellular oxidative stress 
and altered Fe homeostasis[276]. Interestingly, PKAN presents with many features typical of 
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PD including clinical manifestations of rigidity, tremor, and dystonia, as well as pathological 
features such as Lewy pathology and Fe deposition[277].   
1.5.4 Alterations of Fe in Parkinson’s disease 
Although the Neurodegeneration with Brain Iron Accumulation family of disorders are 
predominantly genetic, similarities between these disorders and PD have aided in our 
understanding of the detrimental effects of Fe dyshomeostasis on neuronal health. Despite the 
fact that Fe is naturally abundant in the basal ganglia and increases during the normal ageing 
process[278], reports as early as 1924[279] demonstrate further elevations in Fe in the basal 
ganglia of PD. The first study examining the SN specifically, demonstrated a 2-fold increase 
of Fe in formalin-fixed SN tissue of the PD brain when compared with control tissues[280]. 
Since then, elevations in Fe have been consistently reported in the degenerating SN of the PD 
brain in both fresh and fixed post-mortem tissues using various techniques including; 
spectrophotometry, inductively-coupled plasma mass spectrometry and X-ray fluorescence 
microscopy (XFM)[177,218,281]. This Fe elevation is reportedly restricted to the regions most 
vulnerable to degeneration – the SN pars compacta[282] and within neuromelanised neurons of 
the SN[177,283]. This suggests Fe elevations are specific to regions prone to degeneration in the 
PD brain. Reports of Fe alterations in the more accessible biofluids sera and cerebrospinal 
fluid of PD patients are inconsistent, with increases[230], decreases[224,227,284] and no change in 
Fe levels reported[232,285]. Investigating whether Fe is altered in biofluids and reflects the 
changes reported in central Fe levels will be an important step in determining their use as a 
biomarker for PD. 
Due to the association between Fe and neurodegeneration in the PD brain, detecting Fe 
changes in these regions in vivo using functional imaging has been a growing area of 
interest[286,287]. Advancements in imaging techniques have resulted in the ability to non-
invasively estimate Fe in vivo using R2/R2* relaxometry[288] and susceptibility-weighted 
imaging[289], confirming nigral Fe elevations in living PD patients[288–290]. Increased SN 
echogenicity as determined by transcranial ultrasound, has also been used as a tool to assess 
Fe by proxy, with increased echogenicity positively correlated with higher levels of Fe and 
ferritin[291]. Although many techniques exist to assess Fe content in both in vivo and in vitro, 
a recent meta-analysis confirmed elevations in nigral Fe in both post-mortem and intravitum 
functional imaging.[292]. With these changes only observed in the degenerating SN, and Fe 
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accumulation demonstrated to both directly and indirectly result in cell death, understanding 
the role of Fe deposition in the PD brain is an essential determinant in elucidating the 
underlying aetiology of this disorder.  
1.5.5 Potential sources of Fe accumulation in PD 
As ferritin is the predominant Fe storage protein, its impairment can result in increases in the 
redox active labile Fe pool. The crucial role of ferritin in the brain is exemplified in the basal 
ganglia disorder Neuroferritinopathy, a genetic disorder affecting ferritin protein stability[293]. 
Presenting with Fe deposition and progressive neurodegeneration of the basal ganglia causing  
movement disruption, this disorder draws multiple comparisons with PD pathogenesis[293,294].  
Despite consistent reports of increased Fe levels in the SN in PD, reports of ferritin in this 
region are conflicting[295], however most report reductions [296–298].  
Suggested pathways leading to Fe disruption include dysfunctional Fe regulatory proteins[298] 
and enhanced Fe release from ferritin – instigated by reactive chemical species such as 
superoxide, reduced glutathione and quinones[299]. Ferritin homeostasis may also be affected 
by oxidative stress, with ferritin heavy-chain synthesis activated by oxidative species, 
subsequently altering the relative abundance of heavy- to light- chain isoforms – an alteration 
that is observed in the SN in PD[300,301]. Reports of ferritin levels in serum have also been 
conflicting, with reductions[302] and elevations[303] both observed in PD and associated with 
disease stage and duration. Serum ferritin may therefore not be an accurate indication of 
changes in the central disease process. 
Altered Fe export is another avenue which may contribute to, or be affected by, Fe 
accumulation in the PD brain. Ferroportin – the only known Fe exporter, is reduced 
specifically in the SN, negatively correlating with Fe levels in MPTP[304] and 
lipopolysaccharide-induced PD models[305]. Studies of ferroportin levels in the human PD 
brain are essential and, as yet, have not been undertaken. 
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Figure 1.5 Neuronal Fe metabolism in Parkinson’s disease 
Fe enters the neuron as Fe(III) in a complex bound to transferrin and transferrin receptor 1 
(TfR1) which is internalised into an endosome. STEAP then reduces Fe(III) to Fe(II) before 
DMT1 transporting Fe(II) out of the endosome into a labile Fe pool. Fe(II) can then bind to 
neuromelanin, be transferred via transferrin to mitochondria, used in DNA synthesis and 
repair, form Fe-S clusters or be stored in ferritin. Fe is exported from the neuron via 
ferroportin where it is oxidised by ceruloplasmin into Fe(III). Intraneuronal Fe synthesis is 
regulated by IRP and IREs. In Parkinson’s disease, Intraneuronal labile Fe, mitochondrial Fe 
and Fe-bound to neuromelanin is elevated. TfR1: Transferrin receptor 1; STEAP: Six-
transmembrane epithelial antigen of the prostate; DMT1: divalent metal transporter 1; IRP: 
Iron regulatory protein; IRE: Iron regulatory element.  
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Transferrin is involved in Fe import and hepcidin regulation – which in turn controls the 
expression of ferroportin and Fe absorption and release[306]. Transferrin polymorphisms have 
been identified in late onset PD[307] and despite initial reports of no change in transferrin in 
the SN of sporadic PD[308], more recent evidence demonstrates both reduced transferrin 
levels[309] and diminished transferrin receptor binding in this diseased region[310]. Oxidised 
forms of transferrin are also dramatically increased in the SN in PD, and inversely correlated 
with tyrosine hydroxylase levels[311] – suggesting a role in the loss of dopamine and 
dopamine-containing neurons observed in PD. MPTP mice present with reduced transferrin 
levels and concurrent Fe elevation in the SN[309], however following subcutaneous transferrin 
supplementation, the facilitation of Fe export from the SN ameliorates motor deficits and 
normalises nigral Fe levels[309]. In addition to transferrin, Fe is also transported in the non-
protein-bound form via DMT1[312]. Interestingly, DMT1 mutations[313], and elevated DMT1 
levels[314] have been reported in the PD brain. DMT1 is upregulated in 6-hydroxydopamine 
models whilst both 6-hydroxydopamine and MPTP models of PD with mutated DMT1 
demonstrated impaired Fe transport and neuroprotective effects[314].  
As iron regulatory proteins are responsible for the regulation of transferrin, ferroportin and 
ferritin at the translational level, disruption to this signaling pathway could also affect Fe 
accumulation in the PD brain[315]. Interestingly, iron regulatory protein-2 knockdown  
produces dopaminergic neurodegeneration and motor deficits similar to those observed in PD 
including resting tremor, gait abnormalities and bradykinesia[316–318]. Currently, the only 
evidence for Fe regulatory protein dysfunction in the human PD brain is the identification of 
two Fe regulatory protein polymorphisms in PD patients[319]. It is important therefore to 
investigate the specific aspects of Fe metabolism that are altered in vulnerable regions of the 
human PD brain to better understand the causes and consequences of Fe accumulation in this 
disease. 
1.6 Zn 
1.6.1 Zn metabolism 
Zn is the second most abundant metal in living organisms after Fe, and plays an essential role 
in multiple homeostatic, immune and neuromodulatory functions[320]. Zn is absorbed by 
intestinal epithelial cells and around 70% is loosely bound to albumin, with most remaining 
Zn bound to a2-macroglobulin in the blood[321]. In the CNS, the gray matter of the forebrain, 
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and the limbic system, including hippocampal dentate neurons contain the highest 
concentration of Zn[322]. In the brain, most Zn is tightly bound to proteins[323], but about 10-
15% exists free, in cytoplasm or in presynaptic vesicles[324,325]. When released, Zn modulates 
excitatory post-synaptic receptors – predominantly via N-methyl-D-aspartate-specific 
receptors[326,327]. The tight regulation of intracellular Zn homeostasis is therefore necessary to 
ensure that adequate free Zn is available to occupy Zn metalloprotein binding sites, yet not 
exceed a concentration whereby Zn displaces lower affinity divalent cations such as Ni and 
Co from essential metalloproteins[328] 
Being the most abundant trace metal in the brain, Zn is a cofactor for numerous essential 
proteins including DNA recognition Zn finger proteins[322]. Two main solute carrier families, 
SLC30 and SLC39 are responsible for maintaining cellular Zn homeostasis[329], with the 14 
members of the ZIP/SLC39 family involved in increasing cytosolic Zn levels, and the 10 
subforms of ZnT/SLC30 family facilitators of cellular Zn efflux[330]. Although initially 
believed to be involved in Zn transport, human DMT1 does not mediate significant Zn 
transport[331]. Most ZnT transporters form homodimers and consist of 6 transmembrane 
domains each containing a Zn binding site[332], with the exception of ZnT5 and ZnT6 which 
form heterodimers which do not contain a Zn binding site[332,333]. ZnT5 is also unique in that 
it contains an extra 9 fused transmembrane domains[334]. Various stimuli influence ZnT 
expression transcriptionally and post-translationally such as Zn levels[330,335], hormones and 
cytokines[336,337]. Intracellular ZnT transporter expression however, is mediated by a Zn-
sensing transcription factor termed then metal regulatory transcription factor-1[338,339]. 
Cellular distribution of ZnT transporters is dependent on extracellular Zn concentrations[332]. 
The ZnT3 isoform is responsible for accumulation of Zn in vesicles[340,341]. In contrast to ZnT 
transporters, little is known regarding the specific structure and functioning mechanisms of 
ZIP transporters, however, they are generally known to uptake cytosolic Zn from the 
extracellular space[336]. They are suggested to have 8 transmembrane domains and form 
homodimers to facilitate Zn across the cell membrane[342].  
In the CNS, Zn is involved in synaptic neurotransmission and the modulation of most ion 
channels including ligand gated ion channels, Zn-specific receptors[343] and N-methyl-D-
aspartate receptors – which are the most sensitive to extracellular Zn concentration[344]. As 
high Zn concentrations are toxic, once released into the extracellular space, ZIP transporters 
rapidly reuptake Zn into neuronal and glial cells[336]. Intracellular Zn transporters such as 
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ZnT3 and ZnT3 mediate intracellular Zn concentrations, however the majority exists in the 
inactive form bound to the cysteine rich metallothionein family, which buffer up to seven 
ions[328].  
Metallothioneins can bind up to 7 Zn ions in two Zn-thiolate clusters – one with 3 Zn and 9 
cysteines, and the other with 4 ions and 11 cysteines. These ions are bound with varying 
affinity; one bound weakly, two with intermediate and four with high affinity[345]. As not all 
sites of metallothionein are fully occupied at a given time[168], the structure and redox state of 
metallothionein is dependent on the availability of Zn ions, as the more Zn is bound, the less 
reactive metallothionein is towards thiol-oxidising agents[346]. Metallothioneins also buffer 
Zn, providing a labile pool to Zn-associated proteins under Zn-depleted conditions[345,347].  In 
addition to Zn trafficking functions, metallothioneins are also suggested to have antioxidant 
properties and detoxify heavy metals such as cadmium and mercury[169]. Reduced glutathione 
can also bind Zn with relatively low affinity[348], and can modulate Zn transfer from 
metallothioneins[349].  
Zn ions also transiently bind to many proteins involved in cellular Zn re-distribution, 
however these proteins are not recognised as Zn proteins[350]. Some of these are Zn sensors 
such as the metal response element of metal regulatory transcription factor-1[351], a Zn finger 
transcription factor that regulates Zn levels via the regulation of metallothionein[351,352]. Metal 
regulatory transcription factor-1 is another Zn finger protein that is responsible for the 
regulation of ZnT1 and ZnT2 transcription[339], and repression of Zip10[353]. Zn transporter 
expression is also reportedly regulated by another Zn finger transcription factor ZNF658[354].  
1.6.2 Zn in PD 
Conflicting evidence has been reported regarding Zn alterations in PD, with some studies in 
human post-mortem SN reporting an increase[355,356], and some no change[357,358]. As 
previously mentioned with regards to Cu and Fe, these discrepancies may represent natural 
variations in these levels due to a variety of sample-related factors, such as subject age and 
disease severity, or may reflect inconsistencies in methodological approaches in biometal 
analysis of human tissues. An analysis of the strength of evidence and quality of studies using 
meta-analysis would provide more conclusive evidence as to whether Zn is altered in the PD 
brain. Alterations in Zn have also been associated with PD comorbidities such as psychotic 
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complications and depression[359], and increased reporting of visual, olfactory and taste 
problems[360]. With a multifarious role in the brain, impaired Zn homeostasis would impact 
numerous processes including the Zn-associated proteins metallothionein and SOD1, and 
their respective pathways. Further, excess free Zn is demonstrated to exert neurotoxicity 
(especially to postsynaptic neurons), which arises in part due to interference with Cu 
uptake[361], whilst depletion of intracellular Zn also induces neuronal death via apoptosis[362]. 
The detrimental effects of Zn disruption necessitate a more comprehensive understanding of 
its potential alteration in PD brain to elucidate potential Zn-associated pathways that may 
contribute to PD aetiology.  
1.7 Mn in PD 
Due to the similarities between Mn induced parkinsonism (manganism) and PD[363], it was 
suggested that Mn exposure may be a risk factor for PD – although multiple studies have 
failed to identify an association[364,365]. Despite a similar phenotype, patients with manganism 
do not exhibit degeneration of midbrain dopaminergic neurons characteristic of PD – 
indicating that it is a distinct, yet clinically similar disorder to PD[366,367]. The accumulation of 
Mn in the brain is neurotoxic[368,369], and its interaction with dopamine promotes the 
formation of toxic semiquinones[370]. Despite this, post-mortem analysis of the SN and other 
striatal regions of idiopathic PD patients have found no significant elevation in Mn levels in 
these regions when compared with controls[297]. Reports of Mn levels in PD serum and 
cerebrospinal fluid have been conflicting however[371–373], and thus further investigation into 
Mn homeostasis in PD is required. 
1.8 Metalloprotein dysfunction in PD 
As the homeostasis of certain biometals appears altered in the PD brain, it is important to 
determine the subsequent effect of these biometal alterations on the numerous 
metalloproteins that are dependent on these metals. The aforementioned Cu-binding, 
ferroxidase protein ceruloplasmin, has demonstrated impairment in PD. Ceruloplasmin 
activity in cerebrospinal fluid of PD patients is reportedly reduced[374], while ceruloplasmin 
concentration and oxidative activity in PD serum is reduced and continues to reduce with 
disease duration[375]. Ceruloplasmin levels are increased in the SN in PD by up to 90%[376] – 
although this may occur in response to an increased demand for ferroxidase activity resulting 
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from elevated Fe in this region[375]. Despite this increase, ceruloplasmin activity is reported to 
decrease by ~80% in this degenerating brain region, subsequently affecting Fe 
homeostasis[377]. Interestingly, ceruloplasmin knockout mice develop parkinsonism which 
can be rescued by Fe chelation[378], implicating a role for ceruloplasmin in pathogenic Fe 
elevations in degenerating regions of the PD brain.  
Glutathione is an abundant Cu-binding tripeptide suggested to play an intermediate role in Cu 
homeostasis, via the regulation of antioxidant protein-1-Cu binding affinity[379], redox 
state[379], and Cu delivery to antioxidant protein-1[380]. Depleted levels of reduced glutathione  
decrease cellular Cu import by Ctr1[170], suggesting this enzyme may be affected by, or 
contribute to alterations in Cu metabolism within the PD brain. Interestingly reduced 
glutathione also plays a role in Zn metabolism by modulating the transfer of Zn from 
metallothioneins under certain conditions[349]. Reports of glutathione dysfunction in PD have 
focused on impaired antioxidant activity potentially contributing to oxidative stress observed 
in this disease[381,382]. Glutathione levels are reported to increase in PD serum[383], however 
this is not reflected in the brain, with consistent reports of depletions of reduced glutathione 
within the SN – reducing the ratio of the reduced to oxidsed form[384]. Interestingly, depleted 
levels of reduced glutathione is reportedly correlated with PD severity and appears prior to 
other disease hallmarks[140].  
Metallothioneins are multifarious proteins capable of binding numerous metals[345], 
predominantly Cu, Zn and Cd [385]. Metallothionein-I and metallothionein-II isoforms are 
ubiquitously expressed and structurally and functionally very similar, while metallothionein-
III is a neuronal specific isoform that binds Cu and Zn with the main function of inhibiting 
neuronal growth[386]. Despite various roles for metallothionein-I/IIs including antioxidant 
properties and heavy metal detoxification, they are proposed to play a critical role in both Zn 
and Cu homeostasis[387]. Metallothionein-I/IIs sequester Zn and release it as required, acting 
as a Zn ‘sink’[168]. The metalation, distribution and expression of the various metallothionein 
isoforms in PD and relevant models has been little investigated. Reduction in striatal 
metallothionein-I/II levels has been demonstrated in 6-hydroxydopamine mice[388], whilst 
metallothionein-I/IIs knock-out mice demonstrate an increased susceptibility to MPTP 
associated parkinsonism[389]. Currently, only one investigation of metallothioneins in the 
human brain has been conducted, with alterations in several metallothionein isoforms 
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reported in various PD brain regions[390]. Increases in multiple metallothionein-1 sub-
isoforms, and metallothionein-IIA was identified in PD in the SN and frontal cortex, whilst 
metallothionein-III was upregulated in the SN, yet not the cortex[390]. With a major role in Cu 
and Zn homeostasis, and reported antioxidant properties, the potential role of metallothionein 
in PD aetiology is still an important avenue of research.   
1.8.1 SOD1 in PD 
SOD1 is another Cu-dependent protein that has received little attention in PD. Co-localisation 
of SOD1 in Lewy aggregates was the first indication of impaired SOD1 in the PD brain[391]. 
Increased SOD1 expression in the PD brain has since been reported and is proposed to occur 
in an attempt to mitigate oxidative stress in vulnerable regions[392]. Oxidative modifications 
of SOD1 and increased levels of the more acidic SOD1 isoform have been identified in the 
PD brain when compared with healthy aged controls[392]. Evidence of SOD1 activity in the 
SN in PD have been conflicting, with increased cytosolic, and normal mitochondrial SOD 
(SOD2) activity reported[393], whilst others have reported increased mitochondrial SOD2 
activity with normal SOD1 cytosolic activity[394]. SOD1 activity in erythrocytes is reported to 
be significantly lower than age- and sex-matched controls[157], and further decrease with PD 
disease duration – suggesting impaired antioxidant activity as a contributor to oxidative stress 
pathways in PD[395]. No SOD1 mutations have been reported in PD patients where SOD1 is 
altered, indicating these are alterations to the wild-type protein[396]. 
Recently, I co-authored an article reporting, for the first time, abnormal aggregations of the 
antioxidant protein SOD1 in the PD brain, distinct from Lewy pathology also identified in the 
same region[397]. In the PD brain, these aggregates are characterised by deposits of misfolded, 
wild-type SOD1, are rich in ubiquitin and the aforementioned chaperone CCS and, unlike 
Lewy pathology, they do not contain high levels of a-synuclein, and are not of amyloid 
nature[397]. This novel pathology follows the pattern of cell loss in the human PD brain, 
suggesting an aetiological link to PD. As this is a novel pathology, further examination into 
its role in PD aetiology is needed.  
SOD1 is a small intracellular protein of the immunoglobulin superfamily, responsible for 
transforming toxic superoxide radicals into the less harmful hydrogen peroxide species. In 
human neurons, SOD1 exists in various maturation states of metal-free (apo-), partially-
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metallated and fully metallated (holo-) forms[398]. Maturation into the fully functional form of 
the protein occurs following precise post-translational modifications to the monomeric forms 
of the protein – producing a homodimeric, extremely stable structure[399](Figure 3). 
Monomeric SOD1 folds into a b-barrel, producing two large loops termed the electrostatic 
loop and metal-binding loop[399]. Residues within the metal-binding loop form a stable 
disulphide bond between the two monomers[400]. SOD1 maturation is initiated by Zn binding 
and coordination into a tetrahedral arrangement within the metal-binding loops, however the 
specific process behind this is largely unknown[401]. Cu insertion into the active site of the 
protein subsequently occurs through a well-defined and highly complex interaction with CCS 
protein – conferring further structural stability via the facilitation of disulphide bond 
formation[402]. Despite CCS being the predominant Cu insertion mechanism and final step in 
the SOD1 maturation pathway, an as of yet unidentified CCS-independent pathway has also 
been reported[198,403]. Despite the structural stability of mature SOD1, the identified 
misfolding, and subsequent aggregation of this protein within the PD brain indicates 
dysfunction in this maturation pathway, which is likely to implicate monomeric SOD1 being 
the less stable form[404,405].  
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Figure 1.6. CCS-dependent SOD1 maturation pathway  
Monomeric, apo (E,E-) SOD1 incorporates Zn through an unknown mechanism. Zn binds 
transiently to Cu-binding site which triggers the formation of Zn-binding site and migration 
of Zn to this site (E, Zn-SOD1). Zn-biding triggers dimerization and promotes the interaction 
with CCS. Dimeric Zn-bound CCS (E, Zn-CCS) acquires Cu via domain 1 (D1) and a direct 
interaction with Ctr1 or Cu chaperones. The formation of intra-monomeric disulphide bond 
(S-S) is then triggered within domain 3 (D2) of CCS resulting in dimer dissociation. 
Monomeric holo CCS (Cu, Zn-CCS) then interacts with Zn-bound monomeric SOD1 (E, Zn-
SOD1) to form SOD1-CCS heterodimer. A conformational change then occurs to transfer Cu 
from D1 of CCS to SOD1 Cu-binding site. A disulphide bond to Cys146 within SOD1 then 
occurs, triggering the formation of an intra-monomeric disulphide bond. CCS and SOD1 then 
dissociate, allowing the dimerization of holo (Cu,Zn-SOD1). Figure adapted from Trist et al., 
2020 (submitted manuscript). 
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1.9 Lessons from shared molecular mechanisms 
SOD1 aggregates have long been associated with familial forms of another 
neurodegenerative disorder, amyotrophic lateral sclerosis (ALS), and thus, the literature 
regarding the structure, function and dysfunction in this disorder is comprehensive. Applying 
this information may aid in elucidating factors affecting antioxidant function, protein 
misfolding pathways and potential mechanisms of neurotoxicity of SOD1 in the substantia 
nigra in PD.   
Figure 1.7. Immunohistochemical comparison of SOD1 aggregates in the PD brain (A) 
and ALS spinal cord (B). In both the PD brain and ALS spinal cord, aggregates contain 
superoxide dismutase 1(SOD1) and Ubiquitin (Ub) but are immunonegative for 
phosphorylated alpha-synuclein (ps129). Adapted from Trist et al. 2017[397]. 
Over 200 mutations in the gene encoding SOD1 have been associated with familial forms of 
ALS, contributing to about 2% of all ALS cases[406] (http://alsod.iop.kcl.ac.uk). Metal-
binding region mutants are one class of mutations characterised by altered metal binding and 
subsequently impaired disulphide formation that has a strong destabilising effect on the 
protein and results in immature forms and aggregates[407,408]. On the other hand, wild-type 
like mutants typically retain their metal status[408–410], however may present with impaired 
dimerization and reduced enzymatic activity [404,408,411,412]. SOD1 inclusions are identified in a 
high density in degenerating regions of the spinal cord in SOD1-mutant ALS patients, and 
have also been identified in sporadic forms of the disease[413–415], despite conflicting data 
reporting a lack of SOD1 inclusions in sporadic ALS patients[416].  
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In sporadic ALS, post-translational modifications of wild-type SOD1 have been implicated in 
SOD1 aggregation[417,418] and impaired antioxidant capacity, with a loss of enzymatic activity 
reported following SOD1 glycation[419], glutathionylation[420] and up to 90% following 
nitration[418,421]. The most characterised post-translational modifications however, are those 
involved in the maturation process, including the insertion of Cu and Zn ions, and the 
formation of the disulphide bridge. The dissociation of dimeric SOD1 is the predominant 
instigator of SOD1 aggregation and can be triggered by a loss of metal binding and 
dissolution of the disulphide bond[422]. Dimer destabilisation is also reported following 
phosphorylation of serine/threonine residues and following glutathionylation of SOD1[423]. 
Although wild-type and SOD1 mutant proteins are affected differently by these post-
translational modifications, most aberrant post-translational modifications result in 
destabilisation of the protein[417]. Interestingly, as well as aberrant post-translational 
modifications, complete loss of normal post-translational modifications is also a trigger for 
dimer destabilisation and subsequent protein misfolding[424].  
Impaired metal binding to SOD1 is proposed to result in dimer destabilisation as Zn 
influences disulphide bond formation[425] and a lack of Cu-binding reduces the b-barrel of 
each monomer, and reduces both disulphide and electrostatic loop motility[426]. It is also 
suggested that without Cu binding, cysteine residues normally buried deep within the protein 
are exposed on the surface and able to interact with other cysteine residues, thus promoting 
its aggregation[427,428]. Although both Zn and Cu aid SOD1 stability, and both intermediates 
have been reported in ALS models[429], Cu-binding imparts the greater kinetic stability[402,426]. 
SOD1-mutant murine models exhibit high levels of Cu-deficient SOD1 isoforms, proposed to 
be the toxic species[430], exhibiting increased misfolding and aggregation[42]. As 
redistributions of Cu and Zn have been identified in the ALS spinal cord along with 
elevations in Fe[409,431,432], it is suggested that biometal dyshomeostasis may be involved in 
SOD1 alterations identified in familial ALS. Cu-deficient SOD1 aggregates have been 
identified in a cellular model[42] and a transgenic mouse model of ALS[409] providing further 
support for this theory. As of yet however, Cu-deficient SOD1 is yet to be identified in the 
human post-mortem ALS spinal cord.  
Administration of Diacetylbis(N(4)-methylthiosemicarbazonato) Cu (II) or Cu-ATSM, a Cu 
supplementation agent which specifically delivers Cu (II) to regions undergoing oxidative 
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stress and mitochondrial impairment[433,434], increases the proportion of holo-SOD1, reduces 
SOD1 aggregation and mitigates neuronal loss, motor function and overall survival in ALS 
models[435–437]. Understanding whether SOD1 aggregates are metal-deficient in the human 
ALS spinal cord will aid our understanding of the pathogenic process of this protein in ALS 
and provide evidence for the use of Cu supplementation therapies currently in clinical trials 
for ALS.  
Investigations into the mechanisms underlying SOD1 aggregation and their involvement in 
neurodegeneration in ALS, have uncovered that impaired SOD1 antioxidant capacity alone is 
insufficient to cause the highly progressive and selective motor neuron loss associated with 
this disorder[438], and likewise is not proposed to be the sole mediator of neuronal loss in the 
PD brain[439]. Despite presenting with motor dysfunction and tremors, SOD1 knockout 
murine models do not exhibit neuronal loss[440,441]. This suggests that SOD1 aggregates 
exhibit a toxic-gain- of-function, proposed to involve oxidative damage, mitochondrial 
dysfunction and astro-glial cell pathology[442,443]. The precise mechanisms of this toxic-gain-
of-function however, is as of yet unknown.  
In addition to aggregations of SOD1, its specific antioxidant activity when corrected for 
neuronal loss is reduced in the SN of PD brains[397], further implicating alterations in this 
protein as a pathogenic contributor of PD aetiology. This is further supported by evidence of 
SOD1 aggregates exhibiting neurotoxicity in ALS attributed to insufficient Cu-binding to 
SOD1[45,408]. Establishing whether SOD1 aggregates in the PD brain are also a result of 
insufficient Cu-binding is a crucial step in determining the initial cause of SOD1 dysfunction 
and the mechanisms of SOD1 misfolding pathways in PD. Inadequate Cu delivery to SOD1 
via CCS is unlikely to be the cause of Cu-deficiency as SOD1 and CCS expression is highly 
correlated within the SN of PD[397]. An impaired interaction of CCS with SOD1 or an altered 
Cu-binding capacity in this Cu-deficient region of the PD brain is a potential Cu-associated 
pathogenic pathway that requires investigation.  
1.10 Detecting biometal and metalloprotein alterations 
Numerous techniques currently exist to quantify biometals in human tissues, however 
acquiring accurate, fast and reliable measurements of metals in their natural oxidation state, 
and structural state (whether free or bound) is a complex process. Determining the best 
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analytic approach can be dependent on the type of sample and elements required, the 
sensitivity, speed, availability and cost of the technology.  
Atomic absorption spectroscopy, developed in 1953 was one of the first techniques employed 
for spectrochemical analysis of metals in samples[444]. This technique requires atomization of 
a solution usually via flame or graphite furnace atomizers, however hydride-generation or 
cold vaporization atomizers can also be used for specialised techniques[445]. Atoms are then 
exposed to either element specific line radiation or continuum optical radiation, passed 
through a monochromator to select the specific wavelength of interest and measured using a 
detector[446]. Atomic absorption spectroscopy is a highly precise, inexpensive technique with 
high throughput, although it requires relatively large sample quantities and can only analyse 
solutions[445] which may restrict the uses of atomic absorption spectroscopy with very small, 
rare human post-mortem brain tissue samples.  
Mossbauer spectroscopy, developed around the same time as atomic absorption spectroscopy, 
is the measurement of small changes in atomic nucleus energy in response to environment. 
This is produced when a solid sample is exposed to gamma radiation, and the intensity of the 
transmitted beam is measured by a detector[447]. Due to a lack of pre-treatment or unnecessary 
sample handling, Mossbauer has a reduced likelihood of sample contamination, however a 
major limitation of this technique is the relatively poor sensitivity compared to other 
analytical techniques[448]  
Inductively coupled plasma-mass spectrometry is one of the most common methods for 
analysing biometals. It involves the ionisation of the sample to create small polyatomic ions 
that can then be detected at a high sensitivity. Inductively coupled plasma-mass spectrometry 
also has the advantage of  detecting different isotopes, can measure more than one element 
simultaneously and is faster and has a higher sensitivity and selectivity than atomic 
absorption spectroscopy[449]. It can however, also introduce interfering species which 
predominantly affect lighter elements[449]. Inductively coupled plasma-atomic emission 
spectroscopy is a variation of inductively coupled plasma-mass spectrometry where atoms are 
excited, causing them to emit characteristic electromagnetic radiation, which is measured and 
used to determine the specific element. Inductively coupled plasma-mass spectrometry is the 
preferred approach for element analysis as it has a lower detection limit of parts per trillion 
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compared to parts per billion of inductively coupled plasma-atomic emission spectroscopy 
(Table 1.1)[450].  
One of the more recent analytical techniques, laser ablation inductively coupled plasma-mass 
spectrometry is a tandem technique that enables the analysis of the spatial distribution of 
trace elements within the sample with high sensitivity[451]. An additional benefit is the 
variation of sample states able to be analysed, which include powders, hard tissue such as 
teeth, soft tissues such as brain, and liquid with minimal sample preparation[452,453]. Some 
major drawbacks of laser ablation inductively coupled plasma-mass spectrometry arise in 
‘elemental fractionation;’ – whereby ion abundances are a non-stoichiometric representation 
of the sample composition – which is attributed to laser wavelength, incomplete vaporisation 
of ionisation of the sample[454], and ‘matrix effects’ (differences in interaction between the 
sample and the reference matrix)[455]. 
With comparable sensitivity to atomic absorption spectroscopy (parts per billion), micro 
particle-induced X-ray emission is an ion beam analysis technique that exploits element-
specific x-ray emission to analyse multiple elements simultaneously in a non-destructive 
manner[456]. The sample is exposed to a proton beam which causes an electron to be ejected 
from the inner shell and an outer shell electron to relax, resulting in the emission of a photon 
specific to the element. Particle-induced X-ray emission has a spatial resolution of 0.2-2µm 
and detection limit of 1 to 10µg/g, comparable to laser ablation inductively coupled plasma-
mass spectrometry[457]. The requirement of a particle accelerator however, decreases the 
accessibility of this technique[458].  
A similar technique to particle-induced X-ray emission is synchrotron XFM which instead 
uses accelerated electrons to produce synchrotron radiation – enabling higher penetration 
power and smaller wavelengths than electron and visible-light microscopy[459]. Synchrotrons 
consist of a linear accelerator with an electon gun that fires and accelerates electrons before 
they are further accelerated in the booster ring. These electrons then enter the storage ring 
where they circulate close to the speed of light until they are deflected into a straight path by 
a series of magnets and insertion devices (wigglers and undulators) – a process that produces 
photons as synchrotron radiation[460]. The energy of these photons is usually 10-3 to 105 eV, 
and is filtered in the beamline by a monochromator to only emit the specific energy required 
for the experimental application. The X-ray beam then interacts with the sample in a similar 
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manner to particle-induced X-ray emission, whereby an inner shell electron is omitted 
leading to the replacement of this election with an outer shell electron, and the subsequent 
emission of electromagnetic radiation characteristic of the element[461]. The emergence of 
third generation synchrotrons enables the quantification of elements with limits of detection 
reaching 0.1-1µg/g[462], and spatial resolution as low as 10nm at certain facilities such as the 
European Synchrotron and Radiation Facility[463]. Samples can also be fixed (although not 
recommended for metal quantification due to the introduction of, and leaching of 
metals[464,465]), fresh, dried or frozen[466–468].  
Scanning transmission X-ray microscopy (STXM) is a method where a focused X-ray probe 
scans across a specimen and transmits diffraction intensity at all scan points, providing a map 
of the specimen,. The resolution of STXM however, is limited by the brilliance of the X-ray 
source, precision of instrumental setup and quality of X-ray focusing lenses which ultimately 
limit the spot size of the beam[459]. Coherent diffraction imaging is a lensless X-ray imaging 
technique that has recently overcome this resolution limit, however is unable to precisely 
scan large areas. Ptychography is a method that pairs the favourable aspects of STXM and 
coherent diffraction imaging to overcome the limited resolution of STXM, and the inability 
of coherent diffraction imaing to isolate and scan large areas[459]. Synchrotron-based 
ptychography is a tomographic method of processing and overlaying coherent interference 
patterns to obtain structural information, whilst alleviating the issue of aligning XFM and 
transmitted light microscopy images[469]. A very new and useful technique, ptychography 
enables the observation of finite structural features of samples and can be performed 
simultaneously to submicron biometal quantification using XFM[469]. To date this technique 
has not been applied to in situ imaging of complex materials such as human postmortem 
brain tissues. Although the most sensitive technique for biometal quantification, the 
requirement of a synchrotron light source for XFM may limit the practicality of this 
technique.  
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Table 1.1. Advantages and disadvantages of biometal quantification techniques 
Technique Advantages Disadvantages Limit of 
Detection 
Spatial 
resolution 
Atomic 
absorption 
spectroscopy 
Highly precise Spatially resolved 
information is 
limited to physical 
size of the tissue 
section 
1010-1013 50µm 
Inexpensive Can only analyse 
solutions 
High throughput 
Mossbauer 
Spectroscopy 
No sample pre-
treatment needed 
Poor sensitivity 1011 10-20µm
Inductively 
coupled plasma- 
mass 
spectrometry 
Detect different 
isotopes 
Can produce 
interfering species 10
13-1015 NA 
Can measure multiple 
elements 
simultaneously 
Fast 
High sensitivity 
High selectivity 
Inductively 
coupled plasma- 
atomic emission 
spectrometry 
High throughput Lower resolution 
than inductively 
coupled plasma mass-
spectrometry 
1010-1013 NA 
Can measure multiple 
elements 
simultaneously 
Can produce 
interfering species 
Laser ablation-
inductively 
coupled plasma-
mass 
spectrometry 
Can determine spatial 
distribution 
Elemental 
fractionation 10
7-109 20µm 
Destructive 
High sensitivity 
 Particle 
induced X-ray 
emission 
Very high spatial 
resolution 
Limited accessibility 
1013-1015 0.2-2µm 
Non-destructive 
X-ray
fluorescence 
microscopy 
Highest spatial 
resolution Limited accessibility 
1013-1016 10nm 
Non-destructive 
Can analyse a variety 
of 
sample mediums 
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1.10.1 Metalation studies 
As alterations in biometal levels and their metal-binding properties can affect numerous 
processes. Determining the metalation of metalloproteins in the PD brain is another step 
towards elucidating the role of biometals in pathogenic mechanisms underlying this disorder. 
Although this is a highly complex process, especially in vivo, as many processes alter metal-
binding properties, hyphenated techniques such as tandem liquid chromatography-inductively 
coupled plasma-mass spectrometry, isoelectric focusing combined with laser ablation--
inductively coupled plasma-mass spectrometry and matrix-assisted laser 
desorption/ionisation-time-of-flight mass spectrometry have overcome some of these 
challenges[470]. Their implementation in analysing metalloproteins in the PD brain has the 
potential to elucidate the effects of altered biometals in the degenerating brain and can be 
implemented for future use in determining biomarkers in patient biofluids.  
1.11 Are biometal changes potential biomarkers? 
With no current diagnostic, prognostic, staging or theragnostic marker currently available for 
PD, there is a crucial requirement for further investigation into this field. As PD is a complex 
condition with various clinical phenotypes and rates of progression, it is likely that a 
combination of biomarkers would be required and need independent validation across various 
platforms such as in vivo imaging, biochemical analysis and, if possible, post-mortem 
confirmation. With evidence suggesting a role of biometal alterations in PD aetiology, 
identifying these changes prior to disease, or as an indication of disease stage, would aid in 
the more accurate and earlier diagnosis of, and further understanding of PD progression.  
Using biofluids such as blood and cerebrospinal fluid to identify biomarkers is a relatively 
non-invasive, and easily accessible approach that has been suggested to reflect more central 
diseases processes in PD[471]. Despite numerous studies investigating biometal alterations in 
cerebrospinal fluid and blood components, large variation in analytical techniques, and 
methodological approaches have led to inconsistencies in these data. Obtaining a consensus 
in the literature through use of meta-analyses is important to determine the utility of 
cerebrospinal fluid and blood as biomarkers for PD, and more specifically, as a useful 
indication of biometal alterations in central disease processes in PD. Further, as the 
homeostasis of many biometals are dependent on one other, and underlying disease pathways 
   44 
are unlikely attributed to changes in one element alone, characterising patterns of biometals is 
a more promising approach as a biomarker.  
 
1.11.1 In vivo imaging of biometals 
As a confirmed PD diagnosis is only available post-mortem, the development of in vivo 
imaging markers is essential for both diagnostic and prognostic utility in PD patients. Much 
research has focused on the estimation of Fe in the PD brain using magnetic resonance 
imaging[472]. As Fe is paramagnetic, deposition causes a reduction in T2 relaxation time – the 
rate at which excited protons reach equilibrium or go out of phase with each other – and this 
subsequently causes hypointensity[473]. Relaxometry-based imaging has demonstrated 
correlations between Fe content and motor severity in PD, but not disease duration, 
suggesting elevations in midbrain Fe are an indication of disease state[474].  
Magnetic susceptibility (whether material will become magnetized in an applied magnetic 
field) is another technique that produces contrast between tissues and can be used to estimate 
brain Fe[289,475]. Other magnetic resonance imaging techniques that estimate brain Fe are 
susceptibility-weighted imaging and quantitative susceptibility mapping, which exploit 
magnetic susceptibility (whether material will become magnetized in an applied magnetic 
field) to produce contrast between tissues[476,477]. These techniques are proposed to have 
greater sensitivity to disease severity than relaxometry, yet cannot accurately distinguish PD 
from other parkinsonian conditions[478].  
Ultrasonography is a safe and non-invasive technique that involves subjecting the tissue to 
sound waves that bounce off or are passed through the tissue. This generates ‘echoes’ that 
can be transformed into black and white images[479]. Transcranial sonography is a technique 
which allows imaging of brain parenchyma in two-dimensional slices, and has demonstrated 
utility in determining vulnerability to PD, with PD patients exhibiting a moderate to distinct 
increase in SN echogenicity compared with age matched controls[480,481]. Transcranial 
sonography echogenicity is also able to differentiate between PD and other parkinsonian 
syndromes such as multiple-systems atrophy and progressive supranuclear palsy[482,483]. SN 
hyper-echogenicity has been attributed to increases in Fe in this region[484], confirmed in both 
animal studies involving injections of Fe into the SN[485] and in human post-mortem tissues 
with atomic absorption spectroscopy and immunohistochemical labelling of Fe[291,486]. 
Despite increasing evidence of Fe deposition correlating with increased hyper-echogenicity, 
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echogenicity does not increase with age or disease duration, and certain PD patients do not 
present with SN echogenicity[481].  
Although Cu accumulation can be identified via magnetic resonance imaging based imaging 
with long T1 and long T2 signal identified in the brains of patients with Wilson’s disease[487], 
reductions or small perturbations in Cu levels cannot be accurately identified using these 
techniques. Positron emission tomography however, is a technique that has demonstrated 
promise for imaging Cu metabolism in the brain. This involves a radioactive Cu tracer, 
usually 64Cu, which can be ingested or injected into the patient and tracked due to its decay 
characteristics which produce b-emission or electron capture[488]. Radioactive forms of the 
Cu supplementation agent Cu-ATSM have also been examined, as it is reported to 
preferentially release Cu in hypoxic regions – indentifying areas that seem to require Cu and 
may therefore be deficient[489]. As this is not an entirely accurate method of quantifying brain 
Cu in vivo, a more selective approach is required to determine whether Cu metabolism is 
altered in the PD brain during disease and whether altered Cu is an indication of disease 
stage, or can be used as a diagnostic marker.  
1.12 Are biometal modulation therapies useful for 
Parkinson’s disease?  
With much evidence implicating elevations in Fe in PD aetiology, Fe chelators have been 
investigated in an attempt to mitigate Fe accumulation, attenuate symptoms and preventing 
neuronal loss in vulnerable regions of the PD brain[490]. Multiple Fe chelators have 
demonstrated promise in preclinical PD murine and cell models, including [5-(N-methyl-N-
propargylaminomethyl)-8-hydroxyquinoline], desferrioxamine, deferiprone and deferasirox, 
demonstrating neuroprotection and amelioration of symptoms[491–495]. Deferiprone has also 
progressed to clinical trials where it is well tolerated, reduces SN Fe accumulation (as 
evidenced using magnetic resonance imaging), improves PD symptoms and reduces Fe 
deposition in patients[496]. Targeting Fe chelation to regions exhibiting Fe deposition, and not 
to regions with unaltered Fe levels is necessary however is  necessary to progress the clinical 
utility of this therapeutic approach.  
Cu supplementation has also demonstrated efficacy in PD models, with CuSO4 exhibiting 
neuroprotection and reduced motor deficits in MPTP mice[497] and Cu-ATSM demonstrating 
multiple mechanisms of neuroprotection in four different PD murine models[498]. Cu-ATSM 
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has also progressed to clinical trials, and following tolerability in patients, the dose has now 
been escalated for phase 2 (Clinical trial identifier: NCT03204929). If a large and consistent 
Cu reduction is observed in vulnerable regions of the PD brain, Cu supplementation may 
prove a useful therapeutic approach for this disease. Targeting Cu delivery to deficient areas 
to avoid the detrimental effects of excess Cu in the brain, is a challenge that is yet to be 
overcome.  
1.13 Project summary 
Determining what predisposes selective dopaminergic neurons to degeneration in the SN of 
PD patients is important to understand disease aetiology. With no currently available 
therapeutic approach effectively slowing or halting the disease process, identifying novel 
therapeutic targets in these molecular neurodegenerative pathways is a promising approach to 
produce the first disease-modifying therapy for PD. Increasing evidence is implicating 
alterations in essential biometals and their various metal-associated pathways in neuronal 
vulnerability in the PD brain. Confirming whether biometals – specifically Cu and Fe – are 
altered in the degenerating SN of the PD brain, and whether these changes are consistently 
observed in different PD patient cohorts would further the understanding of PD aetiology. 
Elucidating whether these changes can be detected in more accessible biofluid tissues such as 
serum and cerebrospinal fluid, will determine whether these changes are specific to the site of 
cell loss. As biometals are essential co-factors for various proteins and enzymes and small 
perturbations in their levels and bioavailability demonstrate neurotoxicity, their regulation is 
essential for normal neuronal health.  
Recent identification of dysfunctional SOD1 in vulnerable regions of the PD brain, has raised 
the question of whether this Cu and Zn-associated enzymatic protein is impaired as a result of 
perturbations in these metals. With the enzymatic function and structural stability of this 
protein dependent on the binding of these metals, Cu-deficiency in vulnerable regions of the 
PD brain may affect SOD1 structural stability and antioxidant properties.  
This thesis presents the first investigation of the subcellular localisation of biometal changes 
in the SN in PD to identify the specific location of these alterations and determine the 
subsequent metal-associated pathways that could be affected. Biometal alterations in the PD 
brain and biofluids are also confirmed across various PD cohorts using various 
methodological approaches in a meta-analysis, to determine whether these changes are 
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specific to degenerating regions predominantly affected in PD. Further, this thesis presents 
the first investigation of the elemental and structural composition of Lewy bodies and SOD1 
aggregates in the SN in human PD, performed using synchrotron XFM and ptychography for 
the first time in human postmortem brain tissue. This allowed the more precise identification 
of aggregates in situ and enabled the comparison of structural and elemental features of Lewy 
pathology, SOD1 aggregates and neuromelanin within the PD brain. Identifying specific 
features of these aggregates may aid in the identification of these aggregates without the use 
of immunoabelling, and identifying similarities between SOD1 and Lewy aggregates may 
indicate overlapping or shared misfolding pathways of these two distinct proteinopathies in 
the PD brain.   
1.14 Hypothesis and Aims 
Hypotheses 
1. Cu is reduced, and Fe is elevated, in the SN of the PD brain when compared with
healthy aged-matched controls
2. Cu is reduced and Fe is elevated only in the SN of PD patients and not in PD
cerebrospinal fluid, blood sera or plasma, or in these tissues of aged-matched controls.
3. SOD1 and Lewy aggregates are distinct in structure and elemental composition in the
SN in PD.
4. The Cu:Zn ratio is reduced in SOD1 aggregates in the SN in PD.
Aims 
1. To quantify biometal levels in three regions of the PD brain (substantia nigra,
occipital cortex and anterior cingulate cortex) separated into three fractions – soluble,
membrane-associated and insoluble.
2. To develop and implement the first scale to quantify the quality of biochemical
studies of human tissues
3. To perform a meta-analysis to determine whether biometals are consistently and
significantly altered in the SN in PD when accounting for individual study quality .
4. To characterise the elemental and structural composition of SOD1 and Lewy
aggregates in fresh human SN in PD using synchrotron X-ray fluorescence
microscopy and ptychography.
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1.15  Conclusion 
Increasing evidence implicates biometal dyshomeostasis and oxidative stress in neuronal 
death, which are both identified in the degenerating region of the PD brain. Characterising 
SOD1 aggregates and metal-binding properties in this neurodegenerative disease may 
elucidate neurotoxic pathways contributing to disease aetiology, and identify novel targets for 
the development of disease-modifying therapeutics for PD.  
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CHAPTER 2: META-ANALYSIS OF 
COPPER AND IRON IN PARKINSON’S 
DISEASE BRAIN AND BIOFLUIDS 
R E S E A R C H A R T I C L E
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ABSTRACT: Background: Variations in study quality
and design complicate interpretation of the clinical signif-
icance of consistently reported changes in copper and
iron levels in human Parkinson’s disease brain and
biofluids.
Methods: We systematically searched literature data-
bases for quantitative reports of biometal levels in the
degenerating substantia nigra (SN), CSF, serum, and
plasma in Parkinson’s disease compared with healthy
age-matched controls and assessed the quality of these
publications. The primary outcomes of our analysis con-
firmed SN copper and iron levels are decreased and
increased, respectively, in the Parkinson’s disease brain.
We applied a novel Quality Assessment Scale for Human
Tissue to categorize the quality of individual studies and
investigated the effects of study quality on our out-
comes. We undertook a random-effects meta-analysis
and meta-regression subgroup analysis.
Results: In the 18 eligible studies identified (211 Parkinson’s
disease, 215 control cases), SN copper levels were signifi-
cantly lower (d, -2.00; 95% CI, -2.81 to -1.19; P < 0.001), and
iron levels were significantly higher (d, 1.31; 95% CI,
0.38–2.24; P < 0.01) in Parkinson’s disease. No changes were
detected in CSF, serum, or plasma for any metals (29 studies;
2443 Parkinson’s disease and 2183 control cases) except
serum iron, which was lower in Parkinson’s disease (14 stud-
ies; 1177 Parkinson’s disease and 1447 control cases).
Conclusions: Reductions in copper levels and elevations
in iron were confirmed as characteristic of the de-
generating SN of Parkinson’s disease. Iron in serum was
also changed, but in the opposite direction to that in the
SN and to a lesser extent. © 2019 International Parkinson
and Movement Disorder Society
Key Words: copper; iron; meta-analysis; Parkinson’s
disease
Motor dysfunction in Parkinson’s disease (PD) is
caused by the progressive loss of dopaminergic neurons,
particularly in the ventral substantia nigra (SN),
and the consequent diminution of dopaminergic
transmission by the nigrostriatal pathway. As available
antiparkinsonian therapies do not modify this disease
process,1 identifying pathophysiological processes that
may be effective targets for neuroprotective therapies is
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a major research focus. Over the past decade, dysfunc-
tion of metal-catalyzed pathways in neurodegenerative
disorders has attracted substantial interest.2 Genetic
disorders involving dysregulation of pathways that
require copper and iron, such as Wilson’s disease,3
Menkes disease,4 and neurodegeneration with brain
iron accumulation5 illustrate the essential roles played
by copper and iron in neuronal health and the patho-
logic consequences of major shifts in their levels.
Increased local iron levels in the brains of people with
PD were first noted during the 1920s,6 and abnormal
iron accumulation in sites of neurodegeneration has
since been regularly reported. More recently, reduced
copper concentration and increased iron have been
reported in degenerating brain regions in PD.7 How-
ever, the quality of such studies has been heterogeneous
and affected by problems including small and diverse
sample cohorts, the possibility of postmortem artifacts
caused by metal chelation or contamination, and differ-
ences in preparation procedures and analytic tech-
niques. Altered metal levels in biofluids, such as
cerebrospinal fluid (CSF), serum, and plasma, have also
been described,8 but the relationship between these
changes and those of brain metals is unclear.
Pharmacological modulation of brain metal levels in
PD is being investigated in several clinical trials, including
the administration of the orally bioavailable, permeable
to the blood–brain barrier copper complex Cu(II)ATSM
for restoring normal copper levels in the SN9 (phase 1;
ClinicalTrials.gov Identifier: NCT03204929), and of the
chelator deferiprone to reduce iron levels10 (phase 2;
ClinicalTrials.gov Identifier: NCT02728843). Con-
firming copper and iron changes in regions that degener-
ate in PD would support these therapeutic strategies.
To overcome limitations of individual observation
studies and to increase the statistical power of analysis,
we undertook a systematic review and meta-analysis of
all English-language publications on SN and biofluid cop-
per and iron levels in PD. Meta-analysis is useful for esti-
mating the degree to which variation in the outcomes of
different studies are related to limited sample sizes (sam-
pling variance) and methodology (true heterogeneity).
Further, we evaluated study bias and the validity of meth-
odological design and reporting in individual postmor-
tem and biofluid studies with a scale we specifically
developed for assessing the quality of biochemical studies
of human samples. Study quality provides clinometric
information that enables statistical adjustment of individ-
ual data sets in subsequent subgroup meta-analyses.
Methods and Materials
Search Strategy and Study Selection
Author S.G. searched Web of Science, EMBASE, and
MEDLINE for the terms “copper”/“Cu” or “iron”/
“Fe” or “metal*” AND “Parkinson*” on September
13, 2017. All articles in English published before the
search date were initially included in the analysis. No
search restrictions regarding analytic methods or exper-
imental approach (ie, in vitro or in vivo) were applied.
We undertook this systematic review and meta-analysis
according to the guidelines of the Preferred Reporting
Items for Systematic Reviews and Metal-analyses state-
ment (Fig. 1).11
Data Extraction
The initial search identified 14,487 articles. After
duplicates were excluded, 9026 unique articles were
prescreened by 2 authors (S.G., K.L.D.) according
to predefined exclusion criteria (quantitative mea-
surements of copper, iron, zinc, or manganese in
human postmortem SN tissue, CSF, serum, or blood
in PD patients), 8929 records were excluded
(Fig. 1), and 97 articles were further assessed for
eligibility.
• Forty-one articles reporting metal concentrations in
postmortem SN tissue. Twenty-three articles were
excluded as ineligible according to predefined criteria
(Supplementary Table 2); 18 articles describing data
for 211 PD and 215 control brains were included in
our meta-analysis of postmortem SN reports
(Supplementary Table 3).
• Fifty-six articles reporting metal concentrations in
CSF, serum, or plasma samples. Twenty-seven were
excluded as ineligible according to predefined criteria
(Supplementary Table 4); 29 articles describing data
from 2443 PD and 2183 control cases were included
in our meta-analysis of biofluid metal levels
(Supplementary Tables 5 to 7).
The characteristics of each study (number of samples,
mean metal levels with standard deviations) were
extracted for analysis. The primary outcome was differ-
ence in metal concentrations (iron and copper) between
PD and control tissues. Differences in zinc and manga-
nese levels were also examined as secondary outcomes,
as associations between these biometals and PD pathol-
ogy have been discussed.12,13
The included articles described samples from tissue
donors from a range of ethnic backgrounds and conti-
nents (Europe, Asia, Australia, the Americas). No
donors contributed tissue to both the brain and biofluid
metal data sets. Studies reporting metal concentrations
in SN tissue often also reported data for other brain
regions (frontal, occipital, and temporal cortices, cere-
bellum, striatum). However, given the small sample
sizes for these other regions and the significance of the
SN for PD etiology, we restricted our analysis of brain
tissue levels to the SN.
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Quality Assessment Scale for Biochemical
Analysis of Human Samples
There is no gold standard technique for assessing
metal levels in human tissues. Despite our rigorous
exclusion criteria, the included studies differed in design
and differences in techniques for measuring minor and
trace metals may have affected data quality.14 The sensi-
tivity of the various analytic options differs markedly;
for example, the sensitivity of Mössbauer spectroscopy
is relatively low,15 whereas synchrotron-microprobe x-
ray fluorescence is the most sensitive technique, although
it is usually applied to single-cell rather than regional
analyses. As biometals are extremely sensitive to local
environmental changes,16 we also included studies that
assessed both fresh-frozen and formalin-fixed tissues to
compare the effect of tissue preparation.
Protocols for assessing the quality of quantitative data
from human tissue analyses have not been published.
We therefore developed the Quality Assessment Scale
for Biochemical Analysis of Human Samples (see Sup-
plementary Materials for detail and R code), based on
the Cochrane Collaboration–approved Newcastle–
Ottawa scale for assessing the quality of nonrandomized
studies in meta-analyses.17 Our scale scores aspects of
study design, sample selection, tissue quality, detection
method, and statistical analysis. A maximum 15 points
FIG. 1. PRISMA flowchart of literature search, screening, and eligibility assessment. CSF, cerebrospinal fluid; PD, Parkinson’s disease; SN, substantia
nigra.
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can be allotted: a study with 11–15 points is deemed
high quality, 6–10 points moderate quality, and 0–5
points limited quality (Table 1). We applied our scale to
both SN tissue and biofluid studies. Test-retest reliability
was assessed by 1 author (S.G.), who applied the scale
to both the SN and biofluid data sets at 2 separate times
in one-third of the studies. Inter-rater reliability was
assessed by 2 authors (S.G., K.L.D.) by independently
applying the scale to the same studies.
Data Analysis
All analyses were performed with the metafor pack-
age for R 3.4 (R Core Team). The differences between
the means of the 2 groups in each study (in units of
pooled SD), expressed as effect size, were assessed with
Hedges’ d statistic,18 calculated with the “escalc” func-
tion in metafor.19 Effect sizes were calculated so that a
negative value indicated that metal concentration was
lower in the PD tissue group than in the control tissue
group. Standard interpretive benchmarks for Hedges’
d were applied (0.2 = small, 0.5 = medium, 0.8 = large).
Data for metal concentrations in postmortem SN tis-
sue, CSF, serum, and plasma were analyzed separately.
For each data set, a random-effects meta-analysis
(REMA) model was applied using the “rma” function in
metafor to estimate the overall magnitude and statistical
significance of an effect. The REMA model was pre-
ferred to a fixed-effects model because the included stud-
ies included potential sources of heterogeneity arising
from differences in donor cohorts and analytic methods.
A REMA model weights individual studies according to
both the inverse of within-study variance (square root of
the SE for sampling variances) and between-study vari-
ance, which also depends on sample size. Variation in
effect sizes that could not be attributed to sampling vari-
ance, or “heterogeneity,” was also estimated by each
REMA model. Heterogeneity statistics quantify the
degree to which the results of different studies differ on
factors other than sampling (eg, analytic methods). Each
REMA estimates whether effect size heterogeneity was
statistically significant with the Q statistic. We also
report the proportion of variance in reported effects not
attributable to sampling variance alone (and therefore
ascribed to differences in analytic approach) as I220,21;
values below 25% were deemed low, 25%–75%
medium, and more than 75% high heterogeneity.
Random-effects meta-regression and subgroup ana-
lyses were conducted on data sets categorized by study
quality according to our scale (Supplementary Table 8),
patient age, sex, and postmortem interval (SN tissue
only to assess observed data heterogeneity). Subgroup
analyses also assessed overall effect sizes as a function
of analytic technique, tissue preparation method, and
the significance of differences between subgroups
in REMA.
Assessment of Publication Bias
Publication bias was investigated when 10 or more
data sets reported data on the same variable22 by
Egger’s regression (“regtest” function in metafor)23 and
visualized as funnel plots (Supplementary Figs. 1–3).
Where Egger’s regression detected statistically signifi-
cant evidence of bias (P < 0.05), a trim-and-fill analysis
was applied (metafor “trimfill” function) to estimate
the number, magnitude, and precision of potentially
TABLE 1. Scoring rubric for the Quality Assessment Scale
for Biochemical Analysis of Human Samples
Selection
1. Is the case definition adequate?
a. Yes, both clinical and pathologically defined 2
b. Either clinical or pathologically defined 1
c. No description 0
2. Representation of population?
a. Cases from multiple tissue banks or live cohorts 2
b. Tissue bank or live cohort stated 1
c. Potential for selection biases or not stated 0
3. Selection of controls
a. Controls selected from same tissue banks or live population 1
b. Controls from different source or no description 0
4. Definition of controls
a. No history of disease or confounding condition 1
b. Diagnosed conditions provided but effect on variable
of interest unknown
0
c. No description 0
Comparability
1. Comparability of cases and controls on the basis of the
design or analysis
a. Study controls for the most significant potential moderating
variables x and y (where x is the most important factor), for
example, age, sex, genetic background; 2 points
b. Study controls for only 1 factor (most important)
c. Not controlled or not stated 0
2. Quality of tissue
a. Postmortem delay is <24 hours for postmortem
tissues or biofluids were stored at -20C < 1 hour
after collection; 1 point
1
b. >24 hours for postmortem or > 1 hour for biofluids
or not defined
0
3. Method detail
a. An appropriate method applied and described 2
b. Methods and/or description limited 1
c. Inappropriate method and/or missing crucial information 0
Analysis
1. Ascertainment of exposure
a. Blinded to case/control status 1
b. Unblinded 0
c. No description 0
2. Appropriate and detailed statistical analysis
a. Detailed and appropriate analysis 2
b. Statistical test stated 1
c. No description. 0
3. Elimination of outliers
a. All participants included 1
b. Similar proportion excluded for both groups 1
c. Different exclusion or not stated 0
Maximum score: selection + comparability + analysis = 15
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missing effect sizes and to calculate a revised overall
effect.21,24 The statistical methodology is described in
greater detail in the Supplementary Materials.
Results
Demographic Characteristics of Tissue
Donors: Age
The mean age of SN tissue donors  SD was
76.1  3.7 years for donors with PD, 74.8  5.7 years
for control donors; the difference in mean age between
the 2 groups was 1.6  5.0 years. The mean age of CSF
donors was 65.0  3.5 years for donors with PD,
61.0  5.3 years for control donors; the difference in
mean age was 5.9  11.9 years. The mean age of serum
donors was 64.3  4.4 years for donors with PD,
60.0  5.3 years for control donors; the difference in
mean age was 3.7  4.0 years. The mean age of plasma
donors was 61.5  5.6 years for donors with PD,
58.4  13.9 years for control donors; the difference in
mean age between the 2 groups was 3.1  0.8 years.
Further demographic data are reported in Supplemen-
tary Tables 4–7.
Quality Assessment Scale for Biochemical
Analysis of Human Samples
Test-retest reliability of the scale was high (correla-
tion, 0.99; P < 0.0001) with 91% agreement (n = 11;
κ = 0.889; P < 0.0001). Interrater reliability for 2 inde-
pendent raters was also high (correlation, 0.99;
P < 0.0001), with 82% agreement (n = 11; κ = 0.778;
P < 0.0001). Seven of 18 human postmortem tissue
studies were deemed high quality, 9 moderate quality,
and 2 limited quality. Five of the 12 CSF studies were
categorized as high-quality studies and 7 as moderate-
quality studies. Seven of 17 serum studies were deemed
high quality, 7 moderate quality, and 1 limited quality.
It should be acknowledged that one factor the Quality
Assessment Scale cannot account for is the analytical
validity of the method used. Blank concentrations,
limits of analysis, and potential contamination sources
are not typically reported. This may have the effect of
masking changes in studies that did not report changes
because of the sensitivity of the method used.
Copper Levels in the Substantia Nigra Are
Reduced in PD
Nine of 18 reports on postmortem SN tissue included
quantitative data on copper levels (PD, 127 samples;
control, 134 samples); 6 reported that copper levels
were significantly lower in PD than in control samples,
3 studies found no significant difference (Fig. 2A).
Overall, copper levels were significantly lower in PD
samples (d, -2.00 [large effect]; 95% CI, -2.81 to -1.19;
P = 0.0051; Fig. 2A), but study heterogeneity was sub-
stantial (I2, 83.9%; Q, 59.9; P < 0.0001). The effect
size was similar in the 6 high-quality studies that mea-
sured copper (d, -2.05; 95% CI, -2.95 to -1.16;
P < 0.0001) and the 3 moderate-quality studies (d,
-1.84; 95% CI, -4.04 to 0.36; P = 0.10). The 4 studies
that employed inductively coupled plasma–mass spec-
trometry (d, -2.42; 95% CI, -3.92 to -0.92; P = 0.0016)
and the 3 atomic absorption spectroscopy studies (d,
-2.25; 95% CI, -4.02 to -0.47; P = 0.013) reported
the largest effect sizes; the effect sizes of the 3 micro-
probe x-ray fluorescence/emission and 1 Mössbauer
spectroscopy study were not statistically significant
(Supplementary Table 10). The effect sizes in the 8 stud-
ies using fresh tissue were significant (d, -2.06; 95% CI,
-3.01 to -1.12; P < 0.0001), in contrast to the 2 studies
using formalin-fixed tissue (d, -1.76; 95% CI, -3.72 to
0.21; P = 0.07). Effect sizes were not influenced by age,
sex, or postmortem interval (Supplementary Table 10),
consistent with within-study matching for these
variables. No publication bias was identified (Supple-
mentary Fig. 1A).
Iron Levels Are Elevated in Substantia
Nigra in PD
All but 1 of the 18 postmortem SN tissue articles
reported quantitative iron levels (PD, 203 samples; con-
trol, 221 samples); 13 studies reported that iron levels
were significantly higher in PD than in control samples,
and 4 studies found no significant difference (Fig. 2B).
Overall, iron levels were significantly higher in PD sam-
ples (d, 1.22; 95% CI, 0.36–2.09; P = 0.0055), but
study heterogeneity was substantial (I2, 92.8%; Q,
148; P < 0.0001; Fig. 2B). The effect size was slightly
larger if 2 limited-quality studies (PD, 22 samples; con-
trol, 30 samples) were excluded (d, 1.35; 95% CI,
0.37–2.33; P < 0.007) and was also greater for studies
using unfixed fresh tissue (14 studies: d, 1.48; 95% CI,
0.50–2.46; P < 0.003). Within analytical technique sub-
groups, no technique demonstrated a significant differ-
ence in effect size (Supplementary Table 10). The
between-group difference in postmortem interval signif-
icantly influenced effect size, with increasing differences
in the interval associated with larger effects (slope for
d, 0.09; 95% CI, 0.04–0.15; P < 0.0008), whereas dis-
ease duration, donor age, and sex did not influence
effect size (Supplementary Table 10). Evidence of publi-
cation bias was statistically significant (P < 0.0001;
Supplementary Fig. 1B), but trim-and-fill analyses did
not alter the overall effect.
Zinc Levels in the Substantia Nigra Are
Unchanged in PD
Three of 7 studies that assessed zinc levels in the SN
reported that levels were significantly higher in PD than
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in control samples (Fig. 2C). Meta-analysis of all 7 stud-
ies indicated that zinc levels were similar in PD and
healthy aged control samples (d, 0.64, 95% CI -0.28 to
1.56, P = 0.18; Fig. 2C). Analysis of the 4 high-quality
studies found no difference (Fig. 2C), but the effect size
for the 3 moderate-quality studies was significant (d,
1.83, 95% CI, 0.34–3.32, P = 0.016). Age, postmortem
interval, sex, and disease duration did not significantly
influence the effect (Supplementary Table 9). Publica-
tion bias was statistically significant (P = 0.0072; Sup-
plementary Fig. 1C), but trim-and-fill analyses
estimated no missing studies.
Biometal Levels in CSF, Serum, and Plasma in
People With PD
Eight of the 10 studies that assessed copper levels in
CSF found no difference between samples from donors
with or without PD, whereas 1 study each found signifi-
cantly lower or higher levels in PD donors (Fig. 3A).
Assessments of CSF iron levels in CSF were also mixed,
with 4 reporting they were lower in PD, 2 that they
were higher, and 3 that they were similar to those of
control donors. Of 7 studies of CSF zinc levels 3 found
that they were lower in PD, 1 that they were higher,
and 3 that they were similar to those of control donors
(Fig. 3C). Of 7 studies assessing CSF manganese levels,
1 reported that they were higher in PD, 6 that levels
were similar in PD and control samples (Fig. 3D). Over-
all (11 CSF studies; PD, 576 samples; control, 293 sam-
ples) copper, iron, zinc, and manganese levels in PD did
not significantly differ from those of control donors
(Fig. 3). The only statistically significant differences in
effect size by study quality were that iron (d, -0.53;
95% CI, -0.79 to -0.26; P < 0.0001; I2 = 23.0%) and
zinc (d, -0.52; 95% CI, -0.82 to -0.23; P = 0.0004;
I2 = 0) levels in 4 high-quality studies were lower in PD
than in control samples. There was no evidence of pub-
lication bias (Supplementary Fig. 3).
Of the 15 studies that assessed serum copper, 9 found
that levels were lower in PD, 1 that they were higher,
and 5 that they were similar in PD and control samples.
Overall, serum copper levels were similar in PD and
control samples (14 studies: PD, 1235 samples; control,
1132 samples); study heterogeneity was high
(I2 = 98.8%; Q, 603; P < 0.0001); see Figure 4A.
Five serum iron studies reported that they were lower
in PD, 1 that they were higher, and 8 that they were
FIG. 2. Forest plots of analysis of (A) copper, (B) iron, and (C) zinc in
human postmortem SN tissue. Square marker indicates effect size and
statistical weight of study; horizontal lines indicate 95% CIs. The dia-
mond data markers represent the subtotal and overall effect size and
95% CI. The vertical dashed line shows the summary effect estimate;
the dotted line shows the line of no effect (d = 0). *Studies identifying a
reduction; s^tudies reporting a significant increase. df, degrees of free-
dom; Q, Cochran’s Q.
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FIG. 3. Forest plots of analysis of (A) copper, (B) iron, (C) zinc, and (D) manganese in human CSF.
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similar in PD and control samples (Fig. 4B). Overall,
serum iron levels were significantly lower in PD samples
(14 studies [6 high quality, 7 moderate quality, 1 limited
quality]: PD, 1177 samples; control 1447 samples; d,
-0.77; 95% CI, -1.43 to -0.10; P = 0.024; Fig. 4B);
excluding the limited-quality study (35 PD samples,
33 control samples) rendered the effect nonsignificant
(d, -0.63; 95% CI, -1.28 to 0.03; P = 0.06; Fig. 4C), as
did including only the 6 high-quality studies (PD,
701 samples; control, 761 samples: d, -0.97; 95% CI,
-2.31 to 0.57; P = 0.24; Fig. 4C). Meta-regression ana-
lyses indicated that serum iron level increased with age
(slope, 0.18, 95% CI, 0.06–0.22; P < 0.005), but the
ages of donors in the PD and control cohorts did not
differ nor between these cohorts when high-, moderate-,
and limited-quality studies were individually tested.
Four of 12 studies that assessed serum zinc found
that levels were lower in PD and 8 that they were simi-
lar in PD and control samples (Fig. 4D). Of the 7 studies
that assessed serum manganese, 1 found that levels
were lower in PD and 1 that they were reduced
(Fig. 4E). Overall, serum zinc and manganese levels
were similar in PD and control samples (Fig. 4D,E).
There was no evidence of publication bias for serum
metal studies (Supplementary Fig. 3).
Meta-analysis of plasma metal data was limited by the
small number of studies that met our selection criteria
(5) and data heterogeneity for all 3 metals assessed (cop-
per: d, 0.0, 95% CI, -1.82 to 1.81, P = 0.996,
I2 = 98.6%; iron: d, 0.35, 95% CI, -1.07 to 1.77,
P = 0.63, I2 = 96.4%; zinc, d, -0.40, 95% CI, -0.78 to
-0.01, P = 0.043, I2 = 0%). One copper and 1 zinc study
were deemed limited quality, but their omission did not
change our findings (Supplementary Table 9). There
was no evidence of publication bias for plasma studies.
No Association Between Copper and Iron
Levels in the Substantia Nigra and in Biofluids
Meta-regression indicated that the lower SN copper
levels in PD samples were not correlated with lower
biofluid copper levels in age-matched individuals.
FIG. 4. Forest plots of analysis of (A) copper, (B) iron, (C) zinc, and (D) manganese in human serum.
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Similarly, higher SN iron levels in PD samples were not
mirrored by higher biofluid iron levels before or after
adjusting for age (Supplementary Fig. 4).
Discussion
In the first meta-analysis of SN copper and zinc levels
in people with PD and in accordance with a previous
meta-analysis of iron,25 we found evidence that copper
levels were consistently lower than in healthy controls
and confirmed that iron levels were significantly higher.
The magnitudes of these differences were similar, but in
opposite directions. The studies we analyzed included
donors of different ethnic backgrounds from multiple
continents, suggesting our findings can be generalized
to people with PD worldwide.
Although studies of copper and iron levels in PD have
consistently reported changes restricted to degenerating
brain regions, particularly the SN,26,27 the available
data did not permit meaningful analysis of metal level
changes in other brain regions. The measured differ-
ences in SN iron and copper levels in PD may reflect
redistribution of metals within the SN or between the
SN and other tissues.28 Intranigral redistribution would
be consistent with the significantly higher levels of
intraneuronal iron and lower levels of intraneuronal
copper in PD we have described.7
Despite the high degree of study heterogeneity, the mag-
nitudes of the overall changes our meta-analysis identified
are consistent with those we and others have found in
studies of within-dopaminergic neuron metal concentra-
tions in PD.27,29 We have found these changes in cases of
probable preclinical disease, which suggests that iron and
copper levels change at the cellular level early in the dis-
ease process.30 These findings, however, do not provide
unequivocal evidence for their etiological significance.
Nevertheless, like the discovery of markedly reduced
dopamine levels that motivated the first trials of dopamine
replacement therapy in the early 1960s, our findings pro-
vide strong empirical evidence of specific changes in the
primary region of neurodegeneration in PD, supporting
the rationale of current clinical trials investigating these
changes as targets for disease modification in PD.9,10
Our data support the hypothesis that increased SN iron
levels are at least a biomarker of the disease process,
including in preclinical PD. Elevated SN iron levels
detected by functional ultrasound imaging detection have
been proposed as a risk marker for preclinical PD by the
International Parkinson andMovement Disorders Society
Task Force,31 and quantifying SN iron by MRI imaging
is being investigated both as a biomarker of PD and of
disease progress.32 We did not include functional imaging
of brain iron in PD in our analysis, as this was recently
the subject of meta-analysis.25 Copper and zinc cannot
currently be assessed in vivo with functional imaging.
We also examined whether the effect sizes for changes
in copper and iron levels in the postmortem SN were
matched by changes in intravitam CSF, serum, and
plasma levels in people with PD. Given the close physical
contacts between the brain, CSF, and capillary network,
changes in biometal levels in the more accessible bio-
fluids could potentially be useful biomarkers of central
disease processes.33 Our analysis indicated that biofluid
copper levels were within normal limits in PD, but serum
iron levels were lower than in age-matched healthy con-
trols. One major limitation of our analysis, however,
was that brain and biofluid tissue samples were not sou-
rced from the same donors; a study that compared both
sample types in individuals would be invaluable, but
investigations of this type have not been reported. Bio-
fluid metal levels are derived from various sources, how-
ever, and therefore circulating metal levels may not be
useful for estimating brain metal levels.
We initially weighted individual studies according to
donor group size and variance, but other design aspects,
such as analytic technique and tissue preparation, signif-
icantly influenced effect size, suggesting such factors
should be carefully considered during experimental
design. In contrast, other variables reported to influence
biometal levels, including sex34 and postmortem inter-
val35 did not have significant effects. No robust evidence
that medications influence biometal levels in the human
brain or biofluids has been reported. Monoamine oxi-
dase inhibitors prescribed for patients with PD may
have iron-chelating properties36 that may be relevant to
reports of reduced serum iron levels in PD.37 Little is
known, however, about the effects on brain biometal
levels of other dopamine replacement therapies or of
other medications frequently taken by older people.
Conclusion
Copper levels were significantly lower and iron levels
significantly higher in postmortem SN tissue from PD
patients than from healthy controls. Serum iron levels,
however, were lower in PD than in samples from
healthy age-matched controls. Our findings provide evi-
dence for marked changes in iron and copper levels in
the major site of neurodegeneration in PD. These find-
ings warrant further investigation to define the signifi-
cance of SN biometal levels for the pathophysiology of
PD and to determine whether therapies targeting these
metals would be both feasible and clinically useful.
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Supplementary Methods 
Data extraction 
Where missing quantitative data or subject details would result in the exclusion of a paper, 
corresponding authors were contacted to request these details. Studies where metal analysis was 
performed in non-neurological tissue (n = 170) were further examined for reports of metal levels in 
cerebrospinal fluid (CSF), serum and/or plasma. A total of 89 full-text articles were identified for 
eligibility assessment, with 23 post-mortem tissue and 27 biofluid studies excluded (Supplementary 
Tables 2 and 3). For data presented only in graphical form, data values were extracted using 
GraphClick graph digitizer (version 3.0.3; Arizona Software). When necessary, reported standard 
error of the mean (SEM) was converted to standard deviation (SD) using SEM = SD / √n. 
Publication bias 
Publication bias primarily arises from studies reporting statistically significant data having a 
disproportionately larger share of published articles. This was assessed to determine whether effect 
sizes were distributed as expected under the assumption of no influence of publication bias. 
Variables and subgroup analyses 
Variables with potential to modify the measured effect of PD on metal levels, including type of metal, 
subject age and group sex-ratio, duration of PD, post-mortem interval (PMI, for SN tissue), tissue 
preparation technique and analytical method used were also extracted from each included study. Age 
is well-established as the greatest risk factor for PD,1 and age-matching is essential for an accurate 
and valid interpretation of possible associations with neuropathology. Sex matching between 
diagnostic groups is also applicable as PD incidence is higher in males than females, particularly 
during early disease stages.2 When, for example, age groups were sub-categorized and means and 
SDs reported separately for each category, single cohort mean and SD value was calculated 
according to Cochrane Library guidelines.3 The other moderator variables explored were mean age of 
PD and control patients (mean-centered), mean duration of PD (also mean centered), the difference 
between the mean ages of the PD and control groups, differences in sex ratio (reported as the 
percentage of males), and difference in post-mortem interval (PMI) for SN tissue data. Few studies 
reported medications, and these were therefore not included in the current analysis, and no cohort 
contained patients receiving deep brain stimulation. 
Studies were subgrouped based on sample preparation, with fresh frozen tissues and chemically 
fixed tissues analyzed separately. Fresh frozen tissues have likely undergone fewer processes which 
might change metal levels, whilst formalin fixation is reported to alter iron, copper and zinc from 
tissues and therefore may have influenced or obscured any biometal alterations.4, 5 Although other 
methodological factors, including the effect of storage conditions and time, and metal contaminates 
introduced during sample processing, may also influence biometal levels, many studies did not report 
these conditions, making an assessment of the quality of their data difficult. 
Quality assessment 
As studies varied significantly in analytical technique, methodological approach and reporting of 
information, we therefore developed the Quality Assessment Scale for Biochemical Analysis of 
Human Samples as a versatile and useful reference tool to allow a more direct and sensitive 
comparison and collation of data across multiple studies for meta-analyses, and as an aid in the 
design of high-quality human tissue studies. It is notable that access to human post-mortem is 
restricted by brain bank tissue availability, and information regarding origin, preparation and handling 
of these tissues is also limited. This may account for the overall higher quality rating for biofluids 
compared with post-mortem studies in the current analysis; there will be a large availability of suitable 
patient cohorts for biofluid collection and easier access to clinical data from living patients. 
Additionally, we performed a more rigorous sensitivity analysis by eliminating all ‘limited’ quality 
studies and re-analyzing only ‘high’ and ‘moderate’ quality data using REMA. 
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Comparing metals in tissues 
To investigate any covariances in effect between metal levels in different sample types we fitted 
REMA to a dataset containing post-mortem SN tissue, CSF, and serum simultaneously. In this model, 
sample type (three-level categorical variable) and the mean age of the PD group (mean centered as a 
numeric predictor) were defined as moderating variables and fitted additively. In this model significant 
differences between sample types indicated that, when age-matched, metal levels differed as an 
effect of PD
Supplementary Table 1: Exclusion criteria for initial screening of 9026 records. 
Exclusion criteria Number of records excluded 
No full text article 92 
Animal studies 836 
Protein-bound metals only 165 
Case studies 44 
Cell culture experiments 474 
Imaging 703 
Heavy metal exposure cohorts 228 
No copper, iron or zinc data 814 
Not PD 4154 
Review 667 
Repeat data 144 
No quantitative metal measurements 347 
Unrelated topic 91 
Not brain tissuea 170 
a Records describing samples other than neurological tissue were extracted for identification of CSF, and/or serum, and/or 
plasma studies
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Supplementary Table 2: Excluded studies reporting metal levels in human brain tissue 
Article Year Quantifiable metal data? 
Healthy 
controls? 
Multiple 
samples 
(n > 3)? 
Data 
reproduction? 
Includes 
SN? 
Author 
contacted 
(request)? 
Author 
response? 
Primary 
reason/condition for 
exclusion 
Ayton et al.6 2013 No Yes Yes No Yes Yes No No quantifiable data 
Bauminger 
et al.7 1994 Yes Yes No No Yes No - 
Insufficient sample 
size 
Chwiej8 2010 No Yes Yes No Yes Yes No No quantifiable data 
Chwiej et al.9 2008 No Yes Yes No Yes Yes No Did not report total metal levels 
Chwiej et 
al.10 2007 No Yes Yes No Yes Yes No 
Did not report total 
metal levels 
Chwiej et 
al.11 2005 No Yes No No Yes Yes No 
Insufficient sample 
size 
Ektessabi et 
al.12 1999 Yes Yes No No Yes Yes No 
Insufficient sample 
size 
Friedman et 
al.13 2016 Yes Yes Yes Yes Yes No - 
Reproduced data 
from Galazka- 
Friedman et al.14
Galazka- 
Friedman et 
al.14
2002 No Yes Yes Possible Yes No - No quantifiable data 
Galazka- 
Friedman et 
al.15
2004 No Yes Yes Possible Yes No - No quantifiable data 
Good et al.16 1992 No Yes Yes No Yes 
Yes (age; SD; 
sex; PMI; 
disease 
duration) 
Responded; 
data not 
available 
No quantifiable data 
Griffiths et 
al.17 1999 Yes Yes Yes Yes Yes No - 
Reproduced data 
from Griffiths et al.19
Gu et al.18 1998 Yes Yes Yes No No No - Did not measure SN 
Jellinger et 
al.19 1992 No Yes Yes No Yes No - No quantifiable data 
Yu et al.20 2013 Yes Yes Yes No No No - Did not measure SN 
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Kienzl et 
al.21 1995 Yes Yes Yes Yes Yes No - 
Reproduced data 
from Jellinger et al.21
Oakley et 
al.22 2007 No Yes Yes No Yes 
Yes (raw data; 
sex; PMI; 
disease 
duration) 
No No quantifiable data 
Ramos et 
al.23 2014 No Yes No No Yes 
Yes (raw data; 
age; SD; sex; 
PMI; disease 
duration) 
No No quantifiable data 
Sofic et al.24 1991 Yes No Yes No Yes No - Comorbidity 
Visanji et 
al.25 2013 No Yes Yes No Yes Yes (PMI) 
Responded - 
provided 
range 
No quantifiable data 
Wypjewska 
et al.26 2010 Yes Yes Yes Yes Yes No - 
Reproduced data 
from Galazka- 
Friedman et al.14
Yoshida et 
al.27 2003 No Yes Yes No Yes 
Yes (raw data; 
PMI; disease 
duration) 
No No quantifiable data 
Zecca et 
al.28 2004 Yes 
Yes but no 
PD Yes No Yes No - No PD diagnosis 
Abbreviations: PD = Parkinson’s disease; PMI = post-mortem interval; SD = standard deviation; SN = substantia nigra 
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Supplementary Table 3: Characteristics of included studies with human post-mortem SN metal concentration data 
Article Tissue Source 
Primary 
country 
of study 
origin 
Controls 
n (M:F) 
PD n 
(M:F) 
Control 
mean 
age 
(SD) 
PD 
mean 
age 
(SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD relative 
to Control) 
Davies et al.29
(2014) 
New South Wales 
Tissue Resource 
Centre and the Sydney 
Brain Bank (formalin- 
fixed tissue) 
Australia 10 (3:7) 10 (3:7) 
82.4 
(10.2) 
77.6 
(8.7) 
Clinical; 
pathological 12.7 (4.3) 
Fe, Cu, 
Zn 
Fe +49%, Cu 
-65%, Zn n.s.
(PIXE); Fe 
+26%, Cu -
65%, Zn n.s.
(XFM)a
Davies et al.29
(2014) 
New South Wales 
Tissue Resource 
Centre and the Sydney 
Brain Bank (fresh 
tissue) 
Australia 5 (NR) 5 (NR) 82.4 (6.0) 
80.6 
(6.3) 
Clinical; 
pathological 12.7 (4.3) Fe, Cu 
Fe +35%, Cu 
-34%
Dexter et al.30
(1987) 
Parkinson's Disease 
Society Brain Bank, 
Institute of Psychiatry, 
London 
UK 9 (NR) 7 (NR) 72.4 (1.4) 
75.7 
(1.6) 
Clinical; 
pathological NR 
Fe, Cu, 
Zn 
Fe +35%, Cu 
-34%, Zn
+50%
Dexter et al.31
(1989) 
Parkinson's Disease 
Brain Bank, Salpetriere 
Hospital Paris; 
Parkinson's Disease 
Society Brain bank, 
London 
France, 
UK 
34 
(13:21) 
27 
(16:11) 
81.3 
(1.5) 
74.9 
(1.4) 
Clinical; 
pathological 14.5 (1.5) Fe n.s.
Galazka- 
Friedman et 
al.32 (1996) 
NR Poland 17 (NR) 9 (MR) 64 (6) 70 (4) Clinical; pathological 5.8 (1.2) Fe n.s.
Genoud et al.33
(2017) 
New South Wales and 
Sydney Brain Banks Australia 11 (6:5) 
13 
(9:4) 
80.6 
(4.3) 
81.2 
(2.4) 
Clinical; 
pathological 14 (2.4) 
Fe, Cu, 
Zn 
Fe +105%, 
Cu -54%, Zn 
n.s.
Good et al.16 
(1992) NR USA 3 (NR) 3 (NR) NR NR 
Clinical; 
pathological NR Fe Fe +20%
b
Griffiths et al.34
(1993) 
Cambridge Neural 
Tissue Bank UK 6 (NR) 6 (NR) 
83.3 
(2.1) 
83.6 
(2.4) 
Clinical; 
pathological 7 Fe Fe +50% 
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Article Tissue Source 
Primary 
country 
of study 
origin 
Controls 
n (M:F) 
PD n 
(M:F) 
Control 
mean 
age 
(SD) 
PD 
mean 
age 
(SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD relative 
to Control) 
Loeffler et al.35 
(1995) 
Harvard Brain Tissue 
Resource Center USA 8 (NR) 
14 
(NR) 74.6 (8) 
75.6 
(8.0) 
Clinical; 
pathological NR Fe n.s.
Loeffler et al.36
(1996) 
Harvard Brain Tissue 
Resource Center USA 7 (NR) 
14 
(NR) 
75.7 
(2.8) 
74.9 
(2.3) 
Clinical; 
pathological NR Cu Cu -30% 
Mann et al.37
(1994) 
Parkinson's Disease 
Society Brain Bank, 
Kings College London 
UK 22 (NR) 18 (NR) 
76.7 
(10.9) 
73.7 
(6.2) 
Clinical; 
pathological NR Fe, Zn 
Fe +56%, Zn 
n.s.
Oakley et al.22
(2007) NR UK 14 (NR) 
16 
(NR) 70 (13) 
70 
(11) Clinical NR Fe Fe +44%
c
Riederer et al.38
(1989) NR Germany 4 (1:3) 
13 
(6:7) 
73.0 
(4.1) 76 (6) 
Clinical; 
pathological NR 
Fe, Cu, 
Zn 
Fe +18%, Cu 
-50%, Zn n.s.
Sofic et al.24 
(1991) NR Germany 9 (NR) 
15 
(NR) NR 76.8 
Clinical; 
pathological NR Fe Fe +11% 
Sofic et al.39
(1988) NR Germany 8 (4:4) 8 (4:4) 
71.3 
(12.5) 75.3 
Clinical; 
pathological 7.5 (3.4) Fe Fe +44% 
Szczerbowska- 
Boruchowska et 
al.40 (2012) 
Department of 
Neuropathology, 
Poland 
Poland 4 (NR) 4 (NR) NR NR Clinical; pathological NR 
Fe, Cu, 
Zn 
Fe +30%, Cu 
n.s., Zn +57%
Uitti et al.41
(1989) NR Canada 12 (8:4) 9 (6:3) 70 (NR) 
73 
(NR) 
Clinical; 
pathological NR 
Fe, Cu, 
Zn All n.s. 
Visanji et al.25
(2013) 
Canadian Brain Tissue 
bank Canada 3 (2:1) 3 (2:1) 
62.7 
(15.5) 
69.3 
(12.0) 
Clinical; 
pathological 21 (3.8) Fe Fe +46% 
Wypijewska et 
al.26 (2010) 
Medical University of 
Warsaw Poland and 
Mayo Clinic Florida 
Brain Bank 
Poland; 
USA 29 (NR) 
17 
(NR) NR NR 
Clinical; 
pathological NR Fe, Cu n.s.
a Comparison of two imaging methods; Abbreviations: n.s. = not significant (p > 0.05); M:F = male:female; NR = not reported; PD = Parkinson’s disease; PIXE = particle-induced X-ray emission 
spectroscopy; SD = ±1 standard deviation; SN = substantia nigra; XFM = synchrotron X-ray fluorescence microscopy 
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Supplementary Table 4: Excluded studies reporting metal levels in human CSF/serum/plasma 
Article Year 
Full 
article 
access? 
Quantifiable 
sera metal 
data? 
Quantifiable 
CSF metal 
data? 
Quantifiable 
plasma 
metal data? 
Healthy 
controls? 
Multiple 
samples 
(n > 3)? 
Data 
reproduction? 
Valid 
method? Reasons/conditions 
Abbott et 
al.42 1992 No Yes No No Yes - - Yes Text not accessible 
Bharucha 
et al.43 2008 Yes Yes No No Yes Yes No No 
Method not 
sufficiently described 
Boll et al.44 2008 Yes No Yes No Yes Yes No Yes Age not reported 
Chen et 
al.45 1992 No - - - - - - - Text not accessible 
Chitre et 
al.46 1970 Yes Yes No No Yes Yes No No 
Method not 
sufficiently described 
Costa- 
Mallen et 
al.47
2015 Yes Yes No No Yes Yes No No Method not sufficiently described 
Farhoudi 
et al.48 2012 Yes Yes No No Yes Yes No No 
Method not 
sufficiently described 
Fukushima 
et al.49 2010 Yes No No No Yes Yes No Yes No quantifiable data 
Fukushima 
et al.50 2011 Yes No No No Yes Yes Yes Yes Whole blood/plasma 
Ikeda et 
al.51 2011 Yes Yes No No Yes Yes No No 
Method not 
sufficiently described 
Kanabrocki 
et al.52 1967 Yes Yes No No Yes Yes No No Comorbidity 
Kjellin et 
al.53 1967 Yes Yes Yes No No Yes No Yes Text not accessible 
Larumbe 
et al.54 2001 No - - - - - - - 
Method not 
sufficiently described 
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Madenci et 
al.55 2012 Yes No No No Yes Yes No No 
Method not 
sufficiently described 
Mariani et 
al.56 2013 Yes Yes No No Yes Yes Yes Yes 
Data reproduced in 
Mariani et al.48
Meamar et 
al.57 2015 No - - - - - - - Text not accessible 
Mindadse 
et al.58 1967 No - - - - - - - No quantifiable data 
Molina- 
Arjona et 
al.59
1999 No - - - - - - - Text not accessible 
Pall et al.60 1987 Yes No No No Yes Yes No Yes No quantifiable data 
Petrucci et 
al.61 2006 No - - - - - - - No quantifiable data 
Pino et 
al.62 2005 Yes No No No Yes Yes No Yes Text not accessible 
Torsdottir 
et al.63 1999 Yes No No Yes Yes Yes No Yes Comorbidity 
Vecchiola 
et al.64 1966 No - - - - - - - Text not accessible 
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Supplementary Table 5: Characteristics of included studies with human CSF metal concentration data 
Article Tissue Source 
Primary 
country of 
study origin 
Controls 
n (M:F) 
PD n 
(M:F) 
Control 
mean 
age 
(SD) 
PD mean 
age (SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD 
relative to 
Control) 
Alimonti et 
al.65 (2007) NR UK 20 (17:3) 42 (36:6) 
66.2 
(14.7) 
64.5 
(10.7) Clinical 4.9 (4.3) 
Fe, Cu, 
Zn, Mn 
Fe -26%; 
Cu, Zn, Mn 
n.s.
Bocca et al.66
(2006) NR UK 18 (10:8) 91 (64:27) 
63.3 
(13.8) 65.5 (9.7) Clinical 4.6 (4.1) 
Fe, Cu, 
Mn, 
Fe -60%, 
Cu, Zn n.s.; 
Mn -38% 
Boll et al.67
(1999) NR Mexico 
26 
(12:14)a 49 (32:17) 
58.7 
(2.37) 61.3 (3.0) Clinical 5.3 (1.2) Cu n.s.
Forte et al.68
(2004) NR Italy 13 (6:7) 26 (24:2) 
63.8 
(13.7) 
64.9 
(10.8) Clinical 4.8 (3.8) 
Fe, Cu, 
Zn, Mn 
Fe -122% 
Cu, Zn, Mn 
n.s.
Gazzaniga et 
al.69 (1992) NR Italy 22 (20:2) 11 (10:1) 
63.1 
(NR) 64.9 (NR) Clinical NR 
Cu, Fe, 
Mn n.s.
Hozumi et 
al.70 (2011) NR Japan 15 (6:9) 20 (9:11) 
48.4 
(22.2) 68.7 (5.8) Clinical NR 
Fe, Cu, 
Zn, Mn 
Fe n.s.; Cu 
+46%; Zn
+63%; Mn -
42%
Hu et al.71
(2015) 
Beijing Taitan 
Hospital, 
China 
China 31 (NR) 67 (38:29) NR NR Clinical NR Fe, Cu Fe +15%; Cu n.s. 
Jimenez- 
Jimenez et 
al.72 (1998) 
Hospital 
Príncipe de 
Asturias, 
Madrid Spain 
Spain 37 (16:21) 37 (14:23) 62.4 (17.8) 65.7 (8.8) Clinical 7.0 (6.4) 
Fe, Cu, 
Zn, Mn 
Zn -70%; 
Fe, Cu, Mn 
n.s.
Qureshi et 
al.73 (2006) 
Huddinge 
University 
Hospital. 
Swedeng 21 (8:13) 36 (23:13) 62 (11) 71.06 (15.9) Clinical NR 
Fe, Cu, 
Zn 
Fe +36%; 
Cu n.s.; Zn 
-52%
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Article Tissue Source 
Primary 
country of 
study origin 
Controls 
n (M:F) 
PD n 
(M:F) 
Control 
mean 
age 
(SD) 
PD mean 
age (SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD 
relative to 
Control) 
Sanyal et 
al.74 (2016) 
National 
Neuroscience 
Centre (NNC) 
and Nil Ratan 
Sircar Medical 
College and 
Hospital 
(NRS). 
India 60 (42:18) 50 (34:16) 60.1 (10.4) 
58.7 
(12.4) Clinical NR 
Fe, Cu, 
Zn, Mn 
Fe -16%; 
Cu n.s.; Zn 
-13%; Mn -
37%
Wang et al.75
(2016) 
Beijing Tiantan 
Hospital China 30 (NR) 
145 
(73:72) NR 
59.6 
(11.0) Clinical 3.2 (2.9) Fe Fe +34% 
a ambulatory patients with no known neurodegenerative disease; n.s. = not significant (p > 0.05); M:F = male:female; NR = not reported; PD = Parkinson’s disease; SD = ±1 standard deviation 
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Supplementary Table 6: Characteristics of included studies with human serum metal concentration data 
Article Tissue Source 
Primary 
country of 
study origin 
Controls 
n (M:F) 
PD n 
(M:F) 
Control 
mean 
age 
(SD) 
PD mean 
age (SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD 
relative to 
Control) 
Ahmed et 
al.76 (2010) 
SRM Hospital, 
Tamil Nadu India 42 (25:17) 45 (26:19) 
55.6 
(3.3) 57.6 (9.1) Clinical NR 
Fe, Cu, 
Zn, Mn 
Fe -11%; 
Cu +15%; 
Zn -37%; 
+20% Mn
Bocca et al.66
(2006) NR Italy 18 (10:8) 91 (64:27) 
63.3 
(13.8) 65.5 (9.7) Clinical 4.6 (4.1) 
Fe, Cu, 
Zn, Mn 
Fe n.s.; Cu 
-19%; Zn,
Mn n.s.
Cabrera- 
Valdivia et 
al.77 (1994) 
Urban 
hospitals, 
Madrid 
Spain 68 (32:36) 68 (36:32) 65.8 (8.2) 65.8 (7.9) Clinical 5.3 (5.2) Fe n.s.
Forte et al.78
(2005) NR Italy 44 (33:11) 71 (53:18) 
51.9 
(4.0) 65.5 (9.4) Clinical 4.6 (4.5) 
Fe, Cu, 
Zn, Mn 
Fe -42%; 
Cu n.s.; Zn 
-13%; Mn
n.s.
Forte et al.68
(2004) NR Italy 13 (6:7) 26 (24:2) 
63.8 
(13.7) 
64.9 
(10.8) Clinical 4.8 (3.8) 
Fe, Cu, 
Zn, Mn 
Fe n.s.; Cu 
-22%; Zn,
Mn n.s.
Gangania et 
al.79 (2017) NR India 33 (NR) 35 (NR) 50 57 Clinical NR Fe, Cu 
Fe -77%; 
Cu -31% 
Gellein et 
al.80 (2008) 
Levanger 
Hospital; 
Namsos 
Hospital 
Norway 99 (48:51) 33 (16:17) NR 69.6 (9.2) Clinical NR Fe, Cu, Zn, Mn n.s.
Hegde et 
al.81 (2004) 
Sri 
Venkateswara 
Institute of 
Medical 
Science; J.S.S. 
Medical 
Hospital 
India 25 (13:12) 52 (28:24) 55.4 (6.4) 58.2 (4.7) Clinical 4.8 (2.5) 
Fe, Cu, 
Zn 
Fe -24%; 
Cu -600%; 
Zn -20% 
Hu et al.82
(2015) 
Beijing Taitan 
Hospital China 31 (NR) 
200 
(115:85) NR NR Clinical NR Fe n.s.
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Article Tissue Source 
Primary 
country 
of study 
origin 
Control
s n 
(M:F) 
PD n 
(M:F) 
Control 
mean age 
(SD) 
PD mean 
age (SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD 
relative to 
Control) 
Jimenez- 
Jimenez et 
al.83 (1992) 
Hospital 
Príncipe de 
Asturias, 
Madrid 
Spain 39 (19:20) 39 (20:19) 66.2 (9.5) 67.3 (8.4) Clinical 6.0 (4.2) Cu, Zn n.s.
Jimenez- 
Jimenez et 
al.72 (1998) 
Hospital 
Príncipe de 
Asturias, Madrid Spain 37 (16:21) 37 (14:23) 
62.4 
(17.8) 65.7 (8.8) Clinical 7.0 (6.4) 
Fe, Cu, 
Zn, Mn n.s.
Marder et 
al.84 (1998) NR USA 
353 
(124:229) 
103 
(49:54) 
73.5 
(6.1) 
69.6 
(10.4) Clinical NR Fe Fe -20% 
Mariani et 
al.85 (2013) 
San Giovanni 
Calibita – 
Fatebenefratelli 
Hospital and 
University Campus 
Bio- Medico, Rome 
Italy 112 (40:72) 
174 
(112:62) 62 65.2 (9.7) Clinical NR Fe n.s.
Qureshi et 
al.73 (2006) 
Huddinge 
University 
Hospital. 
Sweden 21 (8:13) 36 (23:13) 62 (11) 71.1 (15.9) Clinical NR 
Fe, Cu, 
Zn n.s.
Sanyal et 
al.74 (2016) 
National 
Neuroscience 
Centre and Nil 
Ratan Sircar 
Medical College 
and Hospital, 
Kolkata 
India 280 (NR) 250 (NR) 56.4 (9.7) 
57.9 
(12.1) Clinical NR 
Fe, Cu, 
Zn, Mn 
Fe -43%; 
Cu -23%; 
Zn, Mn n.s. 
Younes- 
Mhenni et 
al.86 (2013) 
University 
Hospital of 
Monastir 
Tunisia 36 (14:22) 48 (26:22) 59.7 (12.1) 
65.8 
(10.2) Clinical 6.3 (5.5) Cu, Zn 
Cu -31%; 
Zn n.s. 
Zhao et al.87
(2013) 
Wenzhou 
Medical 
University 
China 302 (153:149) 
238 
(121:117) 
65.6 
(12.2) 
66.6 
(11.3) Clinical NR 
Fe, Cu, 
Zn 
Fe +11%; 
Cu n.s.; Zn 
-40%
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Abbreviations: n.s. = not significant (p > 0.05); M:F = male:female; NR = not reported; PD = Parkinson’s disease; SD = ±1 standard deviation 
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Supplementary Table 7: Characteristics of included studies with human plasma metal concentration data 
Article Tissue Source 
Primary 
country of 
study origin 
Controls 
n (M:F) 
PD n 
(M:F) 
Control 
mean 
age 
(SD) 
PD mean 
age (SD) 
PD 
diagnosis 
Duration 
of 
disease 
(SD) 
Measured 
metals 
% change 
(PD 
relative to 
Control) 
Annanmaki 
et al.88
(2007) 
NR Finland 29 (13:16) 30 (23:17) 60.2 (5.1) 60.8 (6.5) Clinical < 10 Fe n.s.
Arnal et al.89
(2010) NR Argentina 79 (41:38) 87 (37:50) 
77.8 
(3.7) 70.0 (4.6) Clinical 6.5 (3.4) Cu n.s.
Bailet et al.90
(2010) 
Grenoble 
Hospital France 30 (11:19) 24 (17:7) 
39.4 
(11.3) 57.8 (8.5) Clinical NR Cu, Zn n.s.
Kocaturk et 
al.91 (2000) NR NR 24 (NR) 30 (NR) 61 64 Clinical NR Cu, Zn n.s.
Kumudini et 
al.92 (2014) 
Nizam's 
Institute of 
Medical 
Sciences, 
Hyderabad 
India 175 (120:55) 
150 
(107:43) 
53.7 
(10.9) 
55.7 
(10.6) Clinical NR Cu, Fe 
Fe +24%; 
Cu +27% 
Abbreviations: n.s. = not significant (p > 0.05); M:F = male:female; NR = not reported; PD = Parkinson’s disease; SD = ±1 standard deviation 
Supplementary Table 8: Results of Quality Assessment Scale for Biochemical Analysis 
of Human Samples 
See Microsoft Excel file ‘Supplementary Table 8 - Results of Study Quality Assessment 
scale.xls’ for data and outcomes. 
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eTable 8: Results of Study Quality Assessment scale 
ID Author Year Title Choice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason PointsChoice Reason Points
#7 Davies et al. 2014
Copper pathology in vulnerable 
brain regions in Parkinson's 
disease
a Clinical and pathologically 2 a From 2 brain banks 2 a Same 1 a No disease 1 a
Age and sex 
matched 2 b <48hrs 0 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 a Same 1 13 High
#8 Dexter et al. 1987 Increased nigral iron content in postmortem Parkinsonian brain a
Clinical and 
pathologically 2 b
From PD society 
brain bank 1 a Same 1 a No disease 1 b
Age not sex 
matched 1 a <24hrs 1 a Detailed methods 1 d Not stated 0 c Not stated 0 c Not stated 0 8 Moderate
#9 Dexter et al. 1989
Increased nigral iron content and 
alterations in other metal ions 
occurring in brain in Parkinson's 
disease
a Clinical and pathologically 2 a From 2 brain banks 2 a Same 1 a No disease 1 b
Age and sex 
matched 1 a <24hrs 1 a Detailed methods 2 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 11 High
#11
Galzka-
Friedman et 
al.
1996
Iron in Parkinsonian and Control 
Substantia
Nigra-A Mossbauer Spectroscopy 
Study
a Clinical and pathologically 2 c Not stated 0 b Not stated 0 a No disease 1 c
Not age or sex 
matched 0 b <48hrs 0 a Detailed methods 2 d Not stated 0 c Not stated 0 c Not stated 0 5 Limited
#15 Genoud et al. 2017
Subcellular 
compartmentalisation of copper, 
iron, manganese and zinc in the 
Parkinson’s disease brain
a Clinical and pathologically 2 a From 2 brain banks 2 a Same 1 a No disease 1 a
Age and sex 
matched 2 a <24hrs 1 a Detailed methods 2 b
Randomise
d/blinded 1 a
Detailed 
statistics 2 c
One PD 
excluded 0 14 High
#16 Good et al. 1992
Neuromelanin-containing 
neurons of the substantia nigra 
accumulate iron and aluminum in 
Parkinson's disease: A LAMMA 
study
a Clinical and pathologically 2 c Not stated 0 b Not stated 0 a No disease 1 b Age matched 1 a <10hrs 1 a Detailed methods 2 d Not stated 0 c Not stated 0 c Not stated 0 7 Moderate
#17 Griffiths et al. 1993
Distribution of iron in the basal 
ganglia and neocortex in 
postmortem tissue in Parkinson's 
disease and Alzheimer's disease
a Clinical and pathologically 2 b
Cambridge neural 
tissue bank 1 a Same 1 a No disease 1 b Age matched 1 b >48hrs 0 a Detailed methods 2 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 9 Moderate
#23 Loeffler et al. 1995
Transferrin and iron in normal, 
Alzheimer's disease, and 
Parkinson's disease brain regions
a Clinical and pathologically 2 c
Brain tissue 
resource centre 1 a Same 1 a No disease 1 a
Age and sex 
matched 2 a <24hrs 1 c
Missing major info 
on technique for 
Fe quantification
0 d Not stated 0 a Detailed statistics 2 c Not stated 0 10 Moderate
#24 Loeffler et al. 1996
Increased regional brain 
concentrations of ceruloplasmin 
in neurodegenerative disorders
a Clinical and pathologically 2 b
From Brain tissue 
resource centre 1 a Same 1 a No disease 1 b Age matched 1 a <24hrs 1 a Detailed methods 2 b Blinded 1 a
Detailed 
statistics 2 c Not stated 0 12 High
#25 Mann et al. 1994
Complex I, iron, and ferritin in 
Parkinson's disease substantia 
nigra
a Clinical and pathologically 2 b
PD society brain 
bank 1 a Same 1 a No disease 1 a
Age and sex 
matched 2 a <24hrs 1 a Detailed methods 2 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 11 High
#26 Oakley et al. 2007
Individual dopaminergic neurons 
show
raised iron levels in Parkinson 
disease
a Clinical 1 c Not stated 0 b Not stated 0 a No disease 1 b Age matched 1 c Not stated 0 a Detailed methods 2 b Blinded 1 b Statistical testmentioned 1 c Not stated 0 7 Moderate
#28 Riederer et al. 1989
Transition metals, ferritin, 
glutathione and ascorbic acid in 
Parkinsonian Brains
a Clinical and pathologically 2 c Not stated 0 b Not stated 0 a No disease 1 b Age matched 1 a <24hrs 1 a Detailed methods 2 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 8 Moderate
#29 Sofic et al. 1991
Selective increase of iron in 
substantia nigra zona compacta 
of parkinsonian brains
a Clinical and pathologically 2 c Not stated 0 b Not stated 0 b Not stated 0 c Not stated 0 c Not stated 0 b
Missing details of 
technique 1 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 4 Limited
#30 Sofic et al. 1988
Increased iron (III) and total iron 
content in post mortem 
substantia nigra of parkinsonian 
brain
a Clinical and pathologically 2 c Not stated 0 b Not stated 0 a No disease 1 a
Age and sex 
matched 2 b >24hrs 0 c
Missing key 
method detial 0 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 6 Moderate
#31
Szczerbowska-
Boruchowska 
et al.
2012
Elemental micro-imaging and 
quantification of human 
substantia nigra using 
synchrotron radiation based x-
ray fluorescence—in relation to 
Parkinson’s disease
a Clinical and pathologically 2 b
Department of 
Neuropathology, 
Poland
1 a Same 1 a No disease 1 b Age matched 1 a <24hrs 1 a Detailed methods 2 d Not stated 0 b Statistical testmentioned 1 c Not stated 0 10 Moderate
Comparability Analysis
1 2 3 4 1 2 3
Assessment
Total points
1 2 3
Quality
SelectionArticle informationTissue
Post-mortem 
substanita nigra
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#32 Uitti et al. 1989
Regional metal concentrations in 
Parkinson's disease, other chronic 
neurological diseases, and 
control brains
a Clinical and pathologically 2 c Not stated 0 b Not stated 0 a No disease 1 a
Age and sex 
matched 2 a <24hrs 1 a Detailed methods 2 b Blinded 1 a
Detailed 
statistics 2 c Not stated 0 11 High
#33 Visanji et al. 2013
Iron deficiency in parkinsonism: 
Region-specific iron 
dysregulation in parkinson's 
disease and multiple system 
atrophy
a Clinical and pathologically 2 b
Canadian Brian 
tissue bank 1 a Same 1 b Not stated 0 a
Age and sex 
matched 2 a 10hrs 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 11 High
#34 Wypijewska et al. 2010
Iron and reactive oxygen species 
activity in parkinsonian 
substantia nigra
a Clinical and pathologically 2 a 2 brain banks 2 a Same 1 a No disease 1 b Age matched 1 a <24hrs 1 a Detailed methods 2 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 11 High
#108 Bocca et al. 2006
Metal changes in CSF and 
peripheral compartments of 
parkinsonian patients
b Clinical 1 c Not stated 0 c Not stated 0 a Healthy 1 a Controls for age and sex 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 9 Moderate
#117 Forte et al. 2004
Trace and major elements in 
whole blood, serum, 
cerebrospinal fluid and urine of 
patients with Parkinson's disease
b Clinical 1 c Not stated 0 a Same bank 1 b affected by peripheral neurological disorders0 b Age but not sex matched 1 a Frozen 1 a Detailed methods 2 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 7 Moderate
#125 Hu et al. 2015
Investigation on abnormal iron 
metabolism and related 
inflammation in Parkinson 
disease patients with probable 
RBD
b Clinical 1 a Beijing Tiantan hospital 1 a Same bank 1 a Healthy 1 a
Age and sex 
matched 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 11 High
#128 Jimenez-Jimenez et al. 1998
Cerebrospinal fluid levels of 
transition metals in patients with 
Parkinson's disease
b Clinical 1 a
Several hospitals; 
Hospital Príncipe de 
Asturias, Madrid 
Spain
2 a Same bank 1 a Healthy 1 a Age and sex matched 2 a Frozen 1 a Detailed methods 2 b Blinded 1 b
Statistical test
mentioned 1 c Not stated 0 12 High
#146 Qureshi et al. 2005
Impact of selenium, iron, copper 
and zinc in on/off Parkinson's 
patients on L-dopa therapy
b Clinical 1 b Huddinge University Hospital 1 a Same bank 1 a Healthy 1 b
Sex matched 
but not age 
matched
1 a Frozen 1 a Detailed methods 2 d Not stated 0 b Statistical testmentioned 1 c Not stated 0 9 Moderate
#147 Sanyal et al. 2016
Metallomic Biomarkers in 
Cerebrospinal fluid and Serum in 
patients with Parkinson's disease 
in Indian population
b Clinical 1 a
National 
Neurosciences 
Centre and Nil 
Ratan Sircar 
Medical College and 
Hospial, Kolkata, 
India
2 a Same bank 1 a Healthy 1 a Age and sex matched 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 12 High
#101 Ahmed et al. 2010
Metallomic Profiling and Linkage 
Map Analysis of Early Parkinson's 
Disease: A New Insight to 
Aluminum Marker for the 
Possible Diagnosis
b Clinical 1 b One tissue bank 1 a Same bank 1 b Not stated 0 a Controls for age and sex 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 10 Moderate
#111Cabrera-Valdivia et al.1994 Peripheral iron metabolism in patients with Parkinson's disease b Clinical 1 a Several hospitals 2 a Same bank 1 b Unspecified 0 a
Age and sex 
matched 2 a Frozen 1 b
Missing technique 
info 1 b Blinded 1 b
Statistical test
mentioned 1 c Not stated 0 10 Moderate
#116 Forte et al. 2005 Metals and oxidative stress in patients with Parkinson's disease b Clinical 1 b London brain bank 1 a Same bank 1 a Healthy 1 b
Sex but not 
age matched 1 b Not specified 0 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 9 Moderate
#120 Gangania et al. 2017
Role of Iron and copper in the 
pathogenesis of Parkinson's 
disease
b Clinical 1 c Not stated 0 b Not stated 0 a Healthy 1 c Not age or sex matched 0 a Frozen 1 c
Missing technique 
info 0 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 4 Limited
#122 Gellein et al. 2008
Trace elements in serum from 
patients with Parkinson's disease--
a prospective case-control study: 
the Nord-Trondelag Health Study 
(HUNT)
b Clinical 1 a
Levanger hospiral 
and Namsos 
hospital, Norway
2 a Same bank 1 a Healthy 1 a Age and sex matched 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 12 High
#123 Hegde et al. 2004
Serum trace element levels and 
the complexity of inter-element 
relations in patients with 
Parkinson's disease
b Clinical 1 a
Sri Venkateswara 
Insitute of Medical 
Science and JSS 
Medical Hospital, 
India
2 a Same bank 1 a Healthy 1 a Age and sex matched 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 12 High
Sera and CSF
Sera only 
Post-mortem
substanita nigra
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#127Jimenez-Jimenez et al.1992
Serum levels of zinc and copper 
in patients with Parkinson's 
disease
b Clinical 1 a
Several hospitals; 
Hospital Príncipe de 
Asturias, Madrid 
Spain
2 a Same bank 1 b Not stated 0 a Age and sex matched 2 a Frozen 1 a Detailed methods 2 b Blinded 1 b
Statistical test
mentioned 1 c Not stated 0 11 High
#135 Marder et al. 1998
Systemic iron metabolism and 
mortality from Parkinson's 
disease
b Clinical 1 c Not stated 0 b Not stated 0 a Healthy 1 b Age matched 1 a Frozen 1 a Detailed methods 2 d Not stated 0 a Detailed statistics 2 c Not stated 0 8 Moderate
#136 Mariani et al. 2016
Association between sex, 
systemic iron variation and 
probability of Parkinson's disease
b Clinical 1 a
San Giovanni 
Calibita-
Fatebenefratelli 
Hospital and 
University Campus 
Bio-Medico, Rome 
Italy
2 a Same bank 1 a Healthy 1 c Not age or sex matched 0 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 10 Moderate
#151Younes-Mhenni et al.2013
Serum Copper, Zinc and Selenium 
levels in Tunisian patients with 
Parkinson's disease
b Clinical 1 b University hospital of Monastir, Tunisia 1 a Same bank 1 a Healthy 1 c
Not age or sex 
matched 0 b Not specified 0 b
Missing minor 
technique info 1 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 6 Moderate
#152 Zhao et al. 2013
Assessing plasma levels of 
selenium, copper, iron and zinc in 
patients of Parkinson's disease
b Clinical 1 b Wenzhou Medical University 1 a Same bank 1 a Healthy 1 a
Age and sex 
matched 2 a Frozen 1 a Detailed methods 2 a
Randomise
d 1 a
Detailed 
statistics 2 c Not stated 0 12 High
#102 Alimonti et al. 2017
Elemental profile of 
cerebrospinal fluid in patients 
with Parkinson's disease
b Clinical 1 c Not stated 0 a Same bank 1 a Healthy 1 a Controls for age and sex 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 10 Moderate
#110 Boll et al. 1999
Reduced ferroxidase activity in 
the cerebrospinal fluid from 
patients with Parkinson's disease
b Clinical 1 b
Movement 
disorders clinic, 
National Institute of 
Neurology and 
Neurosurgery, 
Mexico
1 a Same bank 1 a Healthy 1 a Controls for age and sex 2 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 11 High
#103 Hozumi et al. 2011
Patterns of levels of biological 
metals in CSF differ among 
neurodegenerative diseases
b Clinical 1 b British Brain Bank 1 a Same bank 1 bUnspecific neurological disease0 c
Controls for 
neither but 
age does not 
correlate
0 b Not specified 0 a Detailed methods 2 d Not stated 0 a Detailed statistics 2 c Not stated 0 7 Moderate
#121 Gazzaniga et al. 1992
A case control study of CSF 
copper, iron and manganese in 
Parkinson disease
b Clinical 1 c Not stated 0 b Not stated 0 b Not stated 0 a Age and sex matched 2 a Frozen 1 b Missing prep 1 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 6 Moderate
#104 Annanmaki et al. 2007 Low plasma uric acid level in Parkinson's disease b Clinical 1 b One tissue bank 1 a Same bank 1 a Healthy 1 b Age matched 1 b Not specified 0 b
Missing minor 
technique info 1 d Not stated 0 a
Detailed 
statistics 2 c
5 excluded 
controls 0 8 Moderate
#105 Arnal et al. 2010
Clinical utility of copper, 
ceruloplasmin, and 
metallothionein plasma 
determinations in human 
neurodegenerative patients and 
their first-degree relatives
b Clinical 1 b One tissue bank 1 a Same bank 1 a Healthy 1 b Age but not sex matched 1 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 10 Moderate
#106 Baillet et al. 2010
The role of oxidative stress in 
amyotrophic lateral sclerosis and 
Parkinson's disease
b Clinical 1 b One tissue bank 1 b Not stated 0 a Healthy 1 c Not age or sex matched 0 a Frozen 1 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 8 Moderate
#131 Kocaturk et al. 2000
Superoxide dismutase activity 
and zinc and copper 
concentrations in Parkinson's 
disease
c Not Stated 0 c Not stated 0 b Not stated 0 a Healthy 1 a Age but not sex matched 1 b Not specified 0 b
Missing minor 
technique info 1 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 4 Limited
#132 Kumudini et al. 2014
Association of Parkinson's disease 
with altered serum levels of lead 
and transition metals among 
South Indian subjects
b Clinical 1 b
Nizams Institute of 
Medical Sciences, 
Hyderabad, India
1 a Same bank 1 a Healthy 1 a Age but not sex matched 1 b Not specified 0 b
Missing minor 
technique info 1 d Not stated 0 b
Statistical test
mentioned 1 c Not stated 0 7 Moderate
#148 Torsdottir et al. 1999
Copper, ceruloplasmin, 
superoxide dismutase and iron 
parameters in Parkinson's 
disease
b Clinical 1 c Not stated 0 b Not stated 0 a Healthy 1 a Age but not sex matched 1 b Not specified 0 a Detailed methods 2 d Not stated 0 a
Detailed 
statistics 2 c Not stated 0 7 Moderate
CSF only 
Plasma
Sera only
79
80 
Supplementary Table 9: Outcomes of subgroup meta-analyses per Quality Assessment Scale for Biochemical Analysis of Human Samples 
Sample type Metal Subgroup Articles (n) Controls (n) PD (n) Effect size (CI) Effect size (P) I
2
Overall 17 221 203 1.22 (0.36, 2.09) 0.0055** 92.8 
High 7 118 93 0.86 (0.16, 1.56) 0.0161 82.0 
Fe Moderate 8 60 63 2.10 (-0.08 4.27) 0.0586 95.2 
Limited 2 30 22 0.35 (-0.25, 0.94) 0.2558 0 
Overall ex. limited 15 191 181 1.35 (0.37, 2.33) 0.007* 93.4 
SN Overall 9 134 127 -2.00 (-2.81, -1.19) 0.0051** 92.1 
Cu High 6 100 86 -2.05 (-2.95, -1.16) <0.0001*** 83.9 
Moderate 3 21 28 -1.84 (-4.04, 0.036) 0.1008 87.7 
Overall 7 76 71 0.64 (-0.28, 1.56) 0.175 84.8 
Zn High 4 44 40 -0.04 (-0.76, 0.68) 0.9199 67.3 
Moderate 3 24 23 1.83 (0.34, 3.32) 0.0163* 76.2 
CSF 
Fe 
Overall 
High 
Moderate 
9 
4 
5 
236 
135 
101 
458 
220 
238 
0.003 (-0.74, 0.74) 
-0.53 (-0.79, -0.26)
0.47 (-0.78,1.71)
0.9936 
0.0001*** 
0.464 
94.3 
23.0 
95.0 
Cu 
Overall 
High 
Moderate 
10 
6 
4 
263 
192 
71 
429 
336 
93 
-0.05 (-0.41, 0.31)
-0.16 (-0.35, 0.02)
0.20 (-0.82, 1.22)
0.7917 
0.0859 
0.7064 
78.5 
0 
89.1 
Zn 
Overall 
High 
Moderate 
7 
4 
3 
236 
135 
49 
302 
220 
82 
-0.43 (-1.2, 0.35)
-0.42 (-0.65, -0.19)
-0.46 (-2.58, 1.65)
0.2778 
0.0004*** 
0.6688 
93.1 
0 
96.3 
Mn 
Overall 
High 
Moderate 
7 
4 
3 
185 
135 
50 
277 
220 
57 
-0.19 (-0.59, 0.20)
-0.31 (-0.77, 0.15)
0.01 (-0.78, 0.80)
0.3354 
0.1828 
0.9819 
72.2 
73.7 
74.0 
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Sample type Metal Subgroup Articles (n) Controls (n) PD (n) Effect size (CI) Effect size (P) I
2
Serum 
Fe 
Overall 
High 
Moderate 
Limited 
Overall ex. limited 
16 
6 
7 
1 
15 
1493 
761 
653 
36 
1457 
1219 
701 
441 
35 
1184 
-0.77 (-1.43, -0.10)
-0.67 (-1.91, 0.59)
-0.60 (-1.27, 0.07)
-2.63 (-3.28, -1.98)
-0.63 (-1.28, 0.03)
0.024* 
0.3013 
0.0814 
<0.0001*** 
0.06 
98.0 
98.8 
95.6 
N/A 
98.0 
Cu 
Overall 
High 
Moderate 
Limited 
Overall ex. limited 
15 
8 
6 
1 
14 
1132 
831 
268 
33 
1099 
1235 
882 
318 
35 
1200 
-0.70 (-1.58, 0.18)
-1.23 (-2.60, 0.14)
0.12 (-0.91, 1.15)
-1.42 (-1.96, -0.89)
-0.65 (-1.59, 0.29)
0.1172 
0.0783 
0.8239 
<0.0001*** 
0.1733 
98.8 
99.2 
96.9 
N/A 
98.9 
Zn 
Overall 
High 
Moderate 
12 
7 
5 
956 
800 
156 
966 
740 
226 
-0.50 (-0.97, -0.3)
-0.27 (-0.67, 0.13)
-0.85 (-1.86, 0.16)
0.0378* 
0.1782 
0.1003 
95.2 
91.1 
94.9 
Mn 
Overall 
High 
Moderate 
7 
4 
3 
533 
434 
99 
553 
411 
142 
0.04 (-0.68, 0.75) 
-0.42 (-0.77, -0.07)
0.71 (-0.69, 2.11)
0.9185 
0.0182* 
0.3189 
95.8 
72.2 
95.5 
Plasma 
Fe 
Overall 
Moderate 
2 
2 
199 
199 
190 
190 
0.35 (-1.07, 1.77) 
0.35 (-1.07, 1.77) 
0.6279 
0.6279 
96.4 
96.4 
Cu 
Overall 
Moderate 
Limited 
Overall ex. limited 
4 
3 
1 
3 
279 
255 
24 
255 
291 
261 
30 
261 
-0.00 (-1.82, 1.81)
0.61 (-1.28, 2.50)
-1.88 (-2.52, -1.23)
0.61 (-1.28, 2.50)
0.9963 
0.5264 
<0.0001*** 
0.5264 
98.6 
98.6 
N/A 
98.6 
Zn 
Overall 
Moderate 
Limited 
Overall ex. limited 
2 
1 
1 
1 
54 
30 
24 
30 
54 
24 
30 
24 
-0.40 (-0.78, -0.01)
-0.38(-0.92, 0.16)
-0.41 (-0.95, 0.13)
-0.38 (-0.92, 0.16)
0.043* 
0.169 
0.137 
0.169 
0 
N/A 
N/A 
N/A 
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Abbreviations: CI = confidence interval; Cu = copper; Fe = iron; PD = Parkinson’s disease. 
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Supplementary Table 10: Outcomes of moderating variables subgroup analyses 
Tissue Metal Moderating variable Outcome Articles (n) 
Controls 
(n) 
PD 
(n) Result Effect size (CI) 
Effect size 
(P) I
2
AAS 3 36 23 - -2.25(-4.02, -0.47) 0.013** 
Technique ICP-MS Mossbauer 
4 
1 
55 
17 
63 
29 
- 
- 
-2.42(-3.92, -0.92)
-1.10(-3.98, 1.77)
0.0016*** 
0.4517 85.33 
Synchrotron/PIXE 3 19 19 - -1.53(-3.33, 0.27) 0.0961 
Tissue preparation 
Fresh 
Formalin 
8 
2 
108 
19 
112 
22 
- 
- 
-2.06(-3.01, -1.12)
-1.76(-3.73, 0.21)
<0.0001*** 
0.0799 
85.24 
Mean centred PD Age 7 106 - 
Intercept 
Slope 
-2.33 (-3.19, -1.47)
0.14 (-0.15, 0.42)
<0.0001*** 
0.3451 
79.79 
Cu Age Mean centred Control Age 7 - 101 
Intercept 
Slope 
-2.54 (-3.19, -1.49)
-0.07 (-0.10, 0.25)
<0.0001*** 
0.3871 
79.37 
Difference (PD - Control) 7 106 101 
Intercept 
Slope 
-2.34 (-3.35, -1.33)
0.07 (-0.10, 0.25)
<0.0001*** 
0.4112 
82.36 
SN PMI Difference (PD-Control) 8 118 122 
Intercept 
Slope 
-2.06 (-2.90, -1.22)
0.03 (-0.05, 0.11)
<0.0001*** 
0.4071 
84.79 
Sex Difference % male (PD - Control) 4 57 58 Intercept Slope 
-2.23 (-3.83, -0.62)
-0.05 (-0.15, 0.04)
0.0067** 
0.2855 87.51 
Disease duration Mean centred disease duration 4 54 60 Intercept Slope 
-2.10 (-3.41, -0.79)
-0.77 (-2.13, 0.59)
0.0017** 
0.2686 84.54 
AAS 4 31 25 - 1.87(-0.42, 4.16) 0.1097 
ICP-MS 5 73 85 - 1.69(-0.24, 3.63) 0.0863 
Technique Mossbauer Other 
2 
3 
24 
33 
50 
25 
- 
- 
0.22(-2.81, 3.25) 
1.72(-0.87, 4.32) 
0.8864 
0.1931 94.3 
Spectrophotometry 2 23 17 - 0.65(-2.41, 3.71) 0.6788 
Fe Synchrotron/PIXE 3 19 19 - 0.47(-2.07, 3.02) 0.7135 
Tissue preparation Fresh Formalin-fixed 
14 
4 
173 
30 
188 
33 
- 
- 
1.48(0.50, 2.46) 
0.28(-1.59, 2.15) 
0.003** 
0.7668 92.79 
Age Mean centred PD Age 15 184 - 
Intercept 
Slope 
1.37 (0.36, 2.38) 
0.03 (-0.23, 0.30) 
0.0081** 
0.7961 94.53 
Mean centred Control Age 14 - 195 Intercept 1.45 (0.37, 2.52) 0.0082** 94.68 
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Tissue Metal Moderating variable Outcome Articles (n) 
Controls 
(n) 
PD 
(n) Result Effect size (CI) 
Effect size 
(P) I
2
Slope 0.05 (-0.12, 0.22) 0.5730 
Difference (PD - Control) 14 169 195 Intercept Slope 
1.35 (0.38 ,2.32) 
-0.06 (-0.28, 0.17)
0.0065** 
0.6333 93.46 
PMI Difference (PD-Control) 13 150 159 Intercept Slope 
0.51 (-0.04, 1.07) 
0.09 (0.04, 0.15) 
0.0703 
0.0008*** 79.74 
Sex Difference % male (PD - Control) 8 78 83 Intercept Slope 
0.84 (-0.68, 2.36) 
0.08 (-0.015, 0.18) 
0.2797 
0.0979 92.29 
Disease duration Mean centred disease duration 8 86 86 Intercept Slope 
1.51 (0.14, 2.89) 
-0.07 (-0.38, 0.23)
0.0310* 
0.6325 92.47 
AAS 2 17 20 - 0.15(-1.92, 2.21) 0.8890 
Technique ICP-MS 4 42 44 - 1.01(-0.46,2.49) 0.1783 87.96 
Microprobe 2 12 12 - 0.43(-1.72, 2.58) 0.6943 
Tissue preparation Fresh Formalin 
7 
1 
62 
9 
64 
12 
- 
- 
0.82(-0.19, 1.82) 
-0.53(-3.10, 2.04)
0.1101 
0.6868 84.57 
Mean centred PD Age 6 67 - Intercept Slope 
0.56 (-0.57, 1.69) 
-0.00 (-0.33, 0.33) 
0.3285 
0.9989 89.32 
Zn 
Age Mean centred Control Age 6 - 72 Intercept 
Slope 
0.56 (-0.54, 1.67) 
-0.07 (-0.34, 0.20)
0.3163 
0.6318 
88.85 
Difference (PD - Control) 6 67 72 Intercept Slope 
0.44 (-0.85, 1.73)
0.04 (-0.17, 0.25)
0.5041 
0.7153 88.99 
PMI Difference (PD - Control) 7 62 64 Intercept Slope 
0.89 (-0.22, 2.00)
-0.03 (-0.16, 0.10)
0.1174 
0.6418 86.34 
Sex Difference % male (PD - Control) 3 26 28 Intercept Slope 
-0.29 (-0.89, 0.31)
-0.05 (-0.10, 0.00)
0.3369 
0.0519* 0.00 
Disease duration Mean centred disease duration 3 25 24 
Intercept 
Slope 
0.32 (-1.31, 1.95)
-0.47 (-2.31, 1.36)
0.7035 
0.6135 85.93 
AAS 7 648 715 - 
- 
- 
- 
Intercept 
Slope 
Intercept 
Slope 
0.85(-1.29, 1.06) 
-4.12(-7.25, -0.98)
-0.71(-1.99, 0.57)
-1.42(-4.55, 1.70)
-0.46 (-1.29, 0.37)
-0.01 (-0.20, 0.17)
-0.21 (-0.90, 0.47)
0.06 (-0.08, 0.19)
0.8472 
0.0101** 
0.2800 
0.3721 
0.2740 
0.8926 
0.5418 
0.4274 
Technique Spectrophotometry ICP-MS 
1 
6 
39 
369 
39 
264 98.67 
Serum Cu Other 1 35 33 
Mean centred PD Age 14 1093 - 98.39 
Age 
Mean centred Control Age 13 - 1002 97.61 
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Tissue Metal Moderating variable Outcome Articles (n) 
Controls 
(n) 
PD 
(n) Result Effect size (CI) 
Effect size 
(P) I
2
Sex 
Difference (PD - Control) 
Difference % male (PD - Control) 
13 
13 
1060 
950 
1002 
819 
Intercept 
Slope 
Intercept 
Slope 
-0.74 (-1.97, 0.50)
0.06 (-0.17, 0.30)
-0.02 (-1.21, 1.17)
-0.04 (-0.09, 0.01)
0.2430 
0.5883 
0.9737 
0.1082 
98.66 
98.46 
Disease duration Mean centred disease duration 8 456 324 Intercept Slope 
-0.28 (-1.06, 0.51)
0.37 (-0.42, 1.16)
0.4930 
0.3594 95.55 
Technique 
AAS 
ICP-MS 
Other 
6 
7 
1 
756 
386 
35 
1105 
309 
33 
- 
- 
- 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
-0.81(-1.80, 0.18)
-0.47(-1.40, 0.46)
-2.63(-5.11, -0.14)
-0.77 (-1.30, -0.25)
0.18 (0.06, 0.29)
-0.80 (-1.38, -0.22)
0.13 (0.04, 0.22)
-0.56 (-1.48, 0.36)
-0.07 (-0.24, 0.10)
-0.50 (-1.04, 0.04)
0.01 (-0.02, 0.04)
-0.10 (-0.56, 0.36)
0.10 (-0.36, 0.55)
0.1085 
0.3211 
0.0387* 
0.0039** 
0.0028** 
0.0067** 
0.0059* 
0.2346 
0.4144 
0.0715 
0.3925 
0.6664 
0.6769 
98.04 
Mean centred PD Age 14 1177 - 96.73 
Fe Age Mean centred Control Age 13 - 1348 97.08 
Difference (PD - Control) 13 1144 1348 98.22 
Sex Difference % male (PD - Control) 12 892 1134 94.57 
Disease duration Disease duration 7 437 317 87.31 
Technique AAS ICP-MS 
6 
6 
648 
318 
715 
241 
- 
- 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
-0.17(-0.80, 0.46)
-0.84(-1.49, -0.20)
-0.50 (-0.94, -0.06)
0.09 (-0.01, 0.19)
-0.54 (-1.03, -0.04)
0.08 (-0.03, 0.19)
-0.55 (-1.32, 0.23)
0.00 (-0.14, 0.14)
-0.63 (-1.25, -0.00)
0.01 (-0.03, 0.05)
-0.21 (-0.46, 0.04)
0.43 (0.16, 0.07)
0.592 
0.0105** 
0.0255* 
0.0813 
0.0329* 
0.1624 
0.1680 
0.9825 
0.0492* 
0.5774 
0.0967 
0.0020** 
94.56 
Mean centred PD Age 12 966 - 93.17 
Age Mean centred Control Age 11 - 857 94.19 
Zn 
Difference (PD - Control) 11 933 857 95.98 
Sex Difference % male (PD - Control) 11 716 676 94.68 
Disease duration Mean centred disease duration 7 364 212 47.90 
Mn Technique 
Age 
AAS 
Mass Spec 
Mean centred PD Age 
2 
5 
7 
287 
266 
553 
317 
216 
- 
- 
- 
Intercept 
-0.23(-1.65, 1.19)
0.15(-0.76, 1.06)
0.03 (-0.52, 0.57)
0.7507 
0.7493 
0.9271 
95.3 
90.57 
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Tissue Metal Moderating variable Outcome Articles (n) 
Controls 
(n) 
PD 
(n) Result Effect size (CI) 
Effect size 
(P) I
2
Sex 
Disease duration 
Mean centred Control Age 
Difference (PD - Control) 
Difference % male (PD - Control) 
Disease duration 
6 
6 
6 
4 
-  
520 
303 
225 
434 
434 
253 
112 
Slope 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
-0.16 (-0.29, -0.02)
0.17 (-0.61, 0.95)
-0.09 (-0.26, 0.08)
0.25 (-0.92, 1.43)
-0.02 (-0.22, 0.18)
0.12 (-0.92, 1.17)
-0.01 (-0.06, 0.05)
-0.24 (-0.58, 0.10)
-0.09 (-0.42, 0.24)
0.0199* 
0.6689 
0.3015 
0.6709 
0.8510 
0.8173 
0.7783 
0.1739 
0.5886 
95.87 
96.07 
96.09 
46.56 
AAS 5 183 166 - -0.25(-0.80, 0.31) 0.3897 
Technique ICP-AES ICP-MS 
2 
2 
117 
62 
31 
35 
- 
- 
-0.12(-1.02,0.78)
0.52(-0.40, 1.45)
0.7945 
0.2686 82.17 
Other 1 67 31 - 0.08(-1.13, 1.30) 0.8912 
Mean centred PD Age 9 362 - Intercept Slope 
-0.05 (-0.50, 0.30)
0.01 (-0.12, 0.14)
0.8163 
0.8467 82.96 
Cu Age Mean centred Control Age 9 - 232 
Intercept 
Slope 
-0.06 (-0.35, 0.22)
-0.10 (-0.17, -0.03)
0.6681 
0.0028 61.12 
Difference (PD - Control) 9 362 232 Intercept Slope 
-0.30 (-0.71, 0.12)
0.06 (0.00, 0.12)
0.1594 
0.0417* 74.14 
Sex Difference % male (PD - Control) 8 330 177 Intercept Slope 
0.06 (-0.60, 0.72)
-0.00 (-0.03, 0.02)
0.8553 
0.7761 84.03 
CSF Disease duration Mean centred disease duration 5 245 114 Intercept 
Slope 
-0.13 (-0.36, 0.10)
0.07 (-0.17, 0.32)
0.2708 
0.5631 
0.00 
AAS 4 134 140 - 0.31(-0.91, 1.53) 0.6155 
Technique ICP-AES ICP-MS 
2 
2 
117 
62 
31 
35 
- 
- 
-0.88(-2.61, 0.85)
-0.16(-1.89, 1.57)
0.3165 
0.8562 94.63 
Other 1 145 30 - 0.84(-1.56, 3.25) 0.4924 
Fe Mean centred PD Age 9 458 - 
Intercept 
Slope 
0.01 (-0.71, 0.74)
0.12 (-0.08, 0.32)
0.9713 
0.2241 93.77 
Age Mean centred Control Age 8 - 206 Intercept Slope 
-0.10 (-0.96, 0.75)
-0.05 (-0.22, 0.12)
0.8131 
0.5927 94.84 
Difference (PD - Control) 8 313 206 Intercept Slope 
-0.45 (-1.34, 0.44)
0.08 (-0.03, 0.19)
0.3243 
0.1581 93.28 
Sex Difference % male (PD - Control) 8 408 176 Intercept -0.22 (-136, 0.91) 0.7018 94.21 
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Tissue Metal Moderating variable Outcome Articles (n) 
Controls 
(n) 
PD 
(n) Result Effect size (CI) 
Effect size 
(P) I
2
Slope 0.02 (-0.03, 0.06) 0.4469 
Disease duration Mean centred disease duration 5 341 118 Intercept 
Slope 
-0.33 (-1.01, 0.35)
-0.22 (-0.77, 0.32)
0.3390 
0.4285 
87.38 
AAS 3 123 118 - -1.09(-2.20, 0.01) 0.0524* 
Technique ICP-AES 2 117 31 - -0.30(-1.67, 1.07) 0.6659 91.91 
ICP-MS 2 62 35 - 0.46(-0.92, 1.85) 0.5096 
Mean centred PD Age 7 302 - Intercept Slope 
-0.44 (-1.28, 0.41)
-0.05 (-0.28, 0.19)
0.3153 
0.7038 93.66 
Zn 
Age Mean centred Control Age 7 - 184 Intercept Slope 
-0.42 (-1.05, 0.22)
-0.12 (-0.25, -0.00)
0.1978 
0.0456* 90.13 
Difference (PD - Control) 7 302 184 Intercept Slope 
-0.69 (-1.62, 0.23)
0.06 (-0.05, 0.17)
0.1429 
0.3055 93.40 
Sex Difference % male (PD - Control) 6 252 124 Intercept Slope 
-0.14 (-1.42, 1.15)
-0.02 (-0.08, 0.04)
0.8362 
0.4846 94.23 
Disease duration Mean centred disease duration 4 196 88 Intercept 
Slope 
-0.40 (-0.67, -0.13)
-0.16 (-0.41, 0.09)
0.0036** 
0.2188 
0.00 
AAS 3 98 119 - -0.08(-0.72, 0.55) 0.7955 
Technique ICP-AES 2 117 31 - -0.58(-1.38, 0.22) 0.1528 75.72 
ICP-MS 2 62 35 - 0.03(-0.77, 0.84) 0.9338 
Mean centred PD Age 7 277 - Intercept Slope 
-0.17 (-0.56, 0.21)
0.09 (-0.05, 0.22)
0.3789 
0.1973 68.03 
Mn Age Mean centred Control Age 7 - 185 
Intercept 
Slope 
-0.18 (-0.48, 0.12)
-0.08 (-0.14, -0.01)
0.2404 
0.0154* 53.89 
Difference (PD - Control) 7 277 185 Intercept Slope 
-0.38 (-0.67, -0.08)
0.06 (0.02, 0.10)
0.0119* 
0.0048** 42.30 
Sex Difference % male (PD - Control) 6 227 125 Intercept Slope 
-0.02 (-0.57, 0.53)
-0.01 (-0.04, 0.01)
0.9392 
0.3502 74.73 
Disease duration Mean centred disease duration 4 196 88 
Intercept 
Slope 
-0.36 (-0.63, -0.09)
0.43 (0.18, 0.68)
0.0092** 
0.0008*** 0.00 
AAS 2 54 54 - -1.58(-2.13, -1.02) <0.0001*** 
Technique ICP-MS 1 150 170 - 1.22(0.68, 1.76) <0.0001*** 38.15 
Plasma Cu Spectrophotometry 1 87 55 - 1.88(1.25, 2.51) <0.0001*** 
Age Mean centred PD Age 4 291 - Intercept Slope 
-0.01 (-2.16, 2.14)
0.07 (-0.31, 0.45)
0.9938 
0.7073 98.55 
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Tissue Metal Moderating variable Outcome Articles (n) 
Controls 
(n) 
PD 
(n) Result Effect size (CI) 
Effect size 
(P) I
2
Sex 
Mean centred Control Age 
Difference (PD - Control) 
Difference % male (PD - Control) 
4 
4 
3 
-  
291 
261 
279 
279 
255 
Intercept 
Slope 
Intercept 
Slope 
Intercept 
Slope 
-0.01 (-1.82, 1.80)
0.07 (-0.06, 0.19)
0.43 (-1.25, 2.12)
-0.12 (-0.28 0.05)
0.42 (-1.73, 2.57)
-0.05 (-0.18, 0.07)
0.9938 
0.3156 
0.6154 
0.1625 
0.7016 
0.4018 
98.51 
98.35 
98.94 
Abbreviations: AAS = atomic absorption spectroscopy; CI = confidence interval; Cu = copper; Fe = iron; ICP-AES = inductively coupled plasma-atomic emission spectroscopy; ICP-MS = inductively coupled 
plasma-mass spectrometry; PD = Parkinson’s disease; PIXE = particle induced X-ray emission spectroscopy 
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Supplementary Table 11: Outcomes of meta-regression analyses 
Test Outcome Compared with Comparison Effect size (CI) Effect size (P) I2
Intercept -2.10 (-2.91, -1.11) <0.0001*** 
Cu SN 
CSF 
Serum 
1.99 (0.73, 3.26)
1.31 (0.15, 2.46)
0.002** 
0.0264* 
97.12 
Plasma 2.02 (0.35, 3.68) 0.0175* 
Intercept 1.16(0.47, 1.85) 0.001*** 
Meta-regression Fe SN 
CSF 
Serum 
-1.16 (-2.32, 0.01)
-1.93 (-2.94, -0.91)
0.0514* 
0.0002*** 
96.83 
Plasma -0.82 (-2.90, 1.26) 0.4404 
Intercept 0.61 (-0.12, 1.35) 0.1119 
Zn SN 
CSF 
Serum 
-1.04 (-2.08, 0.00)
-1.11 (-2.03, -0.18)
0.0503* 
0.0187* 
94.07 
Plasma -1.00 (-2.54, 0.54) 0.2025 
Intercept -3.06 (-4.45, -1.68) <0.0001*** 
CSF 3.19 (1.41, 4.96) 0.0004*** 
Cu SN Serum 2.82 (1.06, 4.59) 0.0017** 96.44 
Plasma 3.45 (1.23, 5.68) 0.0023** 
PD Age 0.07(-0.03, 0.18) 0.1685 
Intercept 0.55 (-0.47, 1.58) 0.2911 
Meta-regression + Age 
Fe SN 
CSF 
Serum 
-0.15 (-1.79, 1.50)
-0.87(-2.45, 0.71)
0.8607 
0.2813 96.78 
Plasma 0.88 (-1.91, 3.66) 0.5369 
PD Age 0.10(-0.01, 0.21) 0.0618 
Intercept 0.14 (-1.03, 1.32) 0.8112 
Zn SN 
CSF 
Serum 
-0.49 (-2.01, 1.04)
-0.52 (-2.03, 0.99)
0.5319 
0.4990 
93.68 
Plasma -0.26 (-2.45, 1.94) 0.8190 
90 
PD Age 0.04(-0.05, 0.14) 0.3926 
Abbreviations: CI = confidence interval; CSF = cerebrospinal fluid; Cu = copper; Fe = iron; PD = Parkinson’s disease; SN = substantia nigra 
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Supplementary Figure 1: Publication bias effect sizes for post-mortem SN tissue 
Funnel plots of publication bias effect sizes for iron, copper, and zinc in post-mortem SN tissue. 
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Supplementary Figure 2: Publication bias effect sizes for CSF 
Funnel plots of publication bias effect sizes for iron, copper, zinc, and manganese in CSF. 
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Supplementary Figure 3: Publication bias effect sizes for serum 
Funnel plots of publication bias effect sizes for iron, copper, zinc, and manganese in serum. 
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Supplementary Figure 4: Age-centered meta-regressions for copper and iron in SN tissue, 
CSF, serum and plasma from PD and controls. 
(A) Copper was significantly reduced in the SN compared with CSF (d, 1.99; CI, 0.725 to 3.26;
p=0.002), serum (d, 1.31; CI, 0.15 to 2.46; P < 0.05) and plasma (d, 2.016; CI, 0.35 to 3.68; P < 0.05)
Iron effect size was significantly different compared with CSF (d, -1.16; CI, -2.32 to 0.01; P = 0.05)
and serum (d, -1.93; CI, -2.94 to -0.91; P < 0.001).
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Subcellular compartmentalisation of copper, iron,
manganese, and zinc in the Parkinson’s disease
brain†
Sian Genoud, a Blaine R. Roberts,b Adam P. Gunn,b Glenda M. Halliday,acd
Simon J. G. Lewis,aef Helen J. Ball,g Dominic J. Hare *bhi and Kay L. Double*a
Elevated iron and decreased copper levels are cardinal features of the degenerating substantia nigra pars
compacta in the Parkinson’s disease brain. Both of these redox-active metals, and fellow transition metals
manganese and zinc, are found at high concentrations within the midbrain and participate in a range of
unique biological reactions. We examined the total metal content and cellular compartmentalisation of
manganese, iron, copper and zinc in the degenerating substantia nigra, disease-affected but non-
degenerating fusiform gyrus, and unaffected occipital cortex in the post mortem Parkinson’s disease brain
compared with age-matched controls. An expected increase in iron and a decrease in copper concentration
was isolated to the soluble cellular fraction, encompassing both interstitial and cytosolic metals and metal-
binding proteins, rather than the membrane-associated or insoluble fractions. Manganese and zinc levels did
not differ between experimental groups. Altered Fe and Cu levels were unrelated to Braak pathological
staging in our cases of late-stage (Braak stage V and VI) disease. The data supports our hypothesis that
regional alterations in Fe and Cu, and in proteins that utilise these metals, contribute to the regional
selectively of neuronal vulnerability in this disorder.
Introduction
The brain contains some of the highest concentrations of iron
(Fe), copper (Cu), zinc (Zn) and manganese (Mn) in the human
body.1 These metals are responsible for numerous cellular
functions including synaptic transmission, myelinogenesis,
energy production and regulation of oxidative stress. Many
of these biochemical processes rely on metals for transfer of
electrons via redox chemistry, neuronal excitation, protein
structure and enzymatic function.2 Alterations in the levels
and distribution of these transition metals are consistently
reported in the Parkinson’s disease brain,3,4 with the best
documented change being elevated levels of Fe in the substantia
nigra pars compacta (SNc). Abnormal deposition of Fe in the
Parkinson’s disease brain was first reported in 1924;5 since then
numerous studies have identified significantly increased Fe
levels within vulnerable brain regions in this disorder beyond
those observed in healthy aged-matched brains.6,7
Additionally, a concomitant decrease in Cu concentration
has also been reported in degenerating regions of the Parkinson’s
disease brain,8,9 while data regarding Zn levels are conflicting.3,10
Occupational exposure to Mn alone has been demonstrated to
cause parkinsonism,11 highlighting the necessity for tight Mn
regulation in the brain.
To date, most studies have described regional alterations in
total metal levels (typically Fe) in whole tissue samples.3,6,12,13
While such studies are useful to identify the neuroanatomical
location of changes in specific metals, alterations at the
cellular and subcellular level in the Parkinson’s disease
brain are less well understood. Determining the cellular
compartment in which these changes occur may aid in deter-
mining the underlying cause of these alterations, and the
pathological effects subsequently produced in their subcellular
environment.
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In this study, we examined the subcellular compartmentalisation
of Mn, Fe, Cu and Zn in three regions of the Parkinson’s
disease brain displaying varying degrees of neurodegeneration
and proteinopathology. We separated tissue samples into three
fractions representing the ‘soluble’, ‘membrane-associated’
and ‘insoluble’ tissue components respectively, to identify the
specific cellular compartment in which metal alterations are
most marked. We also examined whether total metal levels
were altered according to late-stage Braak pathology.
Experimental
Ethics, consent and permissions
Human ethics for this study was granted by the University of Sydney
(ID: 2015/202) and the University of Melbourne (ID: 1136882).
Human brain tissue
In total, fresh frozen human post-mortem brain tissue was obtained
from 13 Parkinson’s disease (PD) subjects and 11 age-matched
controls (Ctrl). Three specific regions were analyzed: substantia
nigra (SN; encompassing both pars reticulata and pars compacta
regions; nPD = 9, nCtrl = 8), fusiform gyrus (FUS; nPD = 9, nCtrl = 8) and
occipital cortex (OCx; nPD = 11, nCtrl = 11) were obtained from the
New SouthWales and Sydney Brain Banks. Demographic details for
these cases are shown in Table 1. All Parkinson’s disease cases were
receiving levodopa at the time of death; other anti-parkinsonian
medications prescribed (n = 1 case per medication) were a
COMT inhibitor, a MAO inhibitor, a drug trial of Sarizotan
(a 5-HT1A agonist and D2 dopamine receptor antagonist), and a
dopamine agonist.
Tissue preparation
Tissue preparation was adapted from our previously published
methods.14–17 Tissue samples (11.6–22.5 mg wet weight) were
homogenised with a hand-held dounce (Omni BioMasher,
Georgia, USA) in 3 tissue weight of Tris buffered saline
(TBS: 50 mM Tris; 150 mM NaCl; pH 8.0) containing EDTA free
protease inhibitors (Roche, NSW, Australia). Samples were
centrifuged at 16 000g for 15 min at 4 1C before the supernatant
fraction was collected and stored at 80 1C. This was termed
the ‘soluble fraction’, and represented all cytosolic proteins and
the interstitium. The remaining tissue pellet was resuspended
in 3 tissue weight of urea buffer (7 M urea; 2 M thiourea, 4%
3-[(3-cholamindopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS); 30 mM Bicine; pH 8.5; Sigma, NSW, Australia) and
centrifuged 16000g for 30 min at 4 1C and the resultant super-
natant was collected and stored at 80 1C. This was termed
the ‘membrane fraction’, representing both membrane-bound
proteins and those encased within cellular organelles. The final
pellet was resuspended in 3 tissue weight of 70% formic acid
overnight before being centrifuged at 16 000g for 30 min and
the resultant supernatant collected and stored at 80 1C. This
was termed the ‘insoluble fraction’, and represented all material
not previously extracted. No observable material remained follow-
ing the final preparation step.
Inductively coupled plasma-mass spectrometry (ICP-MS)
ICP-MS analysis was performed according methods previously
reported.18 Each fraction was randomised before being thawed
on ice and diluted 1 : 20 with 1% HNO3 (v/v; Suprapur grade,
Merk Millipore, VIC, Australia) prior to analysis. Total metal
Table 1 Demographic details for experimental tissue. PD = Parkinson’s disease; PMI = post-mortem interval; SEM = standard error of mean; NA = not
available
Case Age Sex Disease duration Primary cause of death Tissue pH Braak staging of PD PMI
PD1 82 M 5 Cardiorespiratory failure 6.72 V NA
PD2 82 F 15 Cerebrovascular accident 6.95 V NA
PD3 83 F 14 Pneumonia 6.69 V 7
PD4 69 M 17 Bronchopneumonia 5.99 V NA
PD5 90 M 7 Respiratory failure 6.25 V NA
PD6 85 F 17 Cerebrovascular accident 6.58 V 26
PD7 74 M 8 Cerebrovascular accident 5.86 VI NA
PD8 83 F 14 Cardiorespiratory failure 6.2 V 32
PD9 79 M 17 Septicaemia 6.7 VI 42
PD10 88 M 23 Cardiorespiratory failure 6.6 V 5
PD11 82 M 22 Cardiorespiratory failure 6.4 VI 19
PD12 82 M 8 Cardiorespiratory failure 6.3 VI 22
PD13 77 M 15 Aspiration pneumonia 6.4 V 15
Mean (SEM) 81.23 (2.36) 9M : 4F 14 (2.37) — 6.43 (0.56) 9V : 4VI 21 (3.52)
Ctrl1 85 F — Pneumonia 6.4 — 23
Ctrl2 79 M — Pulmonary embolism 6.7 — 8
Ctrl3 84 F — Cardiorespiratory failure 6.5 — 6
Ctrl4 89 F — Metastatic adenocarcinoma 6 — 23
Ctrl5 91 M — Cardiorespiratory failure 5.9 — 13
Ctrl6 89 M — Cardiorespiratory failure 6.1 — 33
Ctrl7 102 F — Acute renal failure 5.92 — NA
Ctrl8 89 M — Cardiorespiratory failure 6.7 — 22
Ctrl9 88 F — Cardiorespiratory failure 6.2 — 31
Ctrl10 49 M — Cardiorespiratory failure 6.5 — 47
Ctrl11 41 M — Cardiorespiratory failure 7 — 48
Mean (SEM) 80.55 (4.30) 6M : 5F — 6.36 (0.60) — 25.4 (3.82)
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levels in each fraction were measured using an Agilent
Technologies 7700 ICP-MS system with a Teflon MiraMist
concentric nebuliser and Scott-type double-pass spray chamber
(Glass Expansion, VIC, Australia). Helium (3 mL min1) was
used as a collision gas for removal of polyatomic interferences.
Measured mass-to-charge (m/z) ratios were 55 (Mn), 56 (Fe),
63 (Cu) and 64 (Zn). External calibration was performed using
multi-element standards (Sigma) diluted in 1% HNO3 and
yttrium (Y; m/z = 89; Accustandard, Connecticut, USA) was used
as reference element via online introduction with a Teflon
T-piece.
Statistical analysis
Statistical analyses were performed using Prism v6.0h (GraphPad,
California, USA) for absolute metal levels, and SPSS v22.0 (IBM),
and CoDaPack for compositional data.19 A Student’s two-tailed
t-test was performed to confirm age-matching, and a chi-squared
test for sex-matching and comparing Braak stage. Tissue samples
were background corrected according to their respective buffers,
adjusted for dilution factors and standardised against original
wet sample weights to obtain concentrations in microgram per
gram (mg g1) of wet tissue weight. Samples below instrument
limit of detection were excluded from analysis.20 Outliers were
identified using the combined robust regression and outlier
removal (ROUT) method with a maximum false discovery rate
of 5%.21 Total metal levels were calculated as the sum of the
metal content in each fraction. Metal concentrations in each
fraction for control and Parkinson’s disease groups were compared
using one-way analysis of variance (ANOVA) followed by Sidak post
hoc correction for multiple comparisons, or a Student’s two-tailed
t-test, as noted in the results. For analysis of metal distribution
within fractions between control and Parkinson’s disease groups,
centered-transformations22 were performed in CoDaPack and the
subsequent compositional data was compared using multi-variate
ANOVA in SPSS. All charts were drawn using Prism. A significant
difference was defined as p o 0.05.
Results
Regional distribution of total metal levels in the healthy and
diseases substantia nigra, occipital cortex and fusiform gyrus
Copper concentrations were regionally varied in the healthy
brain with significantly higher levels of Cu in the healthy SN
compared with the OCx and FUS (+153% vs. OCx, p o 0.01;
+233% vs. FUS, p o 0.001; one-way ANOVA; Fig. 1a). The
concentration of Cu in the Parkinson’s disease SN was approxi-
mately half that of control SN (54%, p o 0.05; Student’s two-
tailed t-test), resulting in the significant difference between
nigral Cu concentration and that in the OCx and FUS observed
in the healthy brain being absent in Parkinson’s disease tissue.
As expected, Fe was significantly higher in the healthy SN
compared with FUS (+106%, p o 0.05) and OCx (+61%, p o
0.05; Fig. 1b). In Parkinson’s disease brain, this greater concen-
tration of nigral Fe was more pronounced, with nigral concen-
trations representing more than twice (+210%) that of the
Parkinson’s disease OCx (p o 0.001) and three times (+338%)
that of the Parkinson’s disease FUS (p o 0.001; all one-way
ANOVA), reflecting an accumulation of Fe within the Parkinson’s
disease SN (+105% vs. control SN, po 0.05; Student’s two-tailed
t-test). Both the Parkinson’s disease OCx and FUS did not show
significant changes in Fe concentration when compared to
healthy controls. Zinc levels were unaltered in the Parkinson’s
disease brain in the three regions analysed, though the control
OCx contained less Zn than both the healthy FUS (24%,
p o 0.01) and SN (22%, p o 0.01; one-way ANOVA; Fig. 1c).
Manganese concentrations were significantly higher in both
healthy and diseased SN, compared with the FUS (+40%, po 0.01)
and OCx (+32%, po 0.01; Fig. 1d). Like Cu and Fe, Mn was more
Fig. 1 Biometal distribution in the occipital cortex (OCx) fusiform gyrus
(FUS) and substantia nigra (SN) of healthy aged controls and Parkinson’s
disease. (a) The concentration of Cu in control tissue was highest in the SN,
though in the Parkinson’s disease brain Cu concentrations decreased to
levels equivalent to that in the control SN. (b) In control brains, the
concentration of Fe in the SN was also significantly higher than the
FUS and OCx regions. Iron concentrations were further elevated in
the Parkinson’s disease SN. (c) Zinc concentrations were lowest in the OCx,
and (d) Mn was highest within the SN. Neither Zn or Mn were altered in the
Parkinson’s disease OCx, FUS or SN. * po 0.05, ** po 0.01, *** po 0.001
(vs. control regions); # p o 0.05, ### p o 0.001 (control vs. Parkinson’s
disease SN). All concentrations are mg g1 wet weight of tissue.
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concentrated in the healthy SN than the OCx (+38%, po 0.01) and
FUS (+49%, po 0.01; one-way ANOVA; Fig. S1b, ESI†), though no
changes were observed within regions according to disease state.
Transition metal alterations in cellular compartments of the
Parkinson’s disease substantia nigra
In the Parkinson’s disease SN, the decreased Cu concentration
was confined to the soluble faction (53%; p o 0.01; Fig. 2a).
No detectable Cu was observed in the insoluble fraction in
control brains, but was detected in four of seven of the
Parkinson’s disease SN samples. Similarly, in this region, we
observed elevations in total Fe levels in the Parkinson’s disease
SN that were also attributable to the soluble fraction (+124%,
po 0.01; Fig. 2b). Although total zinc levels were unchanged in
the Parkinson’s disease SN, the membrane-associated fraction
exhibited a significant decrease in this metal confined to this
brain region (34%; p o 0.01; Fig. 2c; Student’s two-tailed
t-tests). Manganese levels did not differ in any fraction between
controls and Parkinson’s disease tissue (Fig. 2d).
The percentage distribution of Cu, Fe, Zn and Mn (Table 2)
in the insoluble, membrane-associated and soluble fraction
was not altered in any brain region between the healthy aged-
control and Parkinson’s disease brain. This suggests that intrinsic
metal dyshomeostasis (i.e. decreased Cu and increased Fe levels)
is not merely a redistribution of available metals, but instead
remains distributed equivalently, with only absolute levels
markedly altered in the Parkinson’s disease SN.
Are altered metal levels in the Parkinson’s disease substantia
nigra related to late Braak staging?
All cases assessed were late-stage Parkinson’s disease, and at
post mortem all were classified as either Braak stage V and four
stage VI, per the established pathological criteria.23 No signifi-
cant difference in total metal levels were observed in any of
Parkinson’s disease tissue from three regions assessed, other
than a slight, non-significant decrease in Fe levels in the FUS
(12%, p = 0.055) (Fig. S2, ESI†). A significantly higher Fe
concentration in the membrane fraction of the SN (+392%;
p o 0.05), and lower Fe concentration in the soluble phase of
the OCx (31%; po 0.01; Fig. 3), was observed in stage VI cases
compared to stage V, though the small sample size and large
variance within the SN suggests these data should be inter-
preted with caution (see Discussion).
Discussion
The regions selected in this study represent three distinct
pathological states in the Parkinson’s disease brain. The SN
is the primary site of dopaminergic neurodegeneration which
results in the clinical movement disorder.24 The dopaminergic
FUS displays synucleinopathy and atrophy25 and is associated
with visual hallucinations and Parkinson’s disease with dementia,
albeit in the absence of neurodegeneration.26 Finally, the OCx
represents an ‘internal control’, in that this region exhibit neither
Lewy pathology nor degeneration in Parkinson’s disease.
The region-specific distribution of total Cu and Fe in the
three measured regions of the healthy brain we report here
was consistent with previous reports.27–29 In the Parkinson’s
disease brain, significant differences in metal levels were
confined to the SN, specifically a decrease in total Cu and
increase in total Fe. Our group has previously reported a 45%
change in total SN Cu levels,8 while others have reported
similar decreases (51% by Ayton et al.30 and 34 to 45% in
Dexter et al.’s landmark study from 198931). Increased nigal Fe
is a well-established feature of Parkinson’s disease from numerous
observational studies, and was further supported by a recent meta-
analysis of these reports.7
Fig. 2 Within both the Parkinson’s disease and control SN, the majority of
(a) Cu, (b) Fe, and (c) Zn was present in the soluble fraction, followed by the
membrane and insoluble fractions, respectively. (d) For Mn, equivalent
amounts were distributed between the soluble and membrane-bound
fractions. In the Parkinson’s disease SN, the observed reduction in total Cu
and increase in total Fe are confined to the soluble fraction, and a decrease
in Zn within the membrane-associated fraction was also observed,
although total Zn levels were not altered. ## p o 0.01, (control vs.
Parkinson’s disease). All concentrations are mg g1 wet weight of tissue.
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For the first time, we have isolated these changes to the
‘soluble’ cellular fraction, which represents the interstitium
and cytoplasm.17 Within this fraction are aqueous proteins
including antioxidant enzymes, as well as free metals present
in the tissue. Membrane-associated metal–protein complexes
likely comprises of protein channels and pumps involved in
transfer of metals across cell plasma membrane, and metals
found within membrane-bound organelles. Despite moderate
metal concentrations in the membrane-associated fractions
(B35% total Fe, B20% total Cu and B45% total Zn; Table 2),
similar changes in Cu and Fe observed in the soluble fraction
were not observed. Metal–protein interactions for the purpose of
transport across the plasma membrane or directed transport
within the cells are likely to be transient however, and thus only
a small proportion of membrane-associated transport proteins
are likely to have been metal-bound at the time of extraction.
A more stable pool of metals may be represented by plasma
bound organelles such as mitochondria, which internalise Fe,
Cu, Mn and Zn for both specific biological function or the
synthesis of metalloproteins such as Fe–sulfur complexes or
cytochrome c oxidase. Although mitochondrial dysfunction,
and resulting effects on metal levels, are proposed to contribute
to neuronal death in Parkinson’s disease,32 the fractionation
technique used here may have masked subtle changes in mito-
chondrial metal levels and specific isolation of mitochondria from
other membrane-encapsulated metals in Parkinson’s disease and
control samples would be required.
The purpose of the current study was to establish the
specific subcellular compartments in which known alterations
in biometals occur. In doing so, we can then narrow the scope
of future proteomic studies targeting these specific subcellular
compartments using high-throughput shotgun proteomics
methods,33 which are currently underway in our laboratory.
In addition, as both a-synuclein and SOD1 are demonstrated to
aggregate in Parkinson’s disease,34 determining the subcellular
fraction where these metal changes occur allows us to then
identify whether these alterations are associated with the
soluble forms of these proteins, or the aggregated form which
would reside in the insoluble fraction.
The insoluble component of SN homogenates represented
only a small proportion of total metal levels and we observed no
changes in metals in this fraction in any brain region. Within
the healthy SN, the insoluble fraction is likely to comprise of
the insoluble macromolecules neuromelanin and lipofuscin,
Table 2 Percentage distribution of Cu, Fe, Zn and Mn in insoluble, membrane-bound and soluble fractions of control and Parkinson’s disease brain.
All data mean  1SD
OCx FUS SN
Control PD Control PD Control PD
Cu
Insoluble 0.66  1.57 0.16  0.54 40.01 40.01 40.01 2.04  5.30
Membrane 21.41  7.88 19.92  9.78 20.49  3.93 22.13  5.56 14.94  4.97 11.14  5.63
Soluble 77.93  7.28 79.92  9.67 79.51  3.93 77.87  5.56 85.06  4.97 86.82  7.15
Fe
Insoluble 5.10  3.48 6.16  2.97 3.64  3.12 3.48  2.52 5.60  3.71 6.50  3.55
Membrane 36.60  12.68 35.04  12.16 44.56  8.31 41.13  4.39 37.93  8.48 26.56  14.32
Soluble 58.30  10.23 58.79  12.36 51.80  6.50 55.40  4.89 56.47  8.89 66.94  14.44
Zn
Insoluble 7.16  3.78 6.47  2.08 7.37  3.95 6.66  3.46 4.45  1.20 7.33  3.66
Membrane 43.19  7.85 44.34  10.02 48.24  4.43 51.83  4.01 40.40  4.69 29.96  6.62
Soluble 49.65  5.63 49.20  9.58 44.39  5.46 41.51  2.97 55.15  5.16 62.71  4.41
Mn
Insoluble 2.24  2.55 6.47  6.67 2.48  3.71 2.22  2.39 2.46  3.37 4.49  2.80
Membrane 45.05  12.58 44.83  17.92 54.13  7.49 51.67  5.22 44.71  4.03 38.73  14.37
Soluble 52.71  11.72 48.70  15.65 43.39  5.20 46.12  4.85 52.83  4.46 56.77  12.37
Fig. 3 Concentration of (a) Cu, (b) Fe, (c) Zn, (d) and Mn in cellular
fractions according to Braak staging in the Parkinson’s disease OCx, FUS
and SN. Only Fe shows any significant change in concentration between
Braak stage V and VI, with a decrease in the soluble fraction of OCx and
increase in the membrane-bound fraction in the SN in stage VI. # po 0.05;
## p o 0.01. I = insoluble, M = membrane, S = soluble.
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cellular pigments which accumulate in the aging human
brain35 and associate with metals, including Fe, Cu, Zn and
Mn.28,29,35,36 These pigments are highly abundant in the aged
human brain, for example neuromelanin fills almost 50% of
the volume of SN dopaminergic soma in individuals in their
eighth decade of life.37 Using in situ subcellular chemical
imaging, we have previously reported increased Fe and
decreased Cu associated with neuromelanin in the SNc neurons
from the Parkinson’s disease brain,8 although here these
changes may have been obscured by the presence of other
equally abundant, but not disease-related, metal-binding
biomolecules, such as lipofuscin, in this tissue fraction. The
insoluble fraction of the Parkinson’s disease SN is also likely
to include a smaller proportion by mass of small insoluble
proteinaceous deposits, including Lewy bodies24 and SOD1
aggregates.34 While metals have been suggested to induce
a-synuclein oligomerisation and aggregation in vitro,38 it is
unclear whether Lewy bodies retain metal ions. We recently
demonstrated that SOD1 aggregates recently identified in
Parkinson’s disease share pathological similarities with the
deposited protein in familial amyotrophic lateral sclerosis
spinal cord and SN,34 and this class of aggregate has been
shown to be deficient in Cu.39 The different populations of
insoluble protein aggregates in degenerating regions of the
Parkinson’s disease brain may thus display metal associations
that differ from that in the normal soluble protein, a hypothesis
that could be tested using, for example, biochemical imaging
analysis at the single aggregate level.
The disease-affected, but non-degenerating, FUS exhibited
no evidence of perturbed metal levels supporting the hypothesis
that metal dyshomeostasis, and associated oxidative stress, are
restricted to specific degenerating regions of the Parkinson’s
disease brain.40,41 This poses an interesting question regarding
the toxicity of synucleinopathy pathways in brain regions where
metal levels are normal. In vitro evidence suggests that metal
ions interact with a-synuclein to promote oxidative stress and
neuronal death,42 however, we report here that the FUS, which
features accumulation of a-synuclein in Parkinson’s disease in
the absence cell death does not exhibit altered metal levels.
Maintenance of metal homeostasis may thus be sufficient to
mitigate cell death, despite proteinopathy. Further, no measur-
able increase in Fe within the FUS compared to control implies
that increased oxidative stress arising from the Fe/dopamine/
a-synuclein axis does not occur within this brain region.43 The
FUS has recently been established as a site of marked glial
activation in Parkinson’s disease44 which suggests that neuro-
inflammatory processes are not contributing to an increased
amount of total Fe.
Given that many transition metals pose a significant oxida-
tive threat to tissues, the proportion of free, or ‘labile’ metals
present is limited and highly regulated.45 In the healthy cell,
the majority of Fe is present in the cytoplasm as the reduced
ferric species46 and as part of a redox-silenced protein complex,
which may utilise the metal for a specific biological function
(e.g. Fe-catalysed activity of aromatic amino acid hydroxylases) or
provide a mechanism for safe storage (e.g. ferritin). For instance,
labile Fe present in a typical cell is estimated to account for
around 3–5% of total cellular iron (B1–3 mg g1), and labile Cu
in the human cortex has been empirically measured at a similar
concentration.47
Elevated Fe in the Parkinson’s disease SN has long been
associated with neurotoxicity via various mechanisms such as
oxidative,48 ferroptosis,49 and deleterious interactions between
dopamine and Fe.43,50 It has long been argued whether Fe
accumulation in the Parkinson’s disease SN is a potential upstream
cause of disease51,52 or merely an effect of inflammation.53,54
Despite this however, both inflammatory responses, and increased
intraneuronal Fe and altered intracellular Fe-regulating systems
have been implicated Fe dyshomeostasis in neuronal loss in the
PD brain. The importance of brain Fe changes in the aetiology
of Parkinson’s disease may best be demonstrated by removal
of excess levels of this metal. Iron chelation therapy using
deferiprone to lower brain iron levels has showed promise in
pilot clinical studies55 and is now in Phase IIa trials in recently-
diagnosed Parkinson’s disease patients (FAIR PARK II; Clinical-
Trials.gov identifier: NCT02655315).
Dysfunction in a range of Fe regulatory pathways have been
associated with its neuronal accumulation in Parkinson’s
disease,56 which we show here is primarily present in the
soluble tissue fraction. These changes include decreased activity of
the ferroxidase ceruloplasmin, an extracellular protein responsible
for reducing Fe(II) to Fe(III) for transferrin loading after neuronal
export,57 due to a lack of its required Cu cofactor.30 Modulation
of ceruloplasmin has been proposed as a potential therapeutic
strategy for Parkinson’s disease.58
An additional cuproprotein potentially affected by a reduction
in cytosolic Cu is the antioxidant conferring enzyme superoxide
dismutase-1 (SOD1). Recent data has demonstrated increased
SOD1 protein levels, yet a marked decrease in enzymatic activity
in the Parkinson’s disease SN,34 proposed to result due to a lack
of an essential Cu-association with this protein. Given the key
bioactive role for Cu-mediated antioxidant activity in the brain,
Cu modulation is a potential therapeutic avenue for Parkinson’s
disease,59 and the repurposed positron emission tomography
agent copper(II) diacetylbis(N(4)-methylthiosemi-carbazonato),
or CuII(atsm), has shown efficacy in transgenic and neurotoxin
mouse models of Parkinson’s disease.60
The Braak staging scale used to describe the severity of Lewy
pathology in the Parkinson’s disease brain does not necessarily
reflect the more restricted pattern of neuronal loss in this
disorder;24 nevertheless this method is considered the patho-
logical standard for assessing Parkinson’s disease progression
and severity. Braak staging refers to the progressive pattern of
synucleinopathy deposition which originates in the brainstem
and olfactory regions and spreads throughout the brain, classified
according to six distinct stages at autopsy.23 Lewy pathology is first
observed in the SN at stage III, and by stage VI it has spread
throughout the neocortex. As post mortem Parkinson’s disease
cases are typically retrieved at end-stage disease, our analysis was
limited to Braak stage V and VI cases. We did not observe any
consistent progression in the alterations in Cu or Fe levels
between the two stages, suggesting that metal dyshomeostasis
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within the Parkinson’s disease SN occurs during earlier stages of
the disease. This is consistent with reports of elevated Fe and Cu
reductions in the SN of patients with incidental Lewy body
disease,8 considered a prodromal form of Parkinson’s disease.61
A larger scale study examining metal levels in the SN and other
degenerating, and non-degenerating brain regions, fromParkinson’s
disease cases representing all six pathologically confirmed
Braak stages would assist in determining possible relationships
between metal dyshomeostasis and disease progression.
Conclusions
Although decreased Cu and elevated Fe levels in the Parkinson’s
disease SN have been observed in numerous studies over the
past few decades, we present here evidence that these changes
are primarily present within the soluble component of this
primary site of neurodegeneration. Further, no differences
between Braak staging indicates that these alterations are likely
to occur early in the disease process and are not merely a
redistribution of metals within cellular fractions. In line with
our previous studies, we postulate that disturbed levels of Fe and
Cu within the Parkinson’s disease SN results in increased
oxidative stress from excessive labile Fe, as well as an inadequate
cellular response to increased oxidative load by Cu-deficient,
dysfunctional cuproproteins. Combined, these two factors may
represent key mechanisms contributing to neuronal death, but
also practical targets for next-generation therapies.
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Figure S1: Total metal ratios in occipital cortex (OCx) fusiform gyrus (FUS) and substantia 
nigra (SN) of healthy aged controls and Parkinson’s disease. Both (a) Cu:Zn and (b) Cu:Fe 
were higher in the SN of healthy brains, and was decreased in the SN when compared to 
control. (c) The Cu:Mn ratio was decreased in the Parkinson’s disease SN, and the (d) Fe:Mn 
and (e) Fe:Zn ratio increased. * p < 0.05, *** p < 0.001 (vs control regions). # p < 0.05; ## p < 
0.01 (Parkinson’s disease SN vs control SN). All concentrations are µg g-1 wet weight of tissue. 
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Figure S2: Comparison of Braak stage in the Parkinson’s disease OCx, FUS and SN showed 
no significant difference for (a) Cu, (b) Fe, (c) Zn and (d) Mn.  
115
116 
CHAPTER 4: NANOSCALE IMAGING 
OF PARKINSON’S DISEASE 
NEUROPATHOLOGY AND 
NEUROMELANIN USING X-RAY 
FLUORESCENCE MICROSCOPY AND 
PTYCHOGRAPHY  
The following chapter is currently being prepared for submission to Angewandte Chemie as a 
Communication and is presented in this format.   
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Introduction 
Parkinson’s disease (PD) is a common neurodegenerative disorder characterised by 
progressive movement dysfunction and the degeneration of dopamine producing neurons in 
the substantia nigra (SN) pars compacta. Similar to numerous other neurodegenerative 
diseases[499], neuron death in PD is associated with the abnormal deposition of insoluble 
aggregates within degenerating regions of the central nervous system, which are suggested to 
be the products of disturbed molecular pathways in these regions[500]. 
Amyloid-like deposits known as Lewy pathology (Lewy bodies and Lewy neurites), develop 
throughout the PD brain and have long been used as a disease staging and diagnostic marker. 
The 14 kDa synaptic peptide α-synuclein is a primary constituent of Lewy pathology[501], and 
mutations in the gene for this protein are associated with early-onset familial PD[502]. These 
data strongly implicate molecular pathways involving α-synuclein in dopaminergic loss in 
this disorder, but this hypothesis is not without limitations. α-Synuclein deposits are also 
present in other phenotypically distinct movement disorders, including multiple systems 
atrophy and progressive supranuclear palsy, as well as the dementia disorder Dementia with 
Lewy bodies[503]. The temporo-spatial pattern of cell loss, and that of Lewy body distribution, 
are incongruous in the PD brain, suggesting other factors specific to regions of neuron death 
drive α-synuclein-dependent and independent, pathways of neurotoxicity[504]. Nonetheless, as 
protein misfolding indicates impairment of normal protein function, it is important to 
elucidate factors involved in the misfolding and aggregation of α-Synuclein in the PD brain. 
As binding of various biometals enhances α-Synuclein fibrillation and aggregation into Lewy 
pathology in vitro[505], determining the association of biometals with Lewy bodies in situ may 
provide important insight into mechanisms underlying α-Synuclein misfolding and deposition 
in the PD brain.  
We recently reported an abundance of previously unidentified aggregates of the Cu and Zn-
binding antioxidant protein superoxide dismutase 1 (SOD1), that were present in high 
quantities in the degenerating SN and locus coeruleus (a secondary site of neuron loss) in the 
post-mortem PD brain[397]. SOD1 also exhibited reduced antioxidant activity specifically in 
these degenerating brain regions, a change we attribute to structural alterations to the normal 
homo-dimeric, catalytically active form of this protein[397]. Reduced Cu- and Zn-binding to 
SOD1 protein increases its propensity to misfold and aggregate in vitro and in vivo[43], and 
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therefore determining the biometal fingerprint of SOD1 aggregates may also constitute an 
important advance in understanding SOD1 misfolding and reduced catalytic activity, in 
degenerating regions of the PD brain. Loss of SOD1 activity is likely to reduce the capacity 
of dopaminergic neurons in the SN to regulate their high basal oxidative load, which results 
from their naturally high metabolic output and complex axonal arbor[107]. We suggest these 
disease-associated changes to SOD1 protein substantially disrupt the capacity of 
dopaminergic neurons to regulate ROS[506], rendering the cell susceptible to oxidative 
damage such as that mediated by nucleophilic dopamine quinone radicals formed by 
physiological dopamine autooxidation. 
Dopamine autoxidation is a slow physiological process which, in the human brain, prevents 
the build-up of potentially toxic free dopamine[507]. In turn, this process contributes to the 
synthesis of the biopolymer pigment neuromelanin in specific catecholaminergic regions[508]. 
Dopamine-derived granules of neuromelanin sequester and bind biometals with high 
affinity[509], including abundant Fe which is suggested to be stored in neuromelanin in the 
SN[510]. The association of neuromelanin with redox active metals suggests a potential role in 
contributing to oxidative damage in the PD brain[511], although it is currently unclear if 
neuromelanin has a protective, pathological or neutral role in dopaminergic cell death in 
PD[512]. Neuromelanin is depleted in the SN in PD, reflective of the substantial loss of 
dopaminergic neurons in this region[513]. Determining whether a lack of metal chelation, or an 
increased release of redox active metals by neuromelanin is associated with the death of 
neuromelanised neurons in this brain region in PD is not yet determined.   
We used the Bionanoprobe beamline at the Advanced Photon Source (see Supporting 
information Figure S1 for technical beamline details and experimental methods) to examine 
and compare the nanostructure and elemental composition of Lewy bodies and SOD1 
aggregates (proteinopathy), and neuromelanin within chemically unadulterated tissues 
sampled from the SN of 5 human donors who died of PD (Table S1). The Bionanoprobe 
beamline is capable of performing simultaneous X-ray fluorescence microscopy (XFM) and 
ptychography in nanoscale resolution. XFM is a technique that uses synchrotron radiation to 
generate the emission of electromagnetic radiation from a sample, with each unique chemical 
element producing a characteristic emission spectra, the intensity of which is proportional to 
the amount of the corresponding element[461]. This enables the quantification of multiple 
elements simultaneously with high specificity, in a non-destructive manner (reviewed in 
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Pushie et al., 2018[514]). For the current study X-ray fluorescence was collected by the off-
axis SII Vortex-ME4 which measured total emission spectra within a 6.4 µm2 area (80 nm 
pixel width). 
Ptychography is a multimodal scanning X-ray diffraction imaging method that collects phase 
contrast images at intervals limited by the measured diffraction signal rather than the incident 
probe size[515], meaning it is not limited by spatial skew, misalignment, or an observer 
effect[516]. Phase contrast imaging is capable of defining structural features through the 
imaging plane, comparable to a Z-stack in confocal microscopy imaging. This is a substantial 
advantage over conventional photon emission-based structural imaging methods, such as 
Compton scatter imaging, which is limited to superficial surface features. Collection of 
ptychographic and XFM data from the same 10 keV incident beam resulted in spatial 
resolution an order of magnitude higher than alternative measures of density such as photon 
emission from Compton scattering[517]. Ptychography images with pixel widths of 13.5 nm 
and 182.25 nm2 total area were reconstructed from transmitted phase contrast signal collected 
by a PILATUS photodiode array[466].  
We show for the first time that ptychographic reconstructions of phase diffraction images can 
characterise microfeatures of the human post-mortem brain, and in significantly greater detail 
than that obtained using Compton scatter and other conventional methods (Figure 1A 
Compton vs Phase). This was achievable despite the increased architectural complexity of 
human post-mortem brain tissues, compared with previous examples of this technique using 
single cells prepared in highly controlled systems[518]. Proteinopathies and neuromelanin were 
identified in situ in 20µm tissue sections of the SN using immunolabelling, and subsequently 
identified with Compton scatter and X-ray ptychography in facing, unstained serial sections 
from the same fresh frozen SN tissue sample (Figure 1A,B).  
Frequency histograms were used to determine whether Compton scatter and phase diffraction 
within proteinopathies and neuromelanin exhibited an ordered structure, or were skewed, 
suggesting a more disordered, irregular structure. Cross sections through Lewy bodies and 
SOD1 aggregates exhibited similar normal histograms, reflecting a uniform distribution of 
materials within these structures (Figure 1A,B). Left-skewing of the histogram of 
neuromelanin phase contrast (Figure 1C) suggests a more disordered structure, perhaps 
attributable to disorganised random protein adducts (Figure S2) slowly accumulating in 
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neuromelanin over the human lifespan[512]. The three dimensional information available using 
ptychography negates the poor signal-to-noise ratio in Compton scatter images, which result 
from background self-absorption effects arising from the surrounding tissue.  
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Figure 1. Identification of microfeatures using paired immunohistochemical and 
nanostructural techniques. A) Lewy bodies were identified in 20µm fresh frozen tissue 
sections mounted on superfrost slides using anti-phosphorylated (pS129) α-synuclein 
immunolabelling. Immunopositivity was used to locate the same Lewy body within the 
corresponding unstained, facing serial section mounted on a Si3N4 window for simultaneous 
X-ray ptychography and XFM. This process was repeated using an antibody sensitive to
misfolded human SOD1 (B), and brightfield microscopy of neuromelanin granules (C), to
identify and extract fluorescence absorption via XFM (as Compton scatter) and phase
contrast information in each proteinopathy and neuromelanin. Scale bars = 1 µm.
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Following non-destructive ptychographical identification of Lewy bodies, SOD1 aggregates, 
and neuromelanin granules, regions of interest encompassing these dense structures and 
surrounding neuropil were aligned with XFM images to precisely measure the spatial 
distribution, and concentration of, metals contained within these dense microfeatures (Figure 
2A-C). Ptychographic phase change in each dense microfeature was significantly greater than 
the surrounding neuropil, validating the ability of ptychography to delineate dense structures 
not observable using Compton scatter (Figure 2D). Neuromelanin deposits occupied 
approximately three times the area of either Lewy bodies or SOD1 aggregates (+151% vs 
Lewy bodies, p < 0.01; +160% vs SOD1, p < 0.001; Figure S3). Lewy bodies contained 
~40% more Fe than both neuropil and SOD1 aggregates, and ~30% less Zn than SOD1 and 
neuromelanin deposits, but levels of other elements were unchanged compared with other 
tissue compartments (Fig. 2D). SOD1 aggregates were richer in Fe, and Cu compared to the 
tissue matric (+25%; p < 0.01 and +8.6%; p < 0.05; Figure 2D). Compared with neuropil, 
SOD1 aggregates were enriched in K, P, Fe, and Cu (+44.95%, +21.83%, +33.4% and 
+8.66% respectively; all p < 0.01) and both SOD1 and neuromelanin were enriched in S,
relative to the neuropil (+43.5% p < 0.001and +49%; p < 0.05 respectively). This latter
finding is likely indictive of the high cysteine content of SOD1 and the abundance of sulfide
moieties in pheomelanin. Full descriptive statistics for each region of interest are presented in
Table S2.
Lewy bodies are comprised of as many as 300 proteins and organelles, many of which 
naturally associate with metal ions[519,520]. In vivo studies have shown that α-synuclein can 
bind Cu, Fe, Mn, Zn, Co, Ni, Mg and Ca[521–525], however this is the first study of the 
elemental fingerprint of Lewy bodies in the post-mortem PD brain in situ. Similarly, in vivo 
studies of SOD1 aggregates in transgenic murine models of familial amyotrophic lateral 
sclerosis (ALS), demonstrate an association of SOD1 aggregates with Cu, Zn, Ni and Ca 
[526,527], but to date there are no studies of metal-associations with SOD1 aggregates in human 
post-mortem ALS tissues. In the PD brain, SOD1 aggregates are known to also contain the 
specific copper chaperone for SOD1 (CCS) and ubiquitin[397], but it is likely that these 
aggregates contain other metal-binding proteins, and cellular materials. Determining their 
elemental fingerprint is a step towards understanding the composition of these protein 
aggregates, and the potential role of metal-binding in SOD1 and Lewy body misfolding 
pathways.   
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Figure 2. Representative X-ray ptychography and XFM images of A) a Lewy body B) a 
SOD1 aggregate, and C) neuromelanin in situ in the post-mortem substantia nigra in PD 
brain. D) Box plots of phase change represent mean ± SD, Compton inelastic scatter 
emission, and Amass (as ng cm-2) from Kα emission of K, P, S, Fe, Cu and Zn in each defined 
region of interest corresponding to each microfeature. Scale bares = 1µm. nLB = 8, nSOD1 = 
23, nNM = 6, nNP = 32 nPD = 7, † = removed outlier (See Supplementary Methods and 
Materials). * p < 0.05, ** p < 0.01 and *** p < 0.005. 
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As metal content in proteinaceous aggregates and neuromelanin may be increased compared 
with neuropil purely due to an increase in cellular material, metal quantities obtained by 
XFM imaging were normalised to phase density (ptychography images) calculated as element 
per unit density and presented as a ratio of element:phase. Similar to previous reports 
examining amyloid plaques in mice over-expressing mutated β-amyloid[528,529], normalised 
levels of Cu and Fe in SOD1 aggregates and Lewy bodies were equivalent to that in 
surrounding neuropil, whilst normalised Zn levels were elevated in both SOD1 aggregates 
and neuromelanin compared with the neuropil (p < 0.01 and p < 0.05 respectively: Figure 3). 
Although normalised Fe levels in neuromelanin were equivalent to surrounding neuropil 
(Figure 3), the role of neuromelanin in Fe sequestration should still be explored, given that 
existing data demonstrates that Fe levels are higher in PD neuromelanin than in age-matched 
control neuromelanin in SN tissues[234]. Following phase density normalisation, Lewy bodies 
and SOD1 aggregates exhibited equivalent levels of Cu and Fe (p = 0.266 and p = 0.103 
respectively), and levels of K, P, S and Zn remained similar between these proteinopathies.  
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Figure 3. Analysis of element per unit density following normalisation of XFM images to 
phase density in Lewy bodies (LB), SOD1 aggregates, neuromelanin (NM) and neuropil 
(NP). Zn in NP is higher than that in SOD1 aggregates (p < 0.05) and in NM (p < 0.01). 
Cu:Zn ratio is higher in NP than SOD1 aggregates (p < 0.01). Scale bares = 1µm. nLB = 8, 
nSOD1 = 23, nNM = 6, nNP = 32 nPD = 7. Data represent mean ± SD.* p < 0.05 and ** p < 
0.01. 
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SOD1 normally binds one Cu and one Zn ion per monomer to form a functional and stable 
homodimer (Figure 4B). An alteration to the expected 1:1 Cu:Zn ratio in aggregated SOD1 in 
PD brain might therefore reflect an alteration in metal binding to this protein intra vitam, a 
mechanism we have proposed underlies misfolding and aggregation of SOD1 in the PD 
brain[506]. The Cu:Zn ratio in SOD1 aggregates was lower than the expected 1:1 ratio (mean = 
0.76; 95% CI = 0.72 to 0.80; p < 0.0001) and was significantly lower than neuropil (mean = 
0.87; 95% CI = 0.83 to 0.92; -13.04%, p = 0.01). Although SOD1 aggregates are likely to 
contain other proteins that also bind these metals, Cu and Zn pixels were highly correlated 
within the aggregates (Pearson’s r = 0.703), suggestive of physical co-localisation of these 
metals within aggregates. This is supported by Mander’s colocalization analysis which shows 
83% of Cu was colocalised with Zn in aggregates, while only 69.1% of Zn was colocalised 
with Cu. These data suggests that the majority of Cu and Zn is physically co-located, for 
example, bound to SOD1 protein, with almost all Cu found together with Zn. In contrast, 
almost 30% of Zn is localised distally from Cu. These patterns of co-localisation are reflected 
in the phase density-normalised Cu:Zn ratio which was significantly reduced to a mean of 
0.79 in SOD1 aggregates (Figure 3; 95% CI = 0.74 to 0.84; p < 0.0001). Together these data 
strongly suggest that aggregated SOD1 protein is Cu-deficient in the degenerating SN in the 
PD brain. 
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Figure 4. Investigating the Cu:Zn ratio of SOD1 aggregates in the Parkinson’s disease 
substantia nigra. A) Representative X-ray ptychography and X-ray fluorescence images of 
SOD1 aggregates in the post-mortem SN in PD brain. B) Mature, functional holo-SOD1 
normally binds Cu (red spheres) and Zn (green spheres) in a 1:1 Cu:Zn ratio. Pixels 
containing Cu and Zn in XFM images of SOD1 aggregates were highly correlated (Pearson’s 
r = 0.703) and the Cu:Zn ratio was reduced from 1 (95% CI = 0.72 to 0.80; p < 0.0001). The 
Cu:Zn ratio was significantly different in SOD1 aggregates compared with neuropil. ** p < 
0.01.   
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SOD1 aggregates are implicated in neuronal death in familial forms of ALS[530], where 
protein misfolding and aggregation is suggested to arise from metal-deficient SOD1 
species[531]. Cu and Zn-binding are essential mediators of SOD1 stability and catalytic 
activity[192], and both Cu-deficient and Zn-deficient SOD1 intermediates can arise following 
the disruption or prevention of physiological SOD1 maturation[429]. Cu is important for the 
kinetic stability of SOD1[402,426], and Cu-deficient SOD1 isoforms are identified as the 
primary toxic species in misfolded SOD1-derived animal models of ALS[42,430]. We have 
demonstrated that tissue Cu levels are reduced in the degenerating SN in PD[218,532] and 
propose that a lack of Cu-binding to SOD1 underlies reduced SOD1 protein stability, and 
impaired catalytic activity, in this degenerating brain region[533]. 
In murine models of ALS exhibiting misfolded mutant SOD1, administration of the Cu 
supplementation agent Diacetylbis(N(4)-methylthiosemicarbazonato) copper (II) (Cu-ATSM) 
increases the proportion of holo-SOD1, increases SOD1 activity, and reduces SOD1 
aggregation, mitigates neuronal loss and improves both motor function and overall survival 
of these animals[434,436,437]. Cu-ATSM has also been trialled in multiple mouse models of PD, 
where it slows motor and cognitive decline, rescues neuronal loss and improves dopamine 
metabolism[534]. These promising pre-clinical data have resulted in the current clinical trial of 
Cu-ATSM in PD patients (Clinical trial identifier: NCT03204929). The current work 
supports our hypothesis that the vulnerability of the SN in the PD brain is linked to the 
presence of Cu-deficient, toxic SOD1; a mechanism which may be therapeutically targeted to 
achieve neuroprotection by Cu delivery agents such as Cu-ATSM.  
This study provides the first demonstration of the potential of simultaneous synchrotron X-
ray fluorescence microscopy and ptychography to identify and analyse structures at nanoscale 
resolution in situ in a non-destructive manner in complex biological matrices without the 
biochemical interference of immunolabels. We show that this technique can generate 
elemental and structural profiles at a level of detail exceeding that generated by conventional 
imaging techniques.  
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Materials and Methods 
1. Human post-mortem tissue
1.1. Human ethics approval 
This study was approved by the University of Sydney Human Research Committee (approval 
number 2015/202). Human post-mortem brain tissue was obtained from the Imperial Brain 
Bank and King’s College, UK (tissue application TT0932). 
1.2. Sample details 
Fresh-frozen substantia nigra tissue samples were obtained from patients with idiopathic PD 
confirmed by post-mortem examination (n = 7 cases) according to standard diagnostic 
criteria[4]. Subject demographics are listed in Table S1.  
1.3. Sample embedding and storage conditions 
Fresh-frozen tissue blocks were shipped from the UK to Australia on dry ice and were 
immediately embedded in cryomolds using optimal cutting temperature (OCT) compound 
(ProSciTech). Tissue was kept at a maximum temperature of -20 °C during embedding and 
were then flash-frozen by immersion in liquid N2-cooled hexane. Tissue was stored at -80 °C 
until required.  
1.4. Sectioning 
Each tissue block was pierced 3 times with an acupuncture needle (38-gauge, 0.20 mm 
thickness) to guide correct orientation of facing sections. All samples were sectioned at 20 
µm on a CryoStar NX50 cryostat (ThermoFisher Scientific) using C.L. Sturkey ‘Diamond’ 
PTFE-coated stainless-steel disposable microtome blades (ProSciTech, Australia). The 
cryostat chamber was set at -20 °C and the sample holder at -12 °C. For a given pair of facing 
tissue sections, the first section was mounted on a Superfrost™ microscope slide 
(ThermoFisher)and immunolabelled (IHC; see Methods and Materials 2) and the facing 
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section was flipped and mounted on a Si3N4 window for XFM and Ptychography (9 × 9 mm, 
650 nm film thickness, 675 µm frame thickness; Australian National Fabrication Facility, 
Australia).  
2. Immunostaining
2.1. Sample preparation 
The first collected sections were post-fixed by 100% acetone at -30 °C for 10 min before 
being dried for 20 min at room temperature. Sections were repeatedly washed (3 × 5 min) in 
0.1 M PBS (pH 7.4) and peroxidases were quenched with 0.3% H2O2 in PBS for 20 min at 
room temperature. Sections were then washed again and blocked in 0.5% casein in PBS for 
1.5 h at room temperature. 
2.2. SOD1 B8H10 and pS129 α-syn immunolabelling 
Sections were incubated overnight at 4 °C in a 1:80 mouse anti-human SOD1 B8H10 
(Medimabs Inc, Canada, MM-0070-P) primary (1°) antibody solution in 0.5% casein and 0.1 
M PBS. Sections were then washed in three changes of 0.1 M PBS for 5 min each and 
incubated in secondary (2°) anti-mouse HRP (1:1000; Merck, Australia) for 2 h at room 
temperature. After another washing step, sections were then incubated in Cy3 tyramide (λex = 
554 nm, λem = 568 nm; Perkin Elmer, USA) for 10 min at room temperature and then washed 
and in 0.1 M PBS (3 x 5 min). 
Sections were then stained for Lewy bodies using 1:150 rabbit anti-human α-synuclein 
phosphoserine 129 (pS129 α-syn; Abcam, UK, ab51253) 1° antibody, 1:1000 anti-rabbit HRP 
2° antibody (Merck) and Cy5 tyramide (λex = 650 nm, λem = 669 nm; Perkin Elmer). Slides 
were then coverslipped with an 80% glycerol mounting medium.  
2.3. Optical and fluorescence microscopy 
Immunolabelled sections and facing fresh tissue sections mounted on Si3N4 windows were 
imaged using an Olympus VS120 slide scanner (Olympus, Australia) using the red and Texas 
135 
red channels for immunolabelled slides and brightfield for fresh sections. Images from facing 
sections were overlaid using OlyVIA 2.9 software (Olympus) and aggregate-containing 
regions of the SN were identified from fluorescent emission. Pixel coordinates were recorded 
and later transferred to motor stage positions at the Advanced Photon Source (see Methods 
and Materials 3). Acupuncture needle marks were used to triangulate regions of interest on 
the Si3N4 windows for synchrotron imaging. 
3. Synchrotron nanoprobe imaging
3.1. Bionanoprobe operating parameters 
The Bionanoprobe is a hard X-ray nanoprobe located at 9-ID-B, a 65 m beamline located at 
the Advanced Photon Source, Argonne National Laboratory in Illinois, USA (see Figure S1 
for end-station configuration)[535]. 
Scans used a 10 keV incident beam focused by a Fresnel zone plate (70nm outermost zone 
width) to ~100 nm spot on the sample surface with a 80 nm step size and 50 ms dwell time. 
Total X-ray fluorescence emission spectra and far-field diffraction patterns were collected 
simultaneously using a SII Vortex-ME4 and PILATUS 300 K pixel array detector, 
respectively. The Vortex detector was mounted at 90° to the sample surface and the 
PILATUS detector was placed 2.4 m behind the sample with its detection surface 
perpendicular to the beam path. 
Pixel coordinates from OlyVIA 2.9 were directly imported into the Bionanoprobe sample 
stage using the integrated motor control system described in detail by Chen et al. [466]. 
3.2. X-ray fluorescence microscopy 
Elemental spectra were extracted at Kα emission energies and model spectrum was produced 
with the assumption that cold acetone fixed tissues dried to 5 µm thick[536] where 
transmission efficiency ⟶ 100%[537]. Spectra were analysed using MAPS[466] where areal 
mass (Amass; ng cm-2) was fitted for each measured element[538] and exported as text files for 
reconstruction as TIFF images of Amass with a pixel size of 80 nm using Fiji[539].  
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3.3. X-ray ptychography 
Ptychograms were reconstructed with an iterative ePIE algorithm[540] for 100 iterations using 
five orthogonal probe modes in a parallel GPU enabled environment[541]. Expected phase 
value was calculated by modelling the tissue section as model protein (as C30H50N9O10S) with 
the assumption of a uniform density of 1.35 g cm-3[542] Phase change expected through the 
background tissue (neuropil) was calculated by obtaining the index of refraction (δ = 1.20 × 
10-6) and using the formula:[543]
Phase = −k × δ × z 
where z = tissue thickness, k = 2π / λ, and λ = 9.6118 × 10-11. 
The expected phase change was calculated as -1.57 rad and observed phase change in the 
supporting neuropil was -0.67. Following the correction of the arbitrary offset (0.90), area 
and density of reconstructed images were exported as phase (in rad) images with a pixel size 
of 13.5 nm. 
4. Image analysis
4.1. XFM and ptychography image registration 
Ptychography and fluorescence data was aligned by initially scaling XFM images to match 
the resolution of the phase contrast images using bilinear interpolation before alignment 
using control point image registration in MATLAB v2019b (MathWorks, USA). Registered 
data were exported as text images for analysis in Fiji. X-ray ptychography and Compton 
scatter images were constructed from uncorrected phase contrast reconstructions (as rad per 
pixel) and inelastic scatter emission (as counts) data. 
4.2. XFM image quantification 
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Images of Amass (as ng cm-2) for data extraction were prepared in Fiji. Limit of detection 
(LOD) for each element was determined by locating holes in the tissue section correcting 
each pixel for the mean background Amass + 3σ. High intensity spikes in Amass attributed to 
nanoscopic contamination found mainly in transition metals were confirmed by inspection of 
image histograms. Using the ‘Threshold’ tool, upper 1% were masked, designated as an 
undefined ‘not a number’ (NaN) unit, and subsequently excluded from analysis. 
4.3. Data extraction 
Facing immunofluorescence (for pS129 α-syn and SOD1 B8H10) or brightfield microscopy 
photomicrographs were coarsely orientated with ptychographic images as a guide for 
freehand drawing of feature outlines as regions of interest (ROIs) in Fiji. Images were 
normalised by pixel-wise division of Compton scatter emission to correct for variation in 
surface density and self-absorption events[528] The ROI defined by the aligned ptychography 
image was then used to extract area and Amass data from stacked XFM elemental maps. 
4.4. Statistical analysis 
Extracted LOD corrected XFM data were imported into SPSS Statistics v26 (IBM, USA) 
with matching subject demographic data (see Table S1). Datapoints were considered outliers 
if defined by SPSS as ≥3 × the interquartile range (IQ; or 2 standard deviations) and 
identified measurements excluded. 
Normality was assessed using the D’agostino-Pearson omnibus test for Gaussian distribution. 
Non-parametric data were compared using the Kruskal-Wallis multivariate test for 
independent samples with Tukey’s post hoc correction for multiple pairwise comparisons. 
Effects of age, post-mortem interval, and sex were tested using bivariate correlation of 
variables. Statistical significance was reported according to the α = 0.05 value. A 
significantly different Cu:Zn ratio from 1:1 was inferred from a 95% confidence interval that 
did not span 1. 
Box and whisker plots were prepared in Prism v8.3.1 (GraphPad, USA). 
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4.5. Colocalization analysis 
Colocalisation was performed using Mander’s colocalization coefficients in FIJI. Images 
were converted to 8-bit files and limit of detection threshold was applied (as outlined in 
section 4.2) before Cu channels and Zn channels in the region of interest were compared.  
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Supplementary Figures 
Figure S1. Schematic of the Bionanoprobe end-station at the Advanced Photon 
Source. Reproduced from Deng et al.[518] (reproduced per Creative Commons Attribution 
4.0 International License, 2017). 
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Figure S2. Structural nanoimaging of neuromelanin granules schematic 
Neuromelanin pigments are comprised of a dense pheomelanin core encased in a eumelanin 
shell[544] with multiple available sites for Cys-, His-, and Lys-protein adduction[545]. Random 
and disordered protein adducts produce phase contrast images with superior defining 
structural features compared to X-ray fluorescence emission resulting from Compton 
inelastic scatter and associated self-absorption effects in intact brain tissue sections (See 
Figure 1C). 
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Figure S3. Lewy body, SOD1 aggregate, and neuromelanin areas 
Mean area of Lewy bodies, SOD1 aggregates and neuromelanin deposits used for extraction 
of XFM spectra and Amass data. **p < 0.01; ***p < 0.001. 
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Supplementary Tables 
Table S1. Subject demographics 
Characteristics of and case histories PD cohort (n = 5) tissue. 
Case 
number 
Age 
(y) 
Post-mortem 
interval (h) 
Sex Lewy bodies 
(fly scan[a]) 
SOD1 
aggregates 
(fly scan[a]) 
Neuromelanin (fly 
scan[a]) 
1 84 25 F 3 (6, 22, 25) 7 (18[b], 19, 20, 
23, 24, 26) 
- 
2 82 28 M - 4 (45, 46, 78, 
80) 
- 
3 80 29 M 3 (66, 68, 99) 5 (63[b], 64, 96, 
98) 
5 (62, 65, 67, 69, 
70) 
4 81 28 F 2 (106, 109) 3 (107, 108, 
110) 
- 
5 89 54 F - 1 (121) 1 (120) 
Total n 8 20 6 
[a] Scan ID numbers at Bionanoprobe.
[b] 2 features in single scan.
Case 
number 
Time post 
diagnosis 
(y) 
Age of 
onset (y) 
Reported cause of 
death 
Clinical 
presentation 
Medications 
1 13 71 Broncopneumonia, 
old age, Parkinson’s 
disease 
Occasional tremor 
of left ring finger, 
Unsteadiness, late 
onset idiopathic 
Parkinson’s 
disease, L-dopa 
response, slurred 
speech, urinary 
incontinence, 
problems 
swallowing, 
constipation. 
Sinemet, 
Madopar, 
fludrocortisone, 
citalopram, 
adcal D3, 
pregabalin, 
warfarin. 
2 15 61 Urosepsis, 
Parkinson’s disease 
Presentation: 
unilateral tremor 
(limited 
information), 
dysphagia, 
dysarthria, 
rigidity, 
constipation. 
Unknown 
3 Unknown Unknown End-stage 
Parkinson’s disease 
Unknown Unknown 
4 5 76 Unknown Asymmetrical rest 
tremor (left hand), 
micrographia, gait 
disturbance, 
constipation. 
Sinemet, 
Madopar, 
Tramadol, 
alendronic acid 
5 Unknown Unknown Unknown Unknown Unknown 
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Table S2. Chemical characteristics of Lewy bodies, SOD1 aggregates, and 
neuromelanin 
Mean, standard error of the mean (SEM), standard deviation (SD) and inter-sample min-max 
values for Lewy bodies (LB), SOD1 aggregates, neuromelanin (NM) and neuropil. 
Feature n Mean SEM SD Min Max 
Area (µm2) LB 8 18.82 4.55 12.04 5.97 43.05 
SOD1 20 35.62 4.1 16.42 2.77 58.63 
NM 6 159.9 31.48 77.1 69.4 271.7 
Phase (rad) LB 8 -0.69 0.02 0.05 0.75 0.61 
SOD1 20 -0.74 0.13 0.05 -0.83 -0.66
NM 6 -0.68 0.01 0.03 -0.73 -0.65
Neuropil 32 -0.64 0.01 0.03 -0.73 -0.59
Compton 
(counts) LB 8 217.51 14.48 40.95 148.94 268.27 
SOD1 20 237.54 13.83 60.27 183.88 408.8 
NM 6 190.6 6.79 16.64 168.64 216.04 
Neuropil 32 203.65 11.15 63.09 132.13 400.29 
K (ng cm-2) LB 8 266.17 38.99 110.29 110.47 491.76 
SOD1 20 260.21 21.05 94.16 104.01 467.93 
Neuropil 6 220.95 11.3 27.68 172.84 250.26 
NP 32 179.52 12.72 70.83 69.71 394.21 
P (ng cm-2) LB 8 40.81 2.85 7.54 27.5 49.65 
SOD1 20 43.98 2.05 8.19 34.51 62.35 
NM 6 35.07 1.63 3.98 30.97 40.05 
Neuropil 32 36.1 1.47 7.91 25.54 55.65 
S (ng cm-2) LB 8 39.39 3.42 9.06 20.67 47.87 
SOD1 20 49.45 3.09 12.37 33.14 82.67 
NM 6 51.32 5.97 14.62 29.66 70.22 
Neuropil 32 34.45 1.83 9.88 17.78 61.39 
Fe (ng cm-2) LB 8 188.56 16.05 42.48 110.38 227.56 
SOD1 16 188.98 12.67 50.66 120.27 276.8 
NM 6 166.99 6.88 16.86 147.3 187.6 
Neuropil 30 141.68 5.51 29.67 92.8 236.95 
Cu (ng cm-2) LB 8 24.2 1.63 4.32 20.76 32.92 
SOD1 20 25.22 0.57 2.29 22.58 30.82 
NM 6 26.94 1.34 3.28 24.4 31.91 
Neuropil 32 23.21 0.48 2.59 20.26 32.08 
Zn (ng cm-2) LB 8 30.49 1.69 4.47 22.49 35.43 
SOD1 20 33.1 1.3 5.21 26.81 43.27 
NM 6 34.89 2.79 6.82 28.37 47.63 
Neuropil 32 27.34 0.95 5.1 20.64 42.94 
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CHAPTER 5: FINAL DISCUSSION, 
FUTURE DIRECTIONS AND 
CONCLUSIONS  
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5.1 Summary of findings 
Prior to this study, reports of biometal levels in PD brain and biofluids were conflicting. 
Accordingly, the initial aim of this project was to perform a meta-analysis to determine 
whether essential biometals are altered in the degenerating SN of the PD brain compared with 
the healthy age-matched SN, when employing various analytical techniques and 
incorporating diverse PD and control populations. In extracting studies for this meta-analysis, 
it was apparent that studies quantifying biometals in human brain tissues from PD patients 
lack consistency in their analytical approach, and some lack rigour in their conduction and 
reporting of methodology and statistical analysis. This inconsistency raised the issue of a lack 
of standardised guidelines for biochemical studies in human tissues. A Quality Assessment 
Scale for biochemical analyses of human tissues was therefore developed and implemented 
as part of the meta-analysis to categorise individual studies into ‘high’, ‘moderate’ and 
‘limited’ quality studies for further analyses with the aim of determining whether the strength 
of study quality influenced results. Using meta-analysis – the highest form of empirical 
evidence – marked and consistent reductions in Cu levels, and elevations of Fe, in the SN in 
PD were confirmed in the included quantitative human post-mortem studies. Analysis of 
subgroups, based on study quality and technique, indicated a substantial influence of 
methodology on reported biometal alterations – indicating the value of a more standardised 
approach for such studies in future. It is hoped that this Quality Assessment scale, now 
openly available in the published scientific literature, will be used in future to guide 
development of more standardised, high quality studies in a range of fields. An additional 
aim of this study was to determine whether biometal alterations in central disease tissues are 
reflected in more accessible biofluid tissues that could potentially represent biomarkers for 
disease diagnosis and progression. Neither central Cu nor Fe changes were mirrored by 
equivalent changes in sera, plasma or cerebrospinal fluid. Interestingly, Fe levels in sera were 
opposite to Fe changes in the brain, demonstrating slight reduction in PD patients. As the 
elimination of studies deemed of 'limited' quality diminished this Fe reduction, this finding 
requires further validation, optimally using Fe quantification in the SN and sera from the 
same individuals. 
With reductions in Cu and elevations in Fe confirmed in the SN of human post-mortem PD 
tissue, work in the following chapter found that these alterations are confined to the soluble 
fraction of SN tissue. The restriction of Cu and Fe changes to the soluble subcellular fraction 
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suggests that soluble proteins residing in this fraction may contribute to, or are altered by, 
changes in the levels of these biometals. As we have shown that aggregations of the soluble 
Cu- and Zn-binding protein SOD1 concentrate in the degenerating SN of the PD brain, it was 
hypothesised that abnormal aggregation of SOD1 may arise due to a lack of Cu-association 
with SOD1 in this Cu-deficient brain region. The following chapter therefore examined 
whether SOD1 aggregates in the SN in PD exhibit the expected Cu:Zn ratio of 1:1, to 
examine whether impaired metalation may contribute to the misfolding and aggregation of 
this protein in the SN in PD. Structural studies of these micro-aggregates in post-mortem 
neuronal tissue using standard techniques is difficult due to the complex matrix of human 
brain tissue. Cutting edge synchrotron-based ptychography was therefore employed to 
directly image SOD1 aggregates, Lewy bodies and neuromelanin at a resolution of 13.5nm – 
presenting very detailed structural features. This represents the first application of this 
technique in post-mortem human brain tissues; the choice of this method was required as 
Compton inelastic scatter is unable to discern aggregate outlines for micron sized structures 
in situ. Structural features of SOD1 aggregates were analysed and compared to Lewy body 
aggregates, illustrating similar densities and a very similar, homogenous structure throughout 
the aggregates. This similarity in structure is interesting as Lewy bodies are reported to be of 
amyloid nature, whilst SOD1 aggregates are reported to exhibit both amyloid[546] and non-
amyloid structure[397,547]. Ptychography does not however provide information on tertiary 
protein structure conformation, and these data suggest that both of these proteinacoues 
aggregates in the PD brain exhibit ordered structures potentially resulting from similar 
protein misfolding pathways. Neuromelanin on the other hand, exhibited a more disordered 
structure, likely attributable to random protein deposits that accumulate throughout life.   
Synchrotron XFM was performed simultaneously with ptychography to quantify biometals 
associated with SOD1 aggregates, Lewy bodies and neuromelanin in human post-mortem SN 
in PD tissue. SOD1 aggregates and Lewy bodies exhibited similar biometal fingerprints – 
suggesting that numerous metals accumulate on aggregated proteins, or that similar protein 
misfolding pathways exist in the formation of distinct proteinaceous aggregates. In support of 
hypothesis 4 posed in the introduction to this thesis, a significant reduction in the Cu:Zn ratio 
of SOD1 aggregates was observed. This novel finding is consistent with the idea that Cu-
binding to SOD1 is reduced in SOD1 incorporated into these aggregates. Although it is 
notable that these aggregates likely contain other proteins and cellular materials, the high 
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colocalization of Cu and Zn suggests that they are binding to the same structures within the 
aggregates. As Cu-binding is crucial for SOD1 structural support and enzymatic activity, it is 
proposed that Cu-deficient SOD1 misfolds in the SN of the PD brain and may potentiate 
neuronal death in these regions possibly via a toxic gain-of-function mechanism similar to 
that proposed in SOD1 associated ALS[43]. Observation of Cu-deficient, misfolded SOD1 in 
the PD brain supports the use of the Cu supplementation agent Cu-ATSM currently in 
clinical trials for PD, which is reported to deliver Cu to Cu-deficient SOD1 and subsequently 
restore protein stability and catalytic function in ALS mouse models[435].  
This thesis confirms a reduction of Cu and elevation of Fe in the degenerating SN of the PD 
brain, and examines the subsequent impairment of a crucial, Cu-dependent antioxidant 
protein SOD1, and its potential role in PD aetiology. 
5.2 Significance and Implications 
This thesis confirms the presence of Cu and Fe dyshomeostasis in the SN in PD and provides 
a strong empirical basis to investigate if modulating the levels of Fe and/or Cu confers 
neuroprotection, or other clinically relevant benefits to PD patients. Deferiprone, an Fe 
chelator and Cu-ATSM, a Cu supplementation agent, are currently being investigated in 
clinical trials in PD (NCT00943748 and NCT03204929 respectively). Preclinical data shows 
Cu-ATSM ameliorates dopaminergic loss, mitigates motor symptoms and prolongs survival 
(through an undetermined mechanism) in multiple murine models of PD[498]. Fe chelation 
studies in PD are more advanced, with significant reductions in Fe siderosis observed in 
early-stage patients and improvement of clinical symptoms after 6 months of 
treatment[496,548]. This thesis presents evidence that SOD1, a Cu-dependent protein, forms 
aggregates that may themselves be Cu-deficient, in the Cu-deficient and degenerating SN of 
human post-mortem PD tissue. As Cu-deficient SOD1 aggregates are strongly implicated in 
neuronal death in some familial forms of ALS, further investigating similarities between this 
protein pathology in the PD brain, and that in SOD1-associated ALS, may elucidate 
overlapping pathogenic mechanisms of cell death in these clinically distinct 
neurodegenerative disorders. Further, drawing on current knowledge of SOD1 misfolding 
pathways in ALS, potential therapeutic approaches which target toxic SOD1 misfolding 
could be translated for use in PD.  
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5.3 Strengths 
Use of meta-analysis as the highest level of empirical evidence was a major strength of the 
current study – allowing the direct comparison of data obtained from various analytical 
techniques, and tissues employed from diverse PD and control cohorts. Another strength of 
the meta-analysis was the development of a scale to assess the quality of individual studies – 
allowing insight into the influence of study quality on data outcomes.  
In an attempt to understand the molecular processes underlying neurodegeneration in PD, 
numerous animal and cell models of PD have been developed. Although useful in modelling 
certain aspects of the disease, no current animal model accurately emulates the human 
disease aetiology. This is suggested to account for the recurrent failure of therapeutic 
approaches which have demonstrated promise in animal models, to clinical trials[549]. 
Investigating the molecular changes occurring in PD in human tissues is essential to advance 
our understanding of the aetiology of this uniquely human disorder. This knowledge is likely 
to also aid in the improved development of animal models of this disease. The use of fresh 
human post-mortem PD neuronal tissues in the current thesis ensures that our findings most 
accurately represent changes occurring in the human brain during this disease. Fresh tissues 
avoid confounding effects that can arise during tissue processing or fixation, whilst tissues 
from animal models of PD likely present inaccurate recapitulations of the human for of PD.  
Many molecular processes underlying PD such as oxidative stress, are exacerbated during the 
normal ageing process. As age is the greatest risk factor for PD, a strength of the current 
study was the assessment of age as a moderating factor and the matching of PD cohorts with 
healthy control tissues in all experimental datasets. The inclusion of the non-degenerating 
occipital cortex, and the fusiform cortex which exhibits Lewy pathology, yet no neuronal 
loss, was a major strength of Chapter 3, as this confirmed that the reported biometal changes 
occur in degenerating regions and are associated with neuronal loss, and not with Lewy 
pathology. 
Due to their small size, proteinaceous aggregates are difficult to characterise. With SOD1 
aggregates ranging from 5-20µm in diameter, and LB aggregates only slightly larger, 
employing a third-generation synchrotron XFM beamline with the highest spatial resolution 
in the world of 13nm for biometal quantification was a major strength of the study reported in 
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Chapter 4. A unique strength of this study was the direct imaging of protein aggregates in the 
human post-mortem PD brain without use of immunolabelling which is reported to alter 
protein structure and metalation. This ensured that observed features of these aggregates were 
not artefacts or alterations resulting from antibody binding.  
5.4 Limitations 
The use of human post-mortem tissues although a major strength of the current study, is 
inherently limited as it can only determine correlative, and not causative relationships. As PD 
is a slowly progressing neurodegenerative disorder with patients rarely dying in early stage of 
the disease, post-mortem tissues from PD patients are typically representative of end-stage 
disease. Therefore ascertaining whether identified biochemical changes are a primary factor 
underlying cell death, or a secondary process of the disease processes or death itself cannot 
be definitively determined. Despite being the best representation of PD, post-mortem tissues 
cannot delineate temporal patterns of biochemical changes which occur throughout the 
disease process. As no model is currently available which exhibits Cu-deficiency and SOD1 
aggregation specifically in the SN, the development of such a model to perform concurrent 
studies to those conducted in human PD tissues, would aid in elucidating whether the changes 
observed in the human post-mortem brain contribute to neuronal death cascades in PD. The 
development and validation of such an animal model is currently underway by our group. 
A further caveat of much post-mortem tissue research is that sample sizes are often small due 
to limited tissue availability. Small sample sizes can reduce statistical power and may 
therefore, reduce data accuracy. The meta-analysis increased statistical power as many post-
mortem studies were included – substantially increasing the sample size. Despite this, sample 
sizes for Chapter 3 were sufficiently powered (0.822-100% power; a = 0.05, d = 1.06, n = 9) 
as were those in Chapter 4 (90% power; a = 0.05, d = 0.95, n = 7). The amount of aggregates 
scanned in Chapter 4 was also limited by beamtime availability at third-generation 
synchrotron facilities. As beamtime at the Advanced Photon Source bionanoprobe in Chicago 
is internationally competitive, beamtime allocations are extremely limited. As this facility is 
oversubscribed, the maximum beamtime allocation is usually no longer than six days (18 
shifts). Despite this, the current study was allocated five days (15 shifts) after receiving a 
high scoring proposal of 1.2 out of 5 (with 1 being Extraordinary). Although on the upper end 
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of the allocation time allocated, the number of aggregates scanned was limited by the time 
taken to obtain a high-resolution scan of each aggregate (around 5 hours). 
Another limitation of Chapter 4, was the assumption that SOD1 aggregates are comprised 
predominantly of SOD1 protein. As these are newly identified protein aggregates, little is 
known regarding their molecular composition, with only CCS, ubiquitin and SOD1 
confirmed in these aggregates[397]. Therefore, numerous other metal-binding proteins could 
be co-localised within these inclusions and subsequently influence the Cu:Zn ratio. A full 
proteomic analysis of SOD1 aggregates is therefore warranted. Further, as both SOD1 and 
LB aggregates may be at varying maturation stages, this may have also influenced their 
metal-associations. Determining the metalation of SOD1 and LB aggregates in a temporal 
manner in vivo using animal models, or in an in vitro system may resolve these concerns.   
5.5 Future directions 
Per the limitations of human post-mortem tissue studies outlined above, a next step for the 
current project could be to characterise the temporal pattern of biometal alterations in PD. 
Identifying when these changes occur in the disease process is crucial to elucidate the 
progression of molecular cascades leading to neurodegeneration in the PD brain, and identify 
therapeutic targets in these pathways. Further, determining when Cu reduction occurs may 
aid in determining the cause of Cu deficiency in this disease. The advancement of functional 
imaging approaches for in vivo Fe quantification has confirmed Fe deposition in the SN early 
in PD[550]. As no accurate in vivo imaging probe for the quantification of Cu intra-vitum is 
currently available, development of such an approach could determine whether Cu levels are 
reduced in PD vulnerable brain regions prior to clinical manifestation, and whether Cu 
reductions in certain brain regions can be used as a biomarker for PD. Further, this would 
allow the determination of whether Cu deficiency occurs prior to Fe accumulation in the PD 
brain. In vivo quantification of nigral Cu could be a useful diagnostic tool, an indicator of 
disease stage, or preclinical marker for PD.   
As the current study only investigated SOD1 metalation post-aggregation, determining 
whether soluble SOD1 acquires sufficient Cu would establish whether SOD1 misfolding 
occurs due to a lack of Cu-binding, or due to impairment of other protein folding regulatory 
mechanisms such as the ubiquitin-proteasome system or autophagy. Future studies 
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investigating whether soluble SOD1 exhibits altered metal-binding properties in vulnerable 
regions of the PD brain, such as the SN, will provide valuable insight into the misfolding 
pathway of this protein and elucidate potential targets to prevent or mitigate this process. 
The next major question to be addressed, is whether Cu-deficient SOD1 aggregates are toxic 
to neurons. To answer this, in vitro or in vivo models of disease would be needed to 
investigate the toxicity of these aggregates. As it is highly unlikely that PD pathogenesis 
arises solely from one dysfunctional process, developing models that exhibit multiple 
pathogenic aspects identified in human PD brain tissues will further aid in producing a more 
accurate disease model. Development of an animal model presenting with Cu deficiency and 
SOD1 aggregation specifically in regions experiencing neuronal loss in the PD brain would 
provide a disease model for PD, which more accurately represents the human aetiology. 
Although SOD1 aggregates are implicated in neuronal death in ALS, their neurotoxicity in 
the PD brain is undetermined. Examining when and how SOD1 aggregates form, the 
metalation of soluble and aggregated SOD1, and their relationship with neuronal death in 
these models would provide empirical evidence for a causal relationship between post-
translationally modified, wild-type SOD1 and neuronal death observed in the PD brain. 
5.6 Conclusions 
This thesis resolves contention in the literature regarding alterations in Cu, Fe and Zn in the 
SN in PD; confirming Cu reductions, and Fe elevations in the degenerating SN of the PD 
brain. It was demonstrated for the first time that these changes are further restricted to the 
soluble fraction of tissue. The meta-analysis also demonstrates that these changes are not 
reflected in more accessible biofluid tissues which do not therefore provide an accurate 
indication of more central disease processes. The current study also presents the first direct 
imaging of protein aggregates in the human PD brain and the first elemental characterisation 
of both SOD1 and Lewy body proteinopathies in these tissues. Ptychography to examine 
aggregate structure at submicron resolution was also performed for the first time in human 
brain tissues, illustrating high resolution structural features of these proteinaceous aggregates. 
These resulting data are consistent with the hypothesis that SOD1 is Cu-deficient in this 
degenerating brain region, supporting the use of biometal modulation therapies currently in 
clinical trials as a potential disease-modifying therapeutic approach for PD.   
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